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ABSTRACT 
 
GROWTH AND SURVIVAL PATHWAYS IN NORMAL AND MALIGNANT 
 B-LYMPHOCYTES 
 
Author:  Maria R. Gumina 
Advisor: Thomas C. Chiles, Ph.D. 
 
Normal B lymphocytes require extrinsic factors to grow and proliferate. Surface 
receptors (e.g., B-cell antigen receptor, BCR) function, in part, to link growth factors to 
signal transduction/metabolic pathways and the cell cycle machinery.  Accumulating 
evidence indicates that signal transduction-dependent changes in both glucose energy 
metabolism and de novo transcription of the D-type cyclin-cdk4/6 pathway are necessary 
for quiescent B-lymphocytes to enter G1-phase of the cell cycle and grow.  B cell growth 
represents a critical checkpoint for subsequent proliferation and clonal expansion of 
antigen-specific lymphocytes.  On the former, we have shown earlier that acquisition of 
extracellular glucose and metabolism via the glycolytic pathway is required for 
conventional splenic B-2 lymphocytes to grow (i.e., increase cell size and mass) in 
response to antigen challenge; however, the metabolic fate and biological significance of 
glucose-derived carbons are unknown.  Here, we show that in response to BCR ligation, 
glucose carbon flow is directed into a de novo lipogenic pathway that is regulated, in part, 
via phosphoinositide-3 kinase (PI-3K)-dependent activation of ATP citrate lyase (ACL), 
a key rate-limiting enzyme in de novo lipogenesis.  Inhibition of ACL results in a loss of 
B-cell growth and cell viability.  Regarding the latter point, the B-1a lymphocyte subset 
expresses cyclins D2 and D3 that are transiently expressed in a non-overlapping manner, 
notably cyclin D3 expression immediately precedes the G1/S phase transition, suggesting 
distinct functions for these D-type cyclins in B-1a lymphocyte G0-to-S phase progression. 
We show herein that murine B-1a cells deficient in cyclin D3 proliferate normally in 
response to extracellular stimuli, in part, due to a compensatory sustained up-regulation 
of cyclin D2.  In keeping with this, human diffuse large B-cell lymphoma (DLBCL) 
represents a malignant clonal expansion of B cells characterized by several subsets, 
including germinal center (GC) and activated B-cell (ABC) types.  Here, we show that 
the GC-type LY18 human DLBCL exhibits constitutive expression of cyclin D3, but not 
cyclins D1 and D2.  Targeting of cyclin D3-holoenzyme complexes with cell permeable 
chemical- and peptide-based cdk4 inhibitors results in G1-phase arrest and apoptosis via a 
pathway that involves inhibition of pRb phosphorylation.  By contrast, endogenous knock 
down of cyclin D3 with siRNA did not induce growth arrest or apoptosis, in part, due to 
redundancy with cyclin E.  
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INTRODUCTION 
 
I. The Immune System  
The immune system is a complex defense mechanism within an organism that 
identifies and protects against invading pathogens (i.e., viruses, bacteria, parasites).  The 
different immune cells and mediators collaborate in a dynamic network to detect foreign 
pathogens, synchronize an attack, and finally kill and remove the pathogen and damaged 
cells.   
The immune system is divided into two branches, innate and adaptive, each being 
functionally distinct but highly interactive.  Innate immunity is the first line of defense a 
host has against infection and it is non-specific in nature.  Effector cells rapidly respond 
to common surface molecules on the invading pathogen in a similar manner regardless of 
the pathogen and therefore, do not illicit long lasting immunity.  Activation of the innate 
immune response often primes the system for the complex adaptive immune response.  
Adaptive immunity is a specialized and stronger response that offers long lasting 
immunity.  The adaptive branch is divided into humoral immunity orchestrated by B-
lymphocytes (B cells), and cell mediated immunity with T-lymphocytes (T cells).  B and 
T cells recognize pathogens and respond in a highly specific manner based upon the 
unique antigen present on the invading pathogen, while concurrently remaining tolerant 
towards self-antigens.  My study will focus on the specialized B cells of humoral 
immunity.  B cells fight infection caused by extracellular pathogens through the 
generation and secretion of highly specific immunoglobulins (antibodies (Abs)).  
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II. B Lymphocytes 
A.  Development  
B cells are continuously generated by hematopoietic stem cells (HSC) in the bone 
marrow.  Self-renewing HSCs have the potential to generate erythroid, myeloid and 
lymphoid cell lineages.  In order to differentiate, HSC must migrate to the necessary 
environment where they receive the appropriate cues and cytokines to initiate the 
expression of specific transcription factors [1].  For HSC to differentiate into B lymphoid 
progenitors, specific B cell lineage transcription factors must be expressed as well as 
those specific for the other cell lineages suppressed [2].  Specifically, the gene Pu.1 is 
required for HSC commitment into the lymphoid lineages and further the Ikaros gene is 
responsible for the development of B and T lymphocytes [2].  In B cells the Ikaros gene 
encodes a family of transcription factors that control gene rearrangement, 
immunoglobulin (Ig) heavy and light chains, and the gene encoding Igα [1].  As a B cell 
matures it progresses through many strictly controlled developmental stages.  Each 
developmental stage is defined by the molecular changes that accompany random gene 
rearrangements that are required to make functional surface Ig [3].  Each surface Ig 
receptor that is generated maintains its own diversity for a specific antigen, which allows 
a broader response repertoire [4].  B cells undergo early development in the bone marrow 
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and stages are broken down into:  Pro, Pre, Immature, and Mature B cells (see Figure 1).  
 
 
Each stage is further classified based on distinct gene expression profiles, distinct 
expression of microRNA clusters, the presence of cell surface markers and receptors, and 
the assembly of a mature B cell receptor (BCR) [5].  All pro- and pre-B cells reside in the 
bone marrow, whereas immature cells migrate to the periphery where they undergo 
further maturation and become capable of recognizing self from non-self.  At this stage 
the B cells are mature, but naïve because they have not encountered antigen.  They are 
primed and ready to illicit an immune response provided the correct signals. 
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B.  Activation and Terminal Differentiation 
Activation of a B cell begins when a mature, naïve B cell (arrested in G0 of the 
cell cycle) encounters antigen via the BCR and receives the necessary signals to begin 
cell division [6,7,8].  Activation of a B cell results in cell growth (i.e., accumulation of 
cell volume and mass), a change in metabolism (discussed in detail in section III), an 
increase in the expression of class II major histocompatibility complex (MHC) 
molecules, an increase in the expression of IL-4 receptors (IL-4r), and finally, activation 
drives resting cells (G0 of the cell cycle) into G1-phase.  B-cells that begin to proliferate 
undergo clonal expansion and terminal differentiation into Ab secreting plasma cells.  
Each step is tightly controlled by cell cycle together with apoptosis.  Cell cycle regulation 
is a major determinant of homeostasis during B cell development and differentiation [7].  
Binding of an antigen causes the surface Ig on the B cell to become physically 
crosslinked [1,9].  Other surface proteins, Igα and Igβ, associate with the surface Ig to 
form the functional BCR, which can either strengthen or inhibit the signal to proliferate 
[3,6, 8, 9].  Aggregation of the BCR complex recruits a number of tyrosine kinases that 
initiate three main intracellular signaling cascades, each resulting in changes of gene 
expression in the nucleus (see Figure 2) [1].   
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Studying and understanding BCR coupled signals and their cell cycle target is of interest 
because irregular cell cycle often leads to malignant transformation.  
Following activation and proliferation, plasma cell precursors (plasmablast cells), 
or long-lived memory cells emerge from the germinal center (GC) and undergo terminal 
differentiation.  Long lived, antigen specific memory cells are responsible for the 
secondary immune response should the same antigen invade the body again.  This 
response is faster and more aggressive than the first because the memory cells are already 
primed specifically against that particular pathogen.  Plasmablast cells travel to the bone 
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marrow where they give rise to mature plasma cells [6].  Mature plasma cells are 
terminally differentiated B cells that exit the cell cycle, never to proliferate again [10,11].  
They are a very distinct subset of the B cell population and their primary role is to secrete 
copious amounts of antibody specific to the particular antigen [6,11,12]. 
 
III. Bioenergetics and Immune Function 
 A fundamental aspect of immune cell regulation is the prerequisite of metabolic 
substrates to support the bioenergetics associated with lymphocyte development, antigen 
(Ag)-driven clonal expansion, and acquisition of effector functions [13, 14].  For 
example, a recent publication demonstrates the requirement for glucose metabolism in 
supporting Notch-mediated survival of pre-T cells [15].  Recent studies performed in the 
Chiles’ Lab suggest a model in which the modulation of glucose energy metabolism by 
signal input from surface receptors, influence the outcome of B-cell responses.   
 
A.  Energy Metabolism and B Lymphocyte Responses 
 As noted above, an important consequence of BCR signaling is the expression of 
cell surface molecules involved in B cell-T cell collaboration and in promoting cell cycle 
entry of B cells [16].  A hallmark of lymphocytes is their ability to respond immediately 
to Ag challenge, shifting from a quiescent state (G0) to a highly active metabolic state 
within hours.  During this period, transcriptional and translational programs are enacted 
to support growth and acquisition of effect functions [17,18,19].  Although a great deal of 
effort has been directed toward identifying signaling and gene expression programs that 
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link extrinsic signals to B cell responses, little is known about the acquisition of 
metabolic substrates, the regulation of nutrient metabolism, and the biological 
significance of such regulation to B lymphocyte development, survival, and function.  
 Early studies revealed that T cells generate most of their ATP from oxidizing 
glycolytic-derived metabolites (e.g., pyruvate) by the tricarboxylic acid (TCA) cycle in 
the mitochondria [13,20,21,22].  Based on recent studies by Craig Thompson and 
colleagues and the Chiles’ Lab, a clearer picture has emerged of the metabolic responses 
of quiescent T- and B-lymphocytes to antigen receptor ligation [23,24].  B-lymphocytes, 
(like TCR- and CD28-stimulated T cells), rapidly increase glucose uptake and hyper-
induce glycolytic flux in response to BCR cross-linking [23,24].  Pro-survival cytokines 
also mediate glucose energy metabolism in lymphocytes.  To illustrate, IL-7 withdrawal 
from T cells results in a decline in glycolysis and triggering of apoptosis [25].  IL-7 has 
been shown to promote glucose transport-1 (Glut 1) surface trafficking and glucose 
uptake via a Stat5/Akt-dependent pathway [26].  Importantly, mammalian cells 
engineered to express surface Glut1 and the glycolytic enzyme, hexokinase I, resist 
cytokine-withdrawal induced apoptosis indicating an essential role for glucose 
metabolism in protecting mammalian cells from apoptotic death [25].  In our most recent 
findings we discovered that IL-4 induces glycolysis in naïve B cells [27]; inhibition of 
glycolytic flux is sufficient to trigger apoptosis, despite the presence of IL-4, suggesting 
that glycolysis is necessary for the pro-survival action of IL-4.  Based on these and other 
studies, it is currently held that lymphocytes and hematopoietic cells depend on extrinsic 
growth factors, by virtue of their ability to regulate glucose uptake and metabolism, in 
 8 
order to maintain viability and prevent cell death.  The significance of this metabolic 
regulation beyond normal lymphocyte homeostasis is underscored by the various disease 
states that can result from growth factor excess (e.g., cancer or autoimmunity) or 
conditions of which growth factors are limiting (e.g., immunodeficiency).   
   
B.  Phosphatidylinositol 3-kinase (PI-3K)/Akt Controls B-Cell Glucose Energy 
Metabolism 
 Classic biochemistry teaches that intermediary metabolism is homeostatically 
regulated, such that derepression of catabolic pathways occurs as a response to increased 
cellular ADP/ATP ratio.  This ensures that adequate levels of ATP and/or metabolites are 
maintained to support biosynthetic reactions associated with cellular function.  However, 
this has been revised based on studies of hormone-and growth factor-responsive tissues 
wherein extrinsic signals are required for the acquisition of extracellular nutrients and 
their metabolism [13,23,24,28-34].  Akt/PKB kinase has emerged as the link between the 
insulin receptor and increased glucose utilization as well as instructs cells to increase 
transcription and translation [35-37].  Naïve B lymphocytes do not enter the cell cycle 
and proliferate autonomously, but instead require extrinsic growth factors.  For example, 
BCR cross-linking triggers activation of PI-3K, which plays an essential role in B cell 
growth and proliferation [38].  NF-κB-and c-Myc-dependent gene expression programs 
lie downstream of PI-3K and have been implicated in B cell growth and survival [39-41].  
It should not be surprising that signal transduction pathways possess the capacity to 
reprogram glucose metabolism in order to support B cell growth responses.  Recent 
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finding by the Chiles’ Lab point to a critical role for PI-3K signaling in orchestrating 
glucose carbon flow by regulating key glycolytic rate-limiting enzymes that control 
macromolecular synthetic demands imposed by BCR ligation [24].  
 
C.  ATP Citrate Lyase (ACL) and de novo Lipogenesis 
 Germane to my research, one of the biosynthetic fates of glucose is the conversion 
to lipids during de novo lipogenesis.  de novo lipid synthesis is necessary for membrane 
production and lipid-based posttranslational modification of proteins.  Briefly, glucose is 
converted to pyruvate by cellular glycolysis, imported into the mitochondria, 
decarboxylated to acetyl CoA, and condensed with oxaloacetate (OAA) into citrate (see 
Figure 3).  
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Citrate is then either oxidized via the TCA cycle or exported from the mitochondria.  
Once exported from the mitochondria, cytosolic citrate is processed by ATP citrate lyase 
(ACL) to produce cytosolic acetyl CoA and regenerate OAA, which is the key step for 
the biosynthesis of fatty acids, cholesterol and acetylcholine [42-46].  
ACL is a key homotetrameric enzyme linking glucose metabolism to lipid 
synthesis.  Nutrients and hormones regulate the expression level and phosphorylation of 
ACL [44,46,47].  ACL is phosphorylated by GSK-3 on Thr446 and Ser450, and by PKA 
and Akt on Ser454 [48,49].  Phosphorylation on Ser454 abolishes the homotropic allosteric 
regulation by citrate and enhances the catalytic activity of the enzyme [47].   
 As evidence supports a role for PI-3K/Akt signaling in increased glucose uptake 
and glycolytic flux in B cells [24], we do not understand at this time how BCR signaling 
regulates glucose carbon flow into de novo lipogenesis.  ACL is considered to be rate-
limiting for glucose carbon flow into fatty acid and cholesterol synthesis and thus, its 
activation by PI-3K signaling in B cells may reflect an important regulatory mechanism 
by which the BCR reprograms glucose metabolism to support blastogenesis and perhaps, 
contribute to expansion of the endoplasmic reticulum and Golgi compartments, a 
prerequisite for synthesis, assembly and secretion of Ig.  On a related point, plasma 
membrane cholesterol content has been implicated in regulating BCR signaling and B 
cell fate [50].  It is noteworthy that a growing body of evidence supports a critical role for 
ACL in cancer cell pathogenesis [51].  Knockdown of ACL leads to impairment of 
glucose-dependent lipid synthesis and a decrease in cytokine stimulated cell growth and 
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proliferation [45].  My research investigates the regulation and function of ACL in B 
cells stimulated through the BCR. 
 
IV. Cyclin D/cdk4/pRb Pathway in B Lymphocytes 
As mentioned earlier signaling through the BCR triggers B cell activation, which 
is a step necessary step for proliferation and differentiation.  The decision to enter cell 
cycle is regulated by extracellular growth promoting and inhibiting signals [8,51].  It is 
necessary that the B cell is capable of translating these contrasting signals and 
coordinates them with the cell cycle machinery [8].  Understanding B cell cycle is 
necessary because many lymphoproliferative malignancies demonstrate a lack of 
responsiveness to extracellular signals, resulting in a loss of control over cell growth and 
proliferation a trademark of cell transformation [51].     
The cell cycle is a series of events that a cell undergoes in order to grow and 
divide.  It is coordinated with a complex network of tightly regulated proteins that must 
integrate extracellular signals to the intracellular cell cycle machinery in order to 
duplicate its genome.  This investigation will focus on the biochemical signals that 
promote or inhibit the progression of the cell cycle at the first restriction point (R point) 
in G1-phase.  Passing through the R point is irreversible and it determines whether the 
cell is going to commit to S phase entry, revert back to quiescence, or initiate apoptosis 
[8].  It is also at the R point that the cell transitions from serum dependent to independent 
[51].   
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G1-phase is noted for an increase in cell size (i.e., growth), gene expression, and 
protein synthesis required for DNA synthesis.  In a brief summary, progression through 
G1-phase of the cell cycle is extensively regulated by a family of catalytic cyclin 
dependent kinases (cdks) that function together with their regulatory counterparts the D- 
and E-type cyclins [53].  The D-type cyclins (D1, D2, and D3) bind cdk4 and cdk6 in 
mid-G1-phase, while cyclin E binds cdk2 in late-G1-phase (see Figure 4) [54].  
 
Assembled complexes are transported into the nucleus where they must be 
phosphorylated by cdk-activating kinase (CAK) [53].  Together these complexes 
sequentially phosphorylate the retinoblastoma tumor suppressor protein (pRB) and pRB-
related pocket proteins, p107 and p130 [53-55].  This in turn disrupts pRB association 
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with the E2F family of transcription factors, leading to the coordinated transcription of a 
variety of genes that are necessary for S-phase entry, nucleotide synthesis, DNA 
replication, and DNA repair [53,54,56].  E2F response genes include, c-myc, B-myb, 
cdc2, dihydrofolate reductase, thymidine kinase, and the promotor of the E2F-1 gene 
itself [54,57].  Another gene in particular that E2F activates is cyclin E, which in turn 
binds cdk2 thereby activating the kinase complex and creating a positive feedback loop 
that ensures commitment to proliferation [53,58].   
In addition to cyclin accumulation, the proper timing and duration of cdk 
activation are also controlled by regulation of cyclin-cdk assembly, subcellular 
localization, the action of cdk-inhibitors (cdki’s, which will be discussed in section V), 
and posttranslational modifications of cyclin and cdk subunits [59,60].  The 
posttranslational modifications that yield active holoenzymes remain largely undefined; 
however, it has been established that maximal cdk activity is only achieved after nuclear 
import and subsequent phosphorylation by cdk-activating kinase (CAK) on Thr172 in 
cdk4/6 [61-63].  CAK activity appears to be constant throughout the cell cycle, but is 
induced in some cell types during G1-S progression [63-65].  Phosphorylation on Tyr17 of 
cdk4 and cdk6 results in the inhibition of catalytic activity even in the presence of CAK-
mediated phosphorylation [66,67].  Tyr17 phosphorylation is removed by the action of the 
Cdc25 family of protein phosphatases, which are subject to regulation at the protein level 
by extracellular signals [66,68-70].  The protein kinase responsible for Tyr17 
phosphorylation has not been identified.  
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A.  D-type Cyclins   
 In 1982, Tim Hunt first discovered cyclins while doing research using the sea 
urchin egg.  He observed that certain proteins that were otherwise not detectable in the 
unfertilized eggs were synthesized early during fertilization and were later destroyed at 
certain stages of the cell cycle [71].  He called them cyclins and later he and others 
demonstrated that that the cyclins bind and activate the cyclin-dependent kinases, which 
had been identified as a key cell cycle regulator by Paul Nurse.  Both were awarded the 
Nobel Prize in 2001. 
 The D-type cyclins represent a unique protein in the cell cycle.  Unlike other 
cyclins that are periodically induced throughout the cell cycle, the D-type cyclins are up 
regulated and controlled by extracellular mitogenic signals from the environment 
[53,54,72].  If there is a loss of extracellular stimulation prior to the R-point, D-type 
cyclins are degraded, which results in dephosphorylation of pRb and transition back into 
quiescence [59,73,74].  Therefore, the D-type cyclins are critical proteins that connect the 
extracellular environment with the cell cycle machinery in order to initiate genome 
replication [8,53].  In early embryogenesis of Drosophila where cell cycle precedes 
independently of extrinsic signals, the D-type cyclins are absent.  On the other hand, 
constitutively active cyclin D pathways can override the necessary extracellular signals 
and cause a cell to enter the cell cycle prematurely, thereby contributing to oncogenic 
transformation [54,75,76].  
 The mammalian D-type cyclins (cyclin D1, D2, and D3) are encoded by three 
separate genes that share a high degree of amino acid homology and overlapping 
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expression patterns [60,77,78].  All three D-type cyclins have two highly conserved 
domains.  The first domain is the cyclin box (~100 amino acids), which mediates binding 
to cdk and induces its active conformation [79].  The second conserved domain is a N-
terminal LxCxE motif, which is critical for binding with pRb and is believed to play a 
role in orienting the cdk subunit [79].  My study will focus on cyclin D2 and D3, because 
there is no cyclin D1 in lymphoid lineages of mice.  In splenic B-lymphocytes, BCR 
cross-linking induces endogenous cyclin D2 and cyclin D3 protein expression [80-82].  
Studies performed in the Chiles’ Lab demonstrated that NF-κB signaling is required for 
BCR-induced cyclin D2 expression in B cells [83].  Further evidence shows MEK1/2-
p42/44ERK and NF-κB pathways link PI-3K activity to BCR-mediated cyclin D2 
induction [83,84].  On the other hand, the regulation and function of cyclin D3 in B cell 
subsets is not well defined.  The cyclin D3 gene promoter contains multiple transcription 
factor recognition sites, including NF-κB-binding sites, and B cells deficient in c-Rel 
exhibit diminished cyclin D3 induction in response to BCR cross-linking [85,86].  My 
study sought to elucidate the function of cyclin D3 in primary peritoneal B-1a cells and in 
the human diffuse large B cell lymphoma, OCI-LY18. 
The ability to perform specific gene targeted knockouts in mice has allowed the 
direct study of the functions of the D-type cyclins.  Gene targeting studies in mice where 
individual D-type cyclins are knocked out, show that the mice are viable and display 
limited abnormalities and phenotypes, suggesting high levels of functional redundancy 
[51,60,72,87].  Germane to my studies, cyclin D2 deficient mice are viable and display 
normal numbers of splenic B lymphocytes (B220+IgM+); however, they have a 
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significant reduction in the B-1a (CD5+) cell compartment [88-90].  In response to BCR 
cross-linking, B-lymphocytes from cyclin D2 deficient spleens exhibit impaired 
proliferation; however, that proliferation is not completely blocked is believed to be a 
result of redundancy with cyclin D3 in this tissue [88-90].  Cyclin D3 deficient mice are 
also viable, however they display a defect in the development of T-lymphocytes [88,89].  
The molecular mechanisms of compensation between the D-type cyclins are unclear.  
Whether or not they are completely interchangeable or possess distinct biological 
functions remains to be revealed.  In most tissues the remaining D-type cyclins that have 
not been knocked out are up regulated and appear to compensate for the targeted cyclin 
[51,72].  Mice with two D-type cyclins knocked out display the sum of the individual 
knock out phenotypes, while mice with all three D-type cyclins knocked out die at 
embryonic day 17.5 [72].  
 As mentioned above D-type cyclin genes share a high degree of homology with 
each other, however their expression profiles only partially overlap.  Research studies 
have proposed that the specificity of each D-type cyclin lies within its tissue specific 
expression [60].  For example, cyclin D1 is observed in epithelium, while cyclin D3 is 
most ubiquitously expressed in lymphoid tissue [60,91].  A study published by Bartkova 
in 1998, demonstrates that the role of cyclin D3 is not fully redundant [76].  They 
revealed that in lymphocytes, cyclin D3 correlates with proliferation, thereby having the 
potential to be the driving force of oncogenesis in some lymphoid malignancies [76].  In 
a study of human B cells stimulated to proliferate, cyclin D3-cdk6 complexes were found 
to regulate proliferation, not cyclin D2 [92].  Of particular interest, gene expression 
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profiling studies have revealed that cyclin D3 expression is elevated in human GC B cells 
[93].  An important question is why cyclin D2 is not expressed in such highly 
proliferative cells.  One possibility is that in this tissue specific setting, cyclin D2 is 
involved in the regulation of cell growth and not proliferation, which has been established 
in recent studies [51].  Therefore, the GC B cells actively repress cyclin D2 and growth, 
in order to rapidly proliferate [51].  This idea is supported by extensive D3 expression 
studies, which have demonstrated that tissue specific gene profiles for GC B cells favors 
proliferation, not growth.  Lymphocytes are of the few cell types that show D3 expression 
in correlation with proliferation, which provides evidence for cell type-specific utilization 
of D-type cyclins [76,92,94].  
 As noted, D-type cyclins play an important role in growth and proliferation; as a 
result it is not surprising to find that abnormal expression can lead to deregulated growth 
and proliferation thereby becoming the root of several human cancers [87].  In many 
malignancies, overexpression of cyclin D proteins is observed [95].  Understanding the 
normal functions of the D-type cyclins is vital to gain insight into the role that these 
proteins are playing in human malignancies [95].  Studies have shown cyclin D1 is 
overexpressed and rearranged in breast cancer and mantle cell lymphoma, and a subset of 
multiple myeloma [91,95].  In mantle cell lymphoma the translocation involves cyclin D1 
juxtaposed to the Ig heavy chain gene, which results in an overexpression of cyclin D1 in 
lymphoid cells, where typically only cyclins D2 and D3 are expressed [96].  Cyclin D2 is 
overexpressed in wide range of B cell malignancies and cyclin D3 the least studied of the 
three, is expressed in broad range of proliferating cells and is overexpressed in many 
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cancers [76,95].  Recent data suggests that in several hematological malignancies 
(myeloma, plasma cell leukemia, and diffuse large B cell lymphoma (DLBCL)), the 
overexpression of cyclin D3 has a genetic basis because t(6;14)(p21;q32) translocations 
of cyclin D3 and IgH genes have been detected [91]. 
 
V. Cyclin Dependent Kinase Inhibitors (cdki) 
Cdk activity is negatively regulated by two families of inhibitory proteins:  the 
INK4 family and the Cip/Kip family [53].  Cdk inhibitors not only maintain cell cycle 
control necessary for homeostasis, but they also have the potential to induce growth arrest 
and initiate apoptosis in cancer cells.  The integrity of the pRB pathway appears to be 
compromised in most human cancers through an increased activity of the cyclin-cdk 
complexes and highly aggressive lymphomas often acquire alterations in their tumor 
suppressor pathways particularly affecting cdki’s [91].  These inhibitors as they pertain to 
the immune system will be discussed in detail.  
 
A.  The INK4 Family 
The INK4 family is comprised of p15INK4b (p15), p16INK4a (p16), p18INK4c (p18), 
and p19INK4d (p19).  The four INK4 proteins are structurally similar.  They contain pairs 
of anti-parallel α-helices stacked side by side called ankyrin repeats, which are connected 
by a series of hairpin motifs [97].  These structural regions bind the non-catalytic side of 
cdk4/6, which induces an allosteric rotation of 15° between the two lobes of cdk4/6, 
thereby altering the D-type cyclin and ATP binding sites [97].   Signals leading to INK4 
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synthesis are not fully understood.  Studies have revealed that p15 is induced by TGF-β, 
p18/p19 is involved in development and terminal differentiation, and p16 is induced 
during senescence and is also a tumor suppressor [53,96].   
p18 is an essential protein involved in terminal differentiation of mature B cells.  
It is expressed in many tissues and it is required for cell cycle arrest in B cells undergoing 
terminal differentiation into antibody secreting plasma cells [7].  A deficiency of p18 
cannot be compensated by any other cdki, in particular p19, which has a similar 
expression pattern in B cells [11].  Studies demonstrate that p18 binds to cdk6, thereby 
arresting the cells in G1 phase [10].  p18 knock out mice display lymphoproliferative 
disorders with enlarged lymph nodes with hyperplastic germinal centers and expansion of 
plasma cells [97], and p18-/- B cells hyperproliferate in germinal centers never arresting 
in the cell cycle [7].  Cell cycle arrest mediated by p18 is therefore a prerequisite for the 
generation of functional plasma cells. 
My study will focus on p16, which interacts with cdk4 and cdk6, thereby 
disrupting cyclin D and ATP binding, resulting in a block in cell cycle at the R point in 
G1-phase [53].  Of the INK4 family of proteins, only p16 has gained credibility as a 
tumor suppressor gene.  The p16 gene is located in 9p21, which after p53, is the most 
frequently altered locus in human cancer [91].  Without p16 there is an increase in cyclin 
D-cdk4/6 activity followed by an increase in pRb activity, leaving the malignant cell with 
a growth and proliferation advantage [53,96].  Many tumors display an increase in cdk 
activity because of p16 inactivation.  Specifically, p16 appears to play a role in regulating 
proliferation because it is either mutated or deleted in many human tumors of lymphoid 
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origin [98].  Studies in mice have revealed that deletions in p16 and p19 have led to 
spontaneous B cell lymphomas [10,89].  The importance of the interaction between cdk4 
and p16 became apparent with the identification of a mutation in cdk4 in patients with 
familial melanoma [99,100].  This missense mutation results in a mutant cdk4 (R24C) 
protein that loses its affinity for p16 without affecting its ability to bind D-type cyclins 
and form a functional pRb protein kinase, thereby promoting tumor growth [99,100].  
Induced expression of p16 in a tumor cell has been shown to block the binding of cdk4/6 
with D-type cyclins, resulting in G1-arrest [101].  This is under investigation as a 
therapeutic target.  
p15 functions by binding cdk4, thereby preventing D-type cyclin binding or by 
disrupting already bound cyclin D-cdk4 complexes [53,54,56,80].  Studies by Chen-
Kiang and colleagues have revealed that a frequent occurrence in the malignant plasma 
cells of Multiple Myeloma (MM) is inactivation of p15, thereby allowing aberrant 
proliferation [102].  It is proposed that the inactivation of p15 may contribute to MM 
pathogenesis by promoting the expansion of bone marrow myeloma precursors [102].  
Studies have also revealed that mice deficient in p15 demonstrate lymphoproliferative 
disorders, splenic extramedullar hematopoiesis, hyperproliferation in germinal centers, 
and a reduction in serum antibody [89, 97].  Despite the potential role that p15 plays in 
plasma cell malignancies, the physiological role of p15 during terminal B cell 
differentiation remains to be characterized.   
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B. The Cip/Kip Family 
The Cip/Kip protein family is made up of p21Cip1 (p21), p27Kip1 (p27), and p57Kip2 
(p57).  These proteins share a conserved N-terminal region, which mediates cyclin/cdk 
binding, and a non-conserved sequence region, which gives each protein its ability to 
perform different functions [103].  p21 is a downstream transcriptional target of p53 and 
data have shown that it mediates DNA damage induced cell cycle arrest [103].  p57 is 
believed to regulate cell cycle during embryonic development, while p27 is found in 
quiescent cells and is rapidly down regulated when the cells enter G1-phase of the cell 
cycle and begin to proliferate [103].  Loss of Cip/Kip function has not been observed in 
many human cancers.   
My study will characterize, in part, the role of p27 in cell cycle regulation in 
human LY18 cells.  p27 plays two major roles in B cells; first, it is required for assembly 
and nuclear import of D-type cyclins-cdk complexes.  Evidence for a noncatalytic 
function of these complexes is demonstrated in murine fibroblasts lacking p27 and p21 
that failed to assemble cyclin D-cdk complexes [104].  In addition, cyclin D-cdk4 
complexes play an important secondary noncatalytic function by sequestering Cip/Kip 
family members away from cdk2 complexes [53,72,105].  Finally, p27 is able to insert 
into the catalytic cleft of cdk2, thereby preventing the binding of ATP and cyclin E, and 
perturbing the cell cycle [103].   
 In lymphoid tissue, the expression of p27 is inversely related to proliferation.  
p27 expression is high in quiescent cells, whereas in proliferating cells (i.e., germinal 
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centers) it is down regulated [91].  Studies in the immature B cell lymphoma cell line, 
WEHI 231, have identified p27 as a proapoptotic gene [106].  BCR-engagement leads to 
a signaling pathway that results in a decrease in c-Myc levels and an increase in p27 
levels, which promotes apoptosis [106].  In lymphomas, typically the expression of p27 
follows the same inverse relationship with proliferation; however, in some DLBCL a 
wide range of p27 expression often exists; ranging from an absence of p27 protein to an 
overexpression of p27 [91].  There does not seem to be any positive or negative 
correlation between p27 and proliferation in DLBCL. 
Furthermore, studies have demonstrated that p27 deregulation in certain cancers 
leads to poor prognosis [107].  In B-cell Chronic Lymphocytic Leukemia (B-CLL), high 
expression of p27 is associated with an aggressive course and lower spontaneous cell 
death rate of cells in culture [91].  This suggests that p27 may be involved in the 
deregulation of apoptosis and that a mechanism of p27 inactivation other than down-
regulation exists, which allows the tumor cells to overcome the antiproliferative activity 
of this cdki [91].  Restoration of p27 activity and stability may prove to be an effective 
therapy to induce cell cycle arrest in B cell cancers [107]. 
 
VI. B-1 Lymphocytes 
A.  Development and Function 
Two B cell lineages, B-1 cells and conventional splenic B-2 cells (referred to as B 
cells in the earlier text) arise from lymphopoiesis (refer to Figure 1).  Each subset is 
distinguished by numerous phenotypic and functional characteristics.  B-1 cells are 
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distinguished from the more abundant conventional B-2 cells by the expression of the 
pan-T cell surface glycoprotein, CD5 [108].  Additional identifying phenotypic 
characteristics include sIgMhi, sIgDlo, CD43+, Mac1+, CD23-, and B220lo [109,110].  
Peritoneal B-1 cells are further subdivided into CD5+ (B-1a) or CD5- (B-1b) cells.  My 
study will focus on B-1a cells (referred to in the text as B-1).  B-2 cells represent the 
majority of the B cell population and are found primarily in the lymph nodes and spleen.  
B-1 cells are a minor, unique subset of the B cell pool that arises first in ontogeny in the 
fetal omentum and later in the fetal liver and bone marrow, thereby predominating the B-
cell repertoire early in life [1,108].  Concepts regarding the origin of B-1 cells have 
changed over the years.  Early work suggested that B-1 cells exist as a separate lineage, 
distinct from conventional B and T cells [111].  Other studies suggest that there is only 
one B cell lineage, and that B-1 cells are derived by B cell receptor (BCR) signaling 
following interactions between surface Ig and (self-) antigen [112].  More than likely, 
elements of both lineage and differentiation play a role in producing B-1 cells [113].  In 
adult mice, B-1 cells make up the lymphocyte population in the peritoneal cavity and a 
small population in the spleen [114].  B-1 cells are maintained by self-replenishing, 
giving rise to their own progeny, in contrast to B-2 cells, which do not proliferate 
following maturation in the absence of exogenous stimulation.   
B-1 cells are responsible for the majority of non-immune serum IgM and 
contribute substantial amounts of resting IgA [115,116].  The inherent and constitutive 
secretion of immunoglobulin by B-1 cells, in the absense of direct stimulation, 
distinguishes B-1 cells from B-2 cells.  B-1 cell-derived immunoglobulin (Ig) generally 
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adheres more closely to the germline state than B-2 Ig, as a result of diminished somatic 
mutation and reduced length of non-templated N-insertions; thus, they are repertoire 
restricted [117-120].  It has been suggested that B-1 cells play an important role in the 
early immune response against a range of microorganisms by producing a natural 
antibody that provides a low affinity of protection [121-123]. 
B-1 cells are associated with many human disease states characterized by B-cell 
expansion.  They exhibit the inclination for clonal expansion and for malignant 
transformation with age [8,124].  B-1 cells have been implicated in the pathogenesis of 
autoimmunity, because:  a) increased number of B-1 cells are found in patients and 
animals with some autoimmune disorders; b) the elimination of B-1 cells reverses 
autoimmunity in some cases; and, c) B-1 cell Ig displays binding to self antigen [125-
129].  Notably, B-1 cells represent the origin for human chronic lymphocytic leukemia 
(CLL), a B cell malignancy in which the cells express CD5.  Furthermore, studies have 
also demonstrated that in aging mice, monoclonal expansion of B-1 cells resembles CLL 
[130].  
 
B.  Proliferation  
Murine B-1 cells also differ from B-2 cells by the signals necessary to induce 
proliferation.  B-1 cells are self-renewing, whereas B-2 cells arise continually from B cell 
precursors, but fail to proliferate following maturation without an exogenous stimulation. 
This suggests that the regulation of proliferation differs between thse two B cell subsets.   
In ex vivo B-1 cells, BCR signaling fails to induce proliferation but does so in B-2 cells 
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[131,132].  Early studies performed in the Rothstein lab in the late 1980s in collaboration 
with work from the Chiles’ Lab demonstrates that B-1 and B-2 cells differ significantly in 
their response to phorbol esters.  B-1 cells rapidly enter S-phase in response to PMA, 
whereas B-2 cells require a combination of PMA and a calcium ionophore [131,132].  
Thus, in relation to B-2 cells, B-1 cells are hyper-responsive to phorbol esters.  This 
hyper-responsiveness to PMA is further manifested in the rapidity with which S-phase is 
attained; peak thymidine incorporation occurs 24-30 hours after B-1 cells are stimulated 
with PMA, but 54-60 hours after B-2 cells are mitogenically stimulated with PMA plus 
ionomycin [133].  These results, along with the propensity of B-1 cells for self-renewal, 
clonal expansion, and malignant transformation, demonstrate that B-1 cells differ from B-
2 cells in the signaling requirements needed for proliferation and in the molecular 
mechanisms that control Go-S-phase progression.   In further support of this observation, 
PMA-stimulated B-1 cells express cyclins D2 and D3 in a non-overlapping manner 
during G1-phase [65,134].   Specifically, cyclin D2 is rapidly upregulated in early G1-
phase, while cyclin D3 is upregulated after cyclin D2 degradation and peaks in parallel 
with pRb phosphorylation in late G1-phase [134].  In B-2 cells, mitogenic activation leads 
to a coordinate, overlapping induction of both cyclin D2 and D3 [82,134].  Together 
these data suggest that cyclin D3 is uniquely positioned in B-1 cells to play a specific role 
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in mediating the transition from G1-S phase (see Figure 5).  
 
 
VII. Cyclin D/cdk4/pRb Pathway in B Cell Lymphoma 
Understanding the cyclin D/cdk/pRb pathway and the other molecules involved in 
the G1-S phase transition is of particular interest because they are altered in 80% or more 
of human malignancies [97].  Specifically, the genes encoding cdks involved in G1-S 
phase progression are amplified in many DLBCL.  For example, overexpression of cdk4 
and cdk6 has been identified in DLBCL and lymphoid tumors, however the molecular 
studies of cdk4/6 are yet to be analyzed in detail [88,97,135].  The cdk2 gene is often 
overexpressed in many B cell malignancies and its inhibition is a potential target to 
inhibit tumor cell proliferation [136].  High levels of cyclin E have been associated with 
many different human cancers, particularly, breast cancer, leukemia, and Non-Hodgkin’s 
lymphoma [58,137].  Also, transgenic mouse models in which cyclin E is overexpressed 
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develop malignant diseases as a result of accelerated G1-phase of the cell cycle [58,137].  
The role of cyclin E in tumorigenesis has only recently begun to be unfolded.  
It is also important to note that in tumor cells, knockdown of G1-phase proteins 
often results in no phenotype.  The high levels of other proteins may compensate, thereby 
allowing cell cycle progression in malignant cells.  It is possible that particular cyclins 
and cdks have redundant functions and can compensate for the deficiency of a specific 
protein.  For example, studies have revealed that cyclin E has been shown to not only 
overcome a deficiency of other G1-cyclins in yeast, but also does so in higher mammals 
such as mice [58].  In 1999, Geng et al replaced cyclin D1 with cyclin E in a knock-in 
mouse study [138].  Cyclin E was able to rescue all phenotypic manifestations of the 
cyclin D1 deficiency [138].  This compensatory action has also been observed in human 
breast cancer [139].  Furthermore, studies have revealed that cdk2 activity can also be 
dispensable for cancer cell proliferation [140].  High levels of cdk4 activity in these cells 
may compensate for the lack of cdk2 during cell cycle progression [140]. 
 
VIII. Non-Hodgkin’s Lymphoma 
 Non-Hodgkin’s lymphoma (NHL) is a group of heterogeneous 
lymphoproliferative malignancies.  Currently, in the United States, there are an estimated 
66,000 new cases of NHL and 19,000 deaths [141].   There are many different types of 
NHL, which are first classified as B or T cell origin as well as slowing growing or 
aggressive.  My study will focus on B cell origin NHL that accounts for approximately 
85% of NHL in adults [141].   
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 A large part of understanding the biology of a malignant cell is gleaned from its 
non-malignant counterpart-the normal, untransformed cell.  This holds true with B cell 
malignancies.  The malignant cell often resembles a normal B cell during a specific stage 
of B cell differentiation.  B-cell lymphomas retain normal physiologic and phenotypic 
properties of the healthy B cell while also developing pathological abnormalities [142].  
This is a useful tool used in the classification and diagnosis of lymphoma.   
My study will focus on DLBCL, the most common type of NHL in adults, 
accounting for approximately 30-40% of cases [93,142-144].  DLBCL is an aggressive, 
mature B cell malignancy.  Patients typically receive (and can be cured) by anthracycline-
based chemotherapy.  However, the response to treatment is often highly variable.   
 
A.  Diffuse Large B-Cell Lymphoma  
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of lymphomas 
characterized by its diffuse pattern of growth.  It affects people of all ages and typically 
appears as an aggressive, rapidly growing nodal mass often times with extranodal sites 
present [94,142].  The malignant population is made up of large cells with big distinct 
nucleoli and little cytoplasm.   
Gene expression profiling of DLBCL reveals two molecular classifications:  
germinal center (GC)-like and activated DLBCL [93,142,144].  My study will focus on 
GC-like DLBCL, which display a distinct gene expression profile that is preserved in 
normal GC B cells.  There is evidence that suggests most if not all DLBCL’s develop 
within the GC or at a later stage of B cell differentiation [93,142,145].  Furthermore, 
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gene-profiling studies reveal that the rearranged immunoglobulin genes in DLBCL have 
mutations that resemble what is normally found during somatic hypermutation, which 
normally occurs only within GC’s [93,145].  
Often times, the presentation of a malignancy is a result of uncontrolled cell 
proliferation as a result of deregulated apoptosis; however, DLBCL is just the opposite.  
It is observed that the increased proliferation and cell accumulation are a consequence of 
deregulated cell cycle [135].  DLBCL’s commonly display several translocations; 
t(14;18) and t(3;14) juxtapose BCL-2 and BCL-6, respectively with the immunoglobulin 
heavy chain on 14q32 and overexpression of the genes CDK2 in 12q13.3 and CDK4 in 
12q14.1 along the 12q region [146-149]. 
 
B.  OCI-LY18 
My study will focus on the human GC-like DLBCL, OCI-LY18 (LY18).   LY18 
cells were established (1988) in a 56-year-old male, who relapsed with stage IIIB, high-
grade non-Hodgkin’s lymphoma of diffuse large cell immunoblastic type [150].  The cell 
line was established from the patient’s pleural fluid and the cells are characterized as of a 
large size with a high nuclear to cytoplasm ratio and one or more nucleolus [150].  LY18 
cells are further identified based on the immunophenotypic characterization, CD10+, 
CD19+, CD20+, CD21-, CD23-, as well as IgM and light chain λ [150].  The cell line 
carries a three-way translocation involving bands 8q24, 14q32, and 18q21, which lead to 
an alteration of myc-IgH genes [150].  MYC induces proliferation by inducing the genes 
for cell cycle progression, such as cdk4, cyclin D1, D2, and E and it suppresses the 
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inhibitors p15 and p21 [135].  Approximately 6% of DLBCL have c-MYC translocations 
and they are under the control (like the LY18 cells) of the Ig enhancer [135].  The Ig 
enhancers are responsible for the inappropriately high transcription rate of the 
translocated c-myc allele.  The detailed function of c-Myc is not yet completely 
understood, but it is believed to involve the promotion of both cell proliferation and 
apoptosis [151]. The Bcl-2 gene is germline in LY18 cells (it is typically rearranged in 
DLBCL) and the Bcl-6 gene is only moderately expressed with no translocations. 
Of particular interest, I have found that LY18 cells only express cyclin D3.  In 
studying lymphoid malignancies, cyclin D3 has been identified as a potential oncogene 
because it is frequently overexpressed in certain human lymphoid cancer subsets (e.g. B-
CLL) [94,95,152].  In 2002, a study analyzed the clinical significance of cyclin D3 
expression in DLBCL and revealed that increased expression levels of cyclin D3 were at 
advanced stages and had a lower overall survival [152].  Overall, cyclin D3 expression is 
associated with poor clinical outcome in patients with DLBCL [152].  
 
IX. Summary/Aims of Study 
A.  Chapter 1:  The role of cyclin D3 in growth and proliferation in primary peritoneal 
B-1a cells 
In summary, in B-1 cells, but not B-2 cells, stimulated expression of cyclin D2 
and D3 is temporally distinct.  Taken together, these observations suggest that cyclin D3 
is uniquely positioned in B-1 cells to mediate transition through the G1-S boundary, 
which may reflect its role in conventional B-2 cells where cyclin D3 expression overlaps 
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with that of cyclin D2.  To investigate the role of cyclin D3-cdk complexes in G0-S phase 
progression in normal B-1 cells, I used protein transduction technology to specifically 
block assembly and activation of cyclin D3 holoenyzme complexes in normal peritoneal 
B-1 cells.  I also examined the proliferative responses of B-1 cells from cyclin D3-
deficient mice.  
 
B.  Chapter 2:  Cyclin D3-cdk4/6 complexes are dispensable in the growth and survival 
of the human Diffuse Large B-cell Lymphoma, OCI-LY18; evidence for redundancy by 
cyclin E 
Typically, there are two or three D cyclins expressed in overlapping roles in 
normal and malignant cells [76].  Therefore, targeting only one D-type cyclin is not 
useful due to compensation by the remaining cyclins.  LY18 cells express only cyclin D3, 
which out of the D-type cyclins is the least characterized.  This leaves a unique 
opportunity to target cyclin D3-cdk4/6 complexes in LY18 cells and to further elucidate 
the role of cyclin D3 in malignant lymphomas as well as in normal, healthy B cells.  To 
investigate the role of cyclin D3-cdk complexes in G0-S-phase progression in LY18 cells, 
I used protein transduction technology and RNA interference to specifically block 
assembly and activation of cyclin D3 holoenzymes.  The literature and clinical trial 
studies have revealed that small molecule inhibitors of cdk4 may provide a promising 
therapeutic strategy in treatment of human DLBCL’s.  With that in mind I also used a 
small molecular inhibitor to further examine the role of cyclin D3-cdk4/6 in LY18 cells.  
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C.  Chapter 3:  The regulation and function of ATP citrate lyase (ACL) by extrinsic 
signals in splenic B-lymphocytes 
In summary, B-lymphocytes rapidly increase glucose uptake and hyper-induce 
glycolytic flux in response to BCR cross-linking [23,24], and in our most recent findings 
we discovered that IL-4 induces glycolysis in naïve B cells [27].  A high glycolytic rate 
may reflect a requirement to provide sufficient levels of glycolytic intermediates to 
support macromolecular synthesis, associated with B lymphocyte activation.  As 
evidence supports a role for PI-3K/Akt signaling in increased glucose uptake and 
glycolytic flux in B cells [24], it is not understood at this time how BCR signaling 
regulates glucose carbon flow into de novo lipogenesis.  Foremost, I hypothesize that 
glucose-directed de novo lipogenesis in B cells requires a PI-3K-dependent step that 
results in activation of ATP citrate lyase (ACL) via a post-translational mechanism.  With 
this in mind, my studies sought to understand more fully the regulation and biological 
significance of ACL activation as instructed by the BCR and by signaling input from IL-
4.  Furthermore, I will examine the role of PI-3K/Akt signaling pathway in the regulation 
of ACL enzyme activity.  Here I will use specific PI-3K chemical inhibitors as well as PI-
3K deficient-mice. 
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MATERIALS AND METHODS 
  
Reagents and Antibodies 
Anti-cyclin D1 (DCS-6), anti-cyclin D2 (DCS-3.1), and anti-cyclin D3 (DCS-22) 
antibodies (Abs) were purchased from Thermo Fisher Scientific (Fremont, CA).  Anti-β 
actin (AC-15) Ab was purchased from Sigma-Aldrich (St. Louis, MO).  Anti-phospho-
pRbSer807/811 Ab, anti-phospho-cdk2Thr160 Ab, anti-total pRb, anti-phospho-ATP-citrate 
lyaseSer454 Ab, anti-ATP-citrate lyase Ab, and anti-hsp90 Ab were obtained from Cell 
Signaling Technologies (Beverly, MA).  Anti-cdk4 (C-22) Ab, anti-cdk6 (C-21) Ab, anti-
cdk2 (M2) Ab, and anti-p27 (C19) Ab, Protein G agarose, anti-mouse IgG-coupled HRP, 
and anti-mouse cdk4 Ab were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA).  Anti-phospho-pRbThr821 (44-582G) Ab was purchased from Invitrogen Corporation 
(Carlsbad, CA).  Fluorescent-labeled Abs for FACS was obtained from BD Pharmingen 
(San Diego, CA).  Rabbit complement and Lympholyte M were purchased from Accurate 
Chemical and Scientific (Westbury, NY).  All other chemicals were obtained from 
Sigma-Aldrich.  Fluorescent-labeled Abs directed against B220, CD5, CD23, Mac-1, 
CD4, CD8, CD3, and CD14 for FACS and flow cytometric analysis were obtained from 
BD Pharmingen.  Electrochemiluminescence (ECL) reagents were obtained from 
Kirkegaard and Perry Laboratories (Gaithersburg, MD).  F(ab′)2 fragments of goat anti–
mouse IgM were obtained from Jackson ImmunoResearch Labs (West Grove, PA).  
Murine IL-4 was from R&D Systems (Minneapolis, MN).  Phorbol 12-myristate 13-
acetate (PMA) and Lipopolysaccarides (LPS) from Salmonella typhosa (source strain 
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ATCC 10749) were obtained from Sigma-Aldrich and used at 300 ng/ml and 25 µg/ml, 
respectively.  Soluble rCD40L was obtained from transfected J558L cells that secrete a 
chimeric CD40L/CD8α fusion protein and prepared as previously described [153,154].  
Anti-CD8α Ab was obtained from the supernatant of 53-6-72 hybridoma cells and was 
used to cross-link rCD40L [154].  CD40L was used at 1/10 dilution of supernatant and 
anti-CD8α Ab was used at 1/40 dilution of supernatant.  2-Bromo-12,13-dihydro-5H-
indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, (cyclin dependent kinase 4 inhibitor, 
cdk4i), Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), Wortmannin (WT), and 
LY294002 (LY) were obtained from Calbiochem-NovBiochem, Corp. (San Diego, CA).  
siGENOME SMARTpool siRNA was purchased from Thermo Dharmacon Scientific 
(Chicago, IL): p27, cyclin D3, cyclin E, cdk4, cdk6, cdk2, and control (Table 1).  
 
Preparation of Murine B-1a and B-2 Lymphocytes and Cell Culture 
The cyclin D3-deficient mice were obtained from Dr. Piotr Sicinski (Dana-Faber 
Cancer Center, Boston MA; see Cancer Cell 4:451).  p85α−deficient mice 
(BALB/cAnNTac-Pik3r1 N12, back crossed nine times) and BALB/cByj mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME) and housed at Boston 
College.  The studies described below were reviewed and approved by institutional 
animal care and use committees at both institutions.  Mice were cared for and handled at 
all times in accordance with National Institutes of Health and University guidelines.  
Unseparated cells were obtained by peritoneal washout and splenic disruption and stained 
with immunofluorescent Abs directed against B220 and CD5, and were subjected to 
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FACS at 4oC using a Mo-Flo flow cytometer (DakoCytomation, Carpinteria, CA) to yield 
purified peritoneal B-1 (B220+CD5+) and splenic B-2 (B220+CD5-) cells, including the 
use of an anti-CD8 “dump” channel for B cell purification.  Sort-purified B cell 
populations were re-analyzed by immunofluorescent staining with Abs directed against 
CD3 and CD14.  Sort-purified peritoneal B-1a cells and splenic B-2 cells were found to 
be >95% (SEM ± 0.98%) and >96% (SEM ± 0.84%) pure, respectively.  In addition, both 
populations contained less than 1.8% and 1.2% CD3+ or CD14+ cells, respectively.  
Mature B-2 cells were isolated from spleens of mice 8-12 weeks.  T-lymphocytes were 
depleted with anti-Thy-1.2 plus rabbit complement (Accurate Chemical and Scientific), 
macrophages (and other adherent cells) were removed by plastic adherence, and red blood 
cells and nonviable cells were removed by sedimentation on Lympholyte M (Accurate 
Chemical and Scientific).  Small dense B cells were further isolated following 
centrifugation through a discontinuous Percoll gradient as described [24].  B-cells were 
cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), penicillin (100 U/ml), streptomycin (100 µg/ml), 2-mercaptoethanol (50 
µM), and glutamine (2 mM), and incubated at 37 °C in a 5% CO2 atmosphere at 95% 
humidity.  Dr. Raju Chaganti (Memorial Sloan-Kettering Cancer Center, New York, NY) 
kindly provided the human GC-like DLBCL cell line OCI-LY18 (LY18).  The cells were 
maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), penicillin (100 U/ml), streptomycin (100 µg/ml), 2-mercaptoethanol (50 
µM), and glutamine (2 mM) at a cell density of 5 x 105 to 1 x 106 cells/ml (at 37 °C in a 
5% CO2 atmosphere at 95% humidity) [155].  
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TAT Peptides  
TAT-p16 peptides were synthesized by the Biotechnology and Genomics 
Research Center (Utah State University, Logan, UT).  The 32-mer peptides contain an 
NH2-terminal 11 residue TAT protein transduction domain (YGRKKRRQRRR) 
immediately followed by a glycine residue and either a 20-mer wild-type p16 sequence 
(DAAREGFLATLVVLHRAGAR) or a charge-match control sequence 
(ARGRALTAHVDRLGEFVAAL), as described [156,157].  TAT-p27 fusion proteins 
were kindly provided by Dr. Mira Grdisa (Rudjer Boskovic Institute, Zagreb, Croatia)  
[158].  Each fusion protein was coupled to an 11-amino-acid peptide (YGRKKRRQRRR) 
consisting of the NH2-terminal HIV TAT protein transduction domain immediately 
followed by a glycine residue and either a full-length wild-type TAT-p27 fusion protein 
(TAT-p27 WT), a functional truncated N-terminal-TAT-p27 protein (TAT-N’p27), or an 
inactive point mutant-TAT-p27 protein (TAT-ptMut-p27) [159]. 
 
Flow Cytometry 
 For cell cycle phase analysis, B cells (105) were resuspended in 300 µl of PBS 
containing 0.1% (v/v) Triton X-100, 200 µg/ml DNase-free RNase A, and 20 µg/ml 
propidium iodide [108].  B cell fluorescence was then acquired with a BD FACSCanto 
flow cytometer (BD Biosciences).  DNA synthesis was measured by BrdU incorporation 
according to the manufacturer’s instructions (BD Biosciences Pharmingen.  For apoptosis 
measurements, LY18 cells (105) were collected, washed in PBS and then resuspended in 
0.5 ml binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) containing 
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5 µl of FITC-conjugated-Annexin V and 5 µl PI (50 µg/ml).  Cells were incubated at 
room temperature for 15 mins and then analyzed by flow cytometry.  For cell viability 
measurements, 5 x 105 cells were collected by centrifugation at 400 x g for 8 mins, 
washed in FACS buffer (1 x PBS containing 0.5% BSA and 0.01% sodium azide), and 
resuspended in FACS buffer containing 5 µg/ml PI. Samples were incubated on ice for 10 
mins then analyzed by flow cytometry using a BD FACSCanto flow cytometer with BD 
FACS Diva software (BD Biosciences).  Standard deviations for all flow cytometry 
analysis were between 5-10% unless otherwise specified in the figure legends. 
 
Proliferation Assay 
 To measure proliferation, B cells (1-2 x 104 in 0.2 ml) were cultured in 
quadruplicate and stimulated as indicated in the figure legends.  DNA synthesis was 
measured by incubating B cells with 0.5 µCi [3H]thymidine (20 Ci/mmol; New England 
Nuclear, Waltham, MA) during the last 6 hrs of culture.  Cells were then harvested onto 
glass fiber filters and [3H]thymidine incorporation into DNA was quantitated by liquid 
scintillation spectroscopy.   
 
Western Blotting 
LY18 cells and B cells were solubilized in Triton X-100 buffer (20 mM Tris (pH 
7.4), 100 mM NaCl, 0.1% Triton X-100) containing 2.5 µg/ml leupeptin/aprotinin, 10 
mM β-glycerophosphate, 1 mM PMSF, 1 mM NaF, and 1 mM Na3VO4.  Insoluble debris 
was removed by centrifugation at 15,000 x g for 15 mins (4°C).  Lysate protein was 
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separated by electrophoresis through a 7.5%, 10%, or 12% polyacrylamide SDS gel 
(SDS-PAGE) and transferred to an Immobilon-P membrane.  The membrane was blocked 
in TBS-T (20 mM Tris (pH 7.6), 137 mM NaCl, and 0.05% Tween 20) containing 5% 
nonfat dry milk for 60 mins and then incubated overnight (4°C) with primary Ab at 1 
µg/ml in TBS-T. The membrane was washed several times in TBS-T, incubated with a 
1/2,500 dilution of anti-rabbit or anti-mouse IgG-coupled HRP Ab (60 mins) and 
developed by ECL.  Autoradiograms were scanned with Adobe Photoshop 7.0 (Adobe 
Systems, Inc., San Jose, CA) and the mean density of each band was analyzed by the 
ImageJ program (NIH, Bethesda, MD). 
 
Fluorescence Microscopy 
B cells were centrifuged at 600 x g for 10 mins onto glass slides by Cytospin.  For 
imaging D-type cyclins, lymphocytes (2.5 x 105) were fixed with methanol for 10 mins at 
-20oC and then permeabilized with 0.1% Triton X-100 at room temperature.  Cells were 
blocked for 30 mins with 2% BSA in PBS and then washed several times with PBS.  
Detection of cyclin D2 and cyclin D3 was performed by incubating cells with 1:50 anti-
cyclin D2 or anti-cyclin D3 mAbs at 4oC, respectively.  After several washes with PBS, 
cells were incubated with a 1:200 FITC-conjugated Affinipure goat anti-mouse Ab 
(Jackson ImmunoResearch Laboratories, West Grove, PA) for 2 hrs at room temperature.  
The slides were then dried, mounted with Aqua Polymount, and immunofluorescence 
images were captured with a Leica confocal microscope.  
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Nucleofection 
LY18 cells were transfected using the Amaxa nucleofection technology™ 
(Amaxa, Koeln, Germany).  Cells were resuspended in solution V from nucleofector kit 
V, following the Amaxa guidelines for cell line transfection.  Briefly, 2×106 
cells/condition were centrifuged at 90 x g at room temperature for ten minutes.  LY18 
cells were then resuspended in 100 µl of pre-warmed solution V and mixed with 200, 
300, or 400 pmol of siRNA.  The LY18 cell suspension was transferred into the provided 
cuvette and nucleofected with an Amaxa Nucleofector (Amaxa).  LY18 cells were 
transfected using the X-001 pulsing parameter and were immediately transferred into 
wells containing 37 °C, pre-warmed culture medium (Optimem supplemented with 10% 
FCS) in a 6-well plate.  After transfection, cells were cultured from 2 to 48 hrs and 
analyzed by flow cytometry using a BD FACSCanto flow cytometer with BD FACS 
Diva software (BD Biosciences).  
 
Lipid Isolation, Purification, and Quantification 
Total lipids were isolated and purified from lyophilized B-lymphocytes by using 
modifications of previously described procedures [160,161].  B cells (6 x106) were 
stimulated as specified in the figure legends.  At several time points the cultures were 
pulsed for 3 hrs with 6 µCi/ml D-[6-14C] glucose (New England Nuclear).  B cells were 
collected and total lipids extracted in chloroform: methanol (1:1 v/v); the neutral and 
acidic lipids were then separated form the total lipids by using DEAE-Sephadex (A-25; 
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Pharmacia Biotech, Upsala, Sweden) column chromatography as previously described 
[162-164].  The total lipid extract, suspended in solvent A (CHCl3:CH3OH:H2O, 30:60:8 
by vol), was then applied to a DEAE-Sephadex column (1.2 ml bed volume) that had 
been equilibrated with solvent A.  The column was washed twice with 20 ml of solvent 
A, and the entire neutral lipid fraction, consisting of the initial eluent plus washes, was 
collected.  This fraction contained cholesterol, phosphatidylcholine, 
phosphatidylethanolamine, ceramide, sphingomyelin, and cerebrosides.  The acidic lipids 
were then eluted from the column with 30 ml of solvent B (CHCl3:CH3OH:0.8 M Na 
acetate, 30:60:8 by vol).  This fraction contained the gangliosides and other less 
hydrophilic acidic lipids, including free fatty acids, cardiolipin, phosphatidylserine, 
phosphatidylinositol, phosphatidic acid, and sulfatides.  Folch partitioning will remove 
any unincorporated glucose and the gangliosides from the neutral and acidic fractions, 
respectively [165].  The concentration of neutral and acidic lipids will be determined by 
scintillation counting using 1219 Rackbeta Counter (LKB Wallac).   
 
High-Performance Thin-Layer Chromatography 
All lipids were analyzed qualitatively by high-performance thin-layer 
chromatography (HPTLC) according to previously described methods [160-162,164].  
Lipids were spotted on 10 × 20 cm Silica gel 60 HPTLC plates (E. Merck, Darmstadt, 
Germany) using a Camag Linomat V auto-TLC spotter (Camag Scientific Inc., 
Wilmington, NC).  For the analysis of neutral lipids, 4000 dpm were spotted per lane.  To 
enhance precision, an internal standard (oleoyl alcohol) was added to the neutral and 
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acidic lipid standards and samples as previously described [162,164].  Purified lipid 
standards were purchased from Matreya Inc. (Pleasant Gap, PA, USA) or Sigma (St. 
Louis, MO, USA) or were a gift from Dr. Robert Yu (Medical College of Georgia, 
Augusta, GA, USA).  For neutral phospholipids, the plates were developed to a height of 
either 4.5 cm, respectively, with chloroform:methanol:acetic acid:formic acid:water 
(35:15:6:2:1 by vol), then developed to the top with hexanes:diisopropyl ether:acetic acid 
(65:35:2 by vol) as previously described [162,163].  Neutral and acidic lipids were 
visualized by charring with 3% cupric acetate in 8% phosphoric acid solution, followed 
by heating in an oven at 160-170°C for 7 mins.  The percentage distribution of the 
individual radiolabeled lipid bands was determined by scanning the plates using a 
Bioscan imaging system as previously described [166].  These experiments were carried 
out in collaboration with Dr. Thomas Seyfried, Department of Biology, Boston College.   
 
ATP Citrate Lyase (ACL) Enzyme Activity 
 ACL activity was measured via the malate dehydrogenase coupled method [167].  
B cells (8 x106) were stimulated as specified in the figure legends and solubilized in 
RIPA buffer (25 mM Tris (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS) containing 2.5 µg/ml leupeptin/aprotinin, 10 mM β-glycerophosphate, 1 mM 
PMSF, 1 mM NaF, and 1 mM Na3VO4.  Insoluble debris was removed by centrifugation 
at 15,000 x g for 15 mins (4°C).  Whole cell lysates were added at a 1:19 ratio to the 
reaction mixture containing 100 mM Tris-HCL (pH 8.7), 20 mM potassium citrate, 10 
mM MgCl2, 10 mM DTT, 0.5 U/ml malate dehydrogenase, 0.33 mM CoASH, 0.14 mM 
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NADH, and 5 mM ATP (all from Sigma).  Change in absorbance at 340 nm was read 
every 30 secs over 12 mins on a spectrophotometer.  Change in absorbance in the absence 
of exogenous ATP was subtracted from change in absorbance in the presence of ATP.   
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            Chapter 1:  The role of cyclin D3 in the proliferation of primary peritoneal 
B-1a cells 
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RESULTS 
 
TAT-p16 peptidyl mimetics disrupt endogenous D-type cyclin-cdk4/6 complexes in ex 
vivo peritoneal B-1a cells 
 Lane and coworkers [156] established that a 20-mer peptide composed of the third 
ankyrin repeat of the p16INK4a tumor suppressor protein specifically bound to cdk4 and 
cdk6 and blocked cdk4/6 mediated pRb phosphorylation.  With this technology available, 
our approach for studying the role of cyclin D3-cdk4/6 complexes in B-1a cell 
proliferation was to precisely target cyclin D3-cdk4/6 complexes by transducing p16INK4a 
peptidyl mimetics into ex vivo cells.  For efficient transduction the p16INK4a peptidyl 
mimetic was coupled to an 11-mer peptide consisting of the NH2-terminal HIV TAT 
protein domain (denoted as TAT-p16 wild type) [157].  Flow cytometry and confocal 
microscopy revealed transduction of nearly 100% of B-1a cells that had been incubated 
with the TAT-p16-FITC peptide [124].   
 To validate peptide efficiency ex vivo, PMA-stimulated B-1a cells, which express 
cyclin D3-cdk4 complexes as demonstrated by immunoreactive cyclin D3 in 
nondenatured anti-cdk4 immunoprecipitates, were transduced with 10 µM TAT-p16 
wild-type peptides (Figure 1A, Control) [80].  B-1a cells were transduced with TAT-p16 
wild-type peptide at 14 hours after PMA-stimulation, before cyclin D3 induction, 
prevented cyclin D3-cdk4 complex formation (Figure 1A, p16 WT).  The control 
(charge-matched) TAT-p16 (TAT-p16 mutant) peptide, that cannot bind cdk4 or cdk6, 
did not effect cyclin D3-cdk4 complex formation (Figure 1A, p16 Mut).  When 
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evaluating the effects of TAT-p16 peptides on cyclin D3-cdk6 complexes similar results 
were observed (data not shown).  To further evaluate the efficiency of TAT-p16 peptides, 
asynchronously growing murine Bal17 B cells were analyzed.  Bal17 B cells 
constitutively express assembled cyclin D2-cdk4 complexes (Figure 1B, Control).  TAT-
p16 wild-type peptide disrupted cyclin D2-cdk4 complexes in Bal17 B cells and TAT-
p16 mutant peptide had no measurable effect (Figure 1B).  To be sure that transduction of 
TAT-p16 peptides is specific for cyclin D3-cdk4/6 complexes, we measured cdk-
activating kinase-mediated Thr160 phosphorylation on cdk2.  This phosphorylation event 
serves as an indicator for the presence of cyclin E-cdk2 complexes in the nucleus.  PMA-
stimulated B-1a cells transduced with TAT-p16 wild-type peptide, before cyclin E-cdk2 
assembly did not effect Thr160 phosphorylation of cdk2 (Figure 1C, PMA).  B-1a cells 
that were not stimulated with PMA did not express active cyclin E-cdk2 complex 
assembly (Figure 1C, M).  
 
 Transduction of TAT-p16 wild-type peptide into normal peritoneal B-1a cells 
inhibits proliferation 
 Cyclin D2 and cyclin D3 expression in PMA-stimulated B-1a cells does not 
overlap [80, 134].  As a result we were able to directly evaluate the contribution of cyclin 
D3-cdk4/6 holoenzymes in B-1a cell proliferation, by blocking the assembly of 
temporally expressed cyclin D3-cdk4/6 complexes, with transduction of the TAT-p16 
wild-type peptide into B-1a cells at 14 hours after stimulation with PMA.  The 14-hour 
time window was chosen because it is when cyclin D2 protein is undetectable and cyclin 
 46 
D3 protein is not induced until 17 hours post PMA-stimulation.  B cell activation was 
also achieved by stimulation with lipopolysaccaride (LPS) or CD40L.  LPS is a major 
component of the cell wall on gram-negative bacteria, which induces polyclonal B cell 
activation (T cell independent) regardless of BCR antigen specificity [168].  CD40L is a 
T cell membrane protein, which binds the CD40 receptor on B cells and stimulates (T cell 
dependent) B cell division [168].  PMA-, LPS-, and CD40L-stimulated B-1a cells treated 
with TAT-p16 wild-type peptide exhibited a greater than 70% reduction in tritiated 
thymidine incorporation in comparison to control and TAT-p16 mutant peptide treated B-
1a cells (Figure 2A).  Nonstimulated B-1a cells incubated with TAT-p16 peptides did not 
have any effect on the base-line tritiated thymidine incorporation (Figure 2A, Media).  To 
support these data, we also analyzed the cell cycle positions of B-1a cells by propidium 
iodide staining and flow cytometry.  The percentage of PMA-stimulated B-1a cells 
treated with TAT-p16 wild-type peptide in S+G2/M phase of the cell cycle was reduced 
by 70% in comparison to B-1a cells transduced with TAT-p16 mutant peptide (Figure 
2B, PMA).  Similar results were obtained with LPS- or CD40L-stimulated B-1a cells 
(Figure 2B, LPS, CD40L).  TAT-p16 mutant peptide transduced into PMA-stimulated B-
1a cells had a minimal effect on the percentage of cells in S+G2/M-phase of the cell cycle 
in comparison to control B-1a cells (Figure 2B, PMA).  Similar results were obtained 
with LPS- or CD40L-stimulated B-1a cells (Figure 2B, LPS, CD40L). 
 D-type cyclin-cdk4/6 complexes directly phosphorylate pRb on Ser807/811.  To 
establish endogenous pRb phosphorylation levels in B-1a cells treated with TAT-p16 
wild-type peptide, whole cell extracts were prepared and immunoblotted with anti-
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phospho-pRbSer807/811 Ab.  B-1a cells that were not stimulated and therefore not 
proliferating, did not express measurable pRb phosphorylation (Figure 3, M).  PMA-
stimulated B-1a cells demonstrated abundant endogenous phospho-pRbSer807/811 (Figure 3, 
PMA).  Endogenous phospho-pRbSer807/811 was measurably inhibited in B-1a cells treated 
with TAT-p16 wild-type peptide, but not TAT-p16 mutant peptide (Figure 3, p16 WT, 
p16 Mut).  Total protein levels of pRb were not affected by treatment of TAT-p16 
peptides (Figure 3, pRb).  These data demonstrate that in PMA-stimulated B-1a cells, 
TAT-p16 wild-type peptide inhibits phosphorylation of pRb on the D-type cyclin-cdk4/6 
specific Ser807/811 site.   
 
Cyclin D3-deficient mice have normal peripheral B-1 and B-2 lymphocyte 
compartments 
 The results above demonstrate that PMA-stimulated B-1a cells require cyclin D3-
cdk4/6 complexes for proliferation.  Given these data, we were interested in 
understanding whether B-1a cell development and proliferation were affected by loss of 
cyclin D3 [95].  The cyclin D3-deficient mice were a generous gift of our collaborator, 
Dr. Peter Sicinski (Dana-Farber Cancer Institute, Boston, MA).  These mice are viable 
and exhibit a normal life span, however, the impact of cyclin D3 loss on proliferation and 
function of the peritoneal B-1 cells has not been examined.  Thus, cyclin D3-deficient 
mice offer a unique model to test our hypothesis in non-manipulated ex vivo B-1a cells.  
First, we analyzed the splenic and peritoneal lymphoid compartments to confirm that 
cyclin D3 was absent in cyclin D3-deficient mice.  Total murine splenocytes were 
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isolated and stimulated to induce the expression of cyclin D2 and cyclin D3 in B- and T-
lymphocytes [80,82,86].  Splenic cells of wild-type mice express both cyclin D2 and 
cyclin D3, whereas in cyclin D3-deficient lymphocytes only cyclin D2 expression was 
induced and not cyclin D3 (Figure 4, S).  The total number of lymphocytes was decreased 
in cyclin D3-deficient spleens as compared with wild-type littermate spleens (Figure 5A).  
Immunofluorescent staining revealed that this was a result of a decrease in the number of 
B-2 cells in cyclin D3 deficient spleens (Figure 5B, B-2S).  On the other hand there was 
no difference between wild-type littermates and cyclin D3-deficient mice in the total 
number of peritoneal cells, and, more specifically, the number of B-1a cells (B-1aP; 
CD5+B220lowMac-1+), B-1b cells (B-1bP; CD5-B220lowMac-1+), B-2 cells (B-2P; 
B220+CD23+), T cells (T-P; B220-CD5+Mac-1-), and macrophages (M0-P; forward 
scatter high, Mac-1+), recovered by peritoneal washout (Figure 5A and 5C).  Thus, by 
several measures, the development and function of cyclin D3-deficient peritoneal B-1a 
cells appears unaltered. 
 We next evaluated the role of cyclin D3 in peritoneal B-1a proliferation induced 
by PMA.  In contrast to the results obtained when cyclin D3-cdk4/6 complex assembly 
was prevented by transduction of TAT-p16 wild-type peptide into normal B-1a cells, we 
found that cyclin D3-deficient B-1a cells responded comparably to wild-type B cells 
stimulated with PMA (Figure 6).  In addition, the proliferation of cyclin D3-deficient B-
1a cells in response to LPS was similar to wild-type B-1a cells (Figure 6).  In data not 
shown, similar results were obtained with B-1a cell populations stimulated with CD40L.    
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Deregulation of cyclin D2 expression in cyclin D3-deficient B-1a cells 
 At 4 hours, PMA-stimulated cyclin D3-deficient B-1a cells expressed endogenous 
cyclin D2 protein levels that measured approximately 4.5-fold (based on scanning 
densitometry of the ECL exposed film obtained after Western blot of B-1a lysates) 
greater than that of parallel PMA-stimulated B-1a cells from control wild-type mice 
(Figure 7A).   
 Indirect immunofluorescence microscopy of endogenous expression of cyclin D2 
protein was analyzed in cyclin D3-deficient B-1a cells to further provide evidence that 
cyclin D2 may act to compensate for the loss of cyclin D3.  As expected, nonstimulated 
B-1a cells did not express detectable cyclin D2 or cyclin D3 (Figure 8, M); the weak 
fluorescence signal detected in non-stimulated B-1a cells was similar in intensity to that 
of parallel B-1a cells stained with a control isotype mAb (data not shown).  PMA-
stimulated wild-type B-1a cells expressed cyclin D2 and cyclin D3, at 4 and 21 hours, 
respectively, in a non-overlapping manner (Figure 8).  In contrast, immunofluorescent 
staining of cyclin D2 in cyclin D3-deficient B-1a cells revealed that cyclin D2 was 
expressed at both 4 and 21 hours post-PMA stimulation (Figure 8).  These results suggest 
that in PMA-stimulated cyclin D3-deficient B-1a cells, cyclin D2 remains elevated 
throughout the G0/S-phase interval, where as in wild-type B-1a cells, cyclin D2 protein is 
induced in a rapid and transient manner.   
 To assess whether or not cyclin D2 protein was functional in cyclin D3-deficient 
B-1a cells, we measured the levels of endogenous pRb phosphorylation on cyclin D-
cdk4/6-targeted residues, detected by Western blotting (Figure 7B).  At 21 hours 
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following PMA stimulation, cyclin D3-deficient B-1a cell lysates expressed levels of pRb 
phosphorylation comparable to wild-type B-1a cells stimulated with PMA (Figure 7B).  It 
is important to note that cyclin D1 was not expressed in PMA stimulated cyclin D3-
deficient B-1a cells (data not shown).  Further evidence that PMA-induced proliferation 
of B-1a cells in the absence of cyclin D3 may result from compensation by cyclin D2 was 
obtained by transduction of TAT-p16 wild-type peptide into cyclin D3-deficient B-1a 
cells, wherein only cyclin D2 expression is detectable.  TAT-p16 wild-type peptide 
treated B-1a cells resulted in an ~80% reduction of PMA-stimulated tritiated thymidine 
incorporation compared to control and TAT-p16 mutant transduced B-1a cells (Figure 9), 
suggesting that cyclin D2 protein is functional in the absence of cyclin D3. 
 
Turnover of endogenous cyclin D2 and cyclin D3 protein expression levels in PMA 
treated B-1a cells 
 The induction of D-type cyclins by mitogens is controlled, in part, through de 
novo transcription and increased translation, whereas, D-type cyclin turnover is 
controlled via ubiquitin-mediated proteasome degradation [74,60]; however, our 
knowledge of these events is limited.  To begin to understand the molecular mechanisms 
underlying the sustained expression of cyclin D2 in cyclin D3-deficient B-1a cells, we 
examined the protein turnover of cyclin D2 and cyclin D3 in PMA-stimulated B-1a cells.  
To determine the turnover of cyclin D2 and cyclin D3, we measured the levels of 
endogenous cyclin D2 and cyclin D3 in PMA-stimulated B-1a cells in the presence of 
cycloheximide a protein synthesis inhibitor.  Endogenous cyclin D2 expression, induced 
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by PMA, turned over within 40 minutes of cycloheximide treatment, as detected by 
Western Blotting (Figure 10A).  Similar results were observed with the expression of 
endogenous cyclin D3 in PMA-stimulated B-1a cells treated with cycloheximide, 
however, cyclin D3 turned over after 120 minutes (Figure 10B).  Proteins are targeted for 
degradation by ubiquitination and the proteosome pathway, which can be blocked with 
MG132, a specific proteasome inhibitor.  Pretreatment of PMA-stimulated B-1a cells 
with MG132 followed by cycloheximide inhibited the turnover of cyclin D2 (Figure 
10A).  Similar results were observed with cyclin D3 in PMA-stimulated B-1a cells 
pretreated with MG132 followed by cycloheximide (data not shown).  These results 
confirm that D-type cyclin turnover is controlled via ubiquitin-mediated proteasome 
degradation in PMA-stimulated B-1a cells, however it appears that the rate of cyclin D2 
and cyclin D3 turnover may be different. 
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FIGURES AND LEGENDS 
 
 
 
 
Figure 1.  TAT-p16 wild-type peptide blocks formation of cyclin D3-cdk4 complexes 
in B-1a cells.  A, Peritoneal B-1a cells were stimulated with 300 ng/ml PMA to induce 
the expression of cyclin D3 and assembly of cyclin D3-cdk4 complexes (Control).  In 
parallel sets of B-1a cells, 10 µM TAT-p16 wild-type (p16 WT), or TAT-p16 mutant 
(p16 Mut) peptides were added at 14 hrs after PMA, before cyclin D3 induction.  At 20 
hrs, B-1a cells were collected and immunoprecipitated (IP) with 1.5 µg of anti-cdk4 Ab 
as described [134].  The immune complexes were separated by SDS-PAGE and Western 
blotted with anti-cyclin D3 Ab.  The blot was also probed with anti-cdk4 Ab to ensure 
that equal amounts of cdk4 were immunprecipitated.  B, Asynchronously growing Bal17 
B cells were similarly treated with the TAT-p16 peptides for 4 hrs; B cells were then 
collected, immunoprecipitated (IP) with 1.5 µg of anti-cyclin D2 Ab, and the immune 
complexes were analyzed by Western blot with anti-cdk4 Ab.  The blot was also probed 
with anti-cyclin D2 Ab to ensure that equal amounts of cyclin D2 were 
immunoprecipitated.  C, B-1a cells were cultured in media alone (M) or stimulated with 
300 ng/ml PMA for 24 hrs to induce cyclin E-cdk2 assembly.  Where indicated, 10 µM 
TAT-p16 wild-type (p16 WT) or TAT-p16 mutant (p16 Mut) peptides were added during 
the last 4 hrs of PMA treatment.  Phosphorylation of cdk2 on Thr160 was detected by 
Western blotting with an anti-phospho cdk2Thr160 Ab.  The blot was stripped and reprobed 
with an anti-β-actin Ab.  The data are representative of two independent experiments.  
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Figure 2.  TAT-p16 wild-type peptide inhibits DNA synthesis in B-1a cells in 
response to PMA, LPS, or CD40L.  B-1a cells were cultured in media alone, 300 ng/ml 
PMA, 25 µg/ml LPS, or CD40L for 24 hrs.  Where indicated, 10 µM TAT-p16 wild-type 
(WT) or TAT-p16 mutant (Mut) peptides were added at 14 hrs postmitogen addition.  
Control (C) denotes B-1a cells cultured in the absence of added peptides.  A, DNA 
synthesis was monitored by tritiated thymidine incorporation.  Mean results are shown, 
along with lines indicating standard errors of the means (n = 4).  B, For cell cycle 
analysis, B-1a cells were stained with propidium iodide and 10,000 cells were analyzed 
by flow cytometry as described in Materials and Methods.  The data are represented as 
the percentage of B-1a cells in the S+G2/M-phase of the cell cycle.  The data are 
representative of three independent experiments.   
[3 H
]th
ym
id
in
e,
 c
pm
/1
04
 c
el
ls
LPS CD40L
Figure 2
B.
%
S
 +
 G
2/M
 p
ha
se
 c
el
ls
Media PMA LPS CD40L
A.
[3 H
]th
ym
id
in
e,
 c
pm
/1
04
 c
el
ls
  Media  PMA
55
 56 
Figure 3.  TAT-p16 wild-type peptide inhibits pRbSer807/811 phosphorylation in B-1a 
cells in response to PMA.  B-1a cells were cultured in media alone (M) or stimulated 
with 300 ng/ml PMA in the absence or presence of 10 µM TAT-p16 wild-type (WT) or 
TAT-p16 mutant (Mut) peptides.  Whole cell extracts were prepared, and Western 
blotting was performed with an anti-phospho-pRbSer807/811 Ab.  The blot was stripped and 
reprobed with anti-pRb Ab.  
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Figure 4.  D-type cyclin expression in B-1a cells in wild-type and cyclin D3-deficient 
mice.  Total splenic lymphocytes were isolated from wild-type (+/+) and cyclin D3-
deficient mice (-/-) and were either left untreated (M) or were stimulated (S) with a 
mitogenic combination consisting of 300 ng/ml PMA plus 400 ng/ml ionomycin and 25 
µg/ml LPS.  At 24 hrs, lymphocytes were collected, detergent extracts were prepared, and 
then Western blotting was performed with anti-cyclin D2 or anti-cyclin D3 Abs.  The blot 
was stripped and reprobed with an anti-β-actin Ab to verify equal loading of each lane.  
Figure 4
cyclin D3
cyclin D2
   M        S       M        S
+/+             -/-
β−actin
59
 60 
Figure 5.  Initial characterization of B-1a cell lymphoid compartments in wild-type 
and cyclin D3-deficient mice.  A, Peritoneal washout (peritoneum) and spleen cell 
suspensions (spleen) were obtained from cyclin D3-deficient mice (-/-) and wild-type 
littermate control animals (+/+), and total cell numbers were determined.  Mean results 
are shown, along with lines indicating SEs of the mean (n = 6).  B, Spleen cell 
suspensions were obtained from cyclin D3-deficient mice (-/-) and littermate control mice 
(+/+).  The distribution of splenic T cells (T-S; B220-CD5+), B-2 cells (B-2S;  
B220+CD5-), and MZ cells (MZ-S; CD21highCD23low) was determined by 
immunofluorescent staining and flow cytometric analysis and converted to cell number 
based on initial cell counts.  Mean numbers of cells in each lymphoid population are 
shown, along with lines indicating standard errors of the means (n = 6 except for MZ-S 
where n = 2 and the line depicts the range of values).  C, Peritoneal washout cells were 
obtained from cyclin D3-deficient (-/-) and littermate control mice (+/+).  The 
distribution of peritoneal B-1a cells (B-1aP; B220lowCD5+Mac-1+), B-1b cells (B-1bP; 
B220lowCD5-Mac-1+), B-2 cells (B-2P; B220+CD23+), T cells (T-P; B220-CD5+Mac-1-), 
and macrophages (M0-P; forward and side scatter high, Mac-1+) was determined by 
immunofluorescent staining and flow cytometric analysis and converted to cell number 
based on initial cell counts.  Mean numbers of cells in each lymphoid population are 
shown, along with lines indicating standard errors of the means (n = 6).  Experiments 
were performed in collaboration with Dr. Joseph Tumang, Ph.D., The Feinstein Institute 
for Medical Research (Manhasset, NY).  
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Figure 6.  DNA synthesis in B-1a cells in cyclin D3-deficient mice.  B-1a cells from 
wild-type (WT) or cyclin D3-deficient (KO) were cultured in media alone (inset) or 
stimulated with 300 ng/ml PMA or 25 µg/ml LPS for the times indicated.  Incorporation 
of tritiated thymidine was assessed for the final 6 hrs of culture as described in Materials 
and Methods.  Results represent mean values of triplicate cultures with lines indicating 
standard errors of the means.  The data are representative of three independent 
experiments. 
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Figure 7. Expression of cyclin D2 is elevated in PMA stimulated cyclin D3-deficient 
B-1a cells.  A, B-1a cells were isolated from wild type (+/+) and cyclin D3-deficient mice 
(-/-) and cultured in media alone (M) or stimulated with 300 ng/ml PMA (P) for 4 hrs. 
Whole cell extracts were prepared and Western blotting was performed with anti-cyclin 
D2 Ab. The blot was stripped and re-probed with anti-β-actin Ab.  B, Parallel B-1a cells 
were cultured in media alone (M) or stimulated with 300 ng/ml PMA (P) for 21 hrs and 
then Western blotted with anti-phospho-pRbSer807/811 Ab.  
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Figure 8. Cyclin D2 compensates for the loss of cyclin D3 in PMA stimulated cyclin 
D3-deficient B-1a cells.  B-1a cells from wild-type (cyclin D3+/+) and cyclin D3-
deficient (cyclin D3-/-) mice were cultured in media alone (M) or stimulated with 300 
ng/ml PMA for 4 and 21 hrs.  B-1a cells were collected and prepared for indirect 
immunofluorescence staining of cyclin D2 and cyclin D3 as described in the Materials 
and Methods.  The data are representative of two independent experiments. 
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Figure 9. TAT-p16 wild-type peptide inhibits DNA synthesis in PMA stimulated 
cyclin D3-deficient B-1a cells.  Cyclin D3-deficient B-1a cells were cultured in media 
alone or stimulated with 300 ng/ml PMA for 24 hrs.  Where indicated, 10 µM TAT-p16 
wild-type (WT) or TAT-p16 mutant (Mut) peptides were added together with PMA.  C 
denotes control B-1a cells cultured in the absence of added peptide.  DNA synthesis was 
monitored by tritiated thymidine incorporation.  Results represent mean values of 
triplicate cultures with lines indicating standard errors of the means.  The data are 
representative of two independent experiments.  
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Figure 10.  Cycloheximide decreases endogenous cyclin D2 and cyclin D3 in PMA 
treated B-1a.  A, B-1a cells stimulated with 300 ng/ml PMA.  At 3.5 hrs, cells were 
incubated with 10 µg/ml cycloheximide in the presence or absence of 25 µM MG132.  
Whole cell extracts were prepared, and Western blotting was performed with an anti-
cyclin D2 Ab.  The blot was stripped and reprobed with anti-actin Ab.  B, B-1a cells were 
stimulated with 300 ng/ml PMA.  At 21 hrs, cells were incubated in the presence or 
absence of 10 µg/ml cycloheximide.  Whole cell extracts were prepared, and Western 
blotting was performed with an anti-cyclin D3 Ab.  The blot was stripped and reprobed 
with anti-actin Ab to verify equal loading of each lane. 
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  Chapter 2:  Cyclin D3-cdk4/6 complexes are dispensable in the growth and 
survival of the human Diffuse Large B-cell Lymphoma, OCI-LY18; evidence for 
redundancy by cyclin E 
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RESULTS 
 
Human LY18 cells uniquely express cyclin D3 
DLBCL are described as having an increase in cell proliferation and accumulation 
as a consequence of deregulated cell cycle [135].  To begin to evaluate the regulation of 
proliferation in human LY18 cells we examined endogenous protein expression of the 
relevant G1-phase proteins in asynchronously growing LY18 cells.  LY18 cells 
constitutively express cdk4, cdk6, cdk2, phospho-pRbThr821, phospho-pRbSer807/811, and 
pRb (Figure 11).  It is important to note that phosphorylation on Ser807/811 and Thr821 of 
pRb indicates the specific target residues of D-type cyclin-cdk4/6 and cyclin E-cdk2 
kinase activity, respectively.  Interestingly, LY18 cells did not express p27 (Figure 11) or 
any other cdk-inhibitors (i.e., p21 or p16) (data not shown).  Typically, normal and 
malignant B cells express more than one D-type cyclin in an overlapping manner [76], 
however, unique to LY18 cells they only constitutively express cyclin D3, and not cyclin 
D1 or D2 (Figure 11).  As positive controls (where indicated), asynchronously growing 
human HeLa cells and murine A20 lymphoma cells were analyzed.  HeLa cells 
constitutively express cyclin D1, while A20 cells constitutively express cyclin D2, cyclin 
D3, and p27 (Figure 11).  Further analysis revealed that constitutively expressed cyclin 
D3 forms complexes with cdk4 in proliferating LY18 cells, as demonstrated by 
immunoreactive cdk4 in nondenatured anti-cyclin D3 immunoprecipitates isolated from 
exponentially growing LY18 cells as detected by Western blotting (Figure 12, Media).  
By contrast, LY18 cells did not form cyclin D3-cdk4 complexes in nondenatured 
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immunoprecipitates lacking anti-cyclin D3 as evidence by immunoreactive cdk4 (Figure 
12, Control).  Similar results were observed by immunoreactive cdk6 in nondenatured 
anti-cyclin D3 immunoprecipitates in proliferating LY18 cells (data not shown).  
Collectively, these results demonstrate the relatively high protein expression levels of the 
G1-phase proteins, particularly cyclin D3.  Also, cyclin D3, the only D-type cyclin 
expressed in LY18 cells, forms active complexes with cdk4/6. 
 
Transduction of TAT-p16 wild-type peptide into LY18 cells inhibits proliferation 
resulting in apoptosis 
 We sought to directly evaluate the contribution of cyclin D3-cdk4/6 complexes in 
LY18 cell proliferation.  Since endogenous cyclin D3 is expressed in human LY18 cells 
and its expression does not overlap with cyclin D1 or cyclin D2, we were able to directly 
evaluate the contribution of cyclin D3-cdk4/6 complexes in LY18 cell cycle progression.   
Our strategy to assess the role of these holoenzymes in LY18 cells was to precisely target 
cyclin D3-cdk4/6 complexes by transducing p16INK4a peptidyl mimetics (TAT-p16 wild-
type peptide) into proliferating LY18 cells.  We first analyzed cell cycle progression in 
LY18 cells by propidium iodide staining and flow cytometry.  Transduction of TAT-p16 
mutant peptide into LY18 cells had a minimal effect on the percentage of LY18 cells in 
sub-G0/G1-phase of cell cycle in comparison to untreated (M) LY18 cells (Figure 13A).  
By contrast, LY18 cells treated with TAT-p16 wild-type peptide for 24 hours, exhibited 
an increase in the percentage of LY18 cells in sub-G0/G1-phase of the cell cycle by 86% 
in comparison to LY18 cells transduced with TAT-p16 mutant peptide (Figure 13A).  
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Similar results were observed in LY18 cells transduced with TAT-p16 wild-type peptide 
at 12 and 48 hours; specifically, at 12 hours there was a 74% increase and at 48 hours a 
89% increase in hypodiploid DNA, in comparison to LY18 cells transduced with TAT-
p16 mutant peptides (Figure 13A). 
 D-type cyclin-cdk4/6 complexes directly phosphorylate pRb on Ser807/811.  To 
establish endogenous pRb phosphorylation levels in LY18 cells treated with TAT-p16 
wild-type peptide, whole cell extracts were prepared and Western blotting performed 
with anti-phospho-pRbSer807/811 Ab.  Untreated LY18 cells constitutively express 
abundant endogenous phospho-pRbSer807/811, which was inhibited in LY18 cells treated 
with TAT-p16 wild-type peptide, but not TAT-p16 mutant peptide (Figure 14).  These 
data demonstrate that in LY18 cells, TAT-p16 wild-type peptide inhibits phosphorylation 
of pRb on the D-type cyclin-cdk4/6 specific Ser807/811 site.  Collectively, the observed 
results suggest that following treatment with TAT-p16 peptides, cyclin D3-cdk4/6 
complexes are inhibited, thereby disrupting cdk4/6 kinase activity and its 
phosphorylation on pRbSer807/811 in LY18 cells.     
 The results above demonstrate that disruption of cyclin D3-cdk4/6 complexes in 
LY18 cells results in an increase in the percentage of hypodiploid DNA.  To further 
evaluate these results we were interested in determining whether LY18 cells were 
undergoing apoptosis.  The presence of apoptotic cells was confirmed by annexin V-
FITC/PI staining.  LY18 cells treated with TAT-p16 wild-type peptide for 24 hours, 
demonstrated ~100% increase in the percentage of apoptotic cells in comparison to 
untreated (M) LY18 cells (Figure 13B, WT).  In contrast, transduction of TAT-p16 
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mutant peptide into LY18 cells had a minimal effect on the percentage of annexin V-
FITC/PI positive cells in comparison to untreated LY18 cells (Figure 13B, Media, Mut).  
It is important to note that the percentages of hypodiploid DNA (34.8%) (Figure 13A) 
and annexin V-FITC/PI positive cells (78.2%) (Figure 13B) differ at 24 hours as a result 
of the way the LY18 cells were gated.  In measuring apoptosis, LY18 cells that were 
undergoing early apoptosis (annexin V-FITC positive, PI negative) were combined with 
the cells that were dead (annexin V-FITC positive, PI positive) (Figure 13B).  The 
percentage of hypodiploid DNA observed in Figure13A represents the percentage of 
LY18 cells that were dead.  To summarize, disruption of cyclin D3-cdk4/6 complexes, 
mediated by transduction of TAT-p16 peptides, inhibits LY18 cell proliferation resulting 
in apoptosis.   
 
Cyclin dependent kinase 4 inhibitor (cdk4i) inhibits proliferation in LY18 cells by 
inducing G1 cell cycle arrest 
Small-molecular inhibitors have been documented by researchers as a potentially 
useful class of therapeutic agents in NHL’s [151].  Many small molecular inhibitors, 
specifically, cdk inhibitors have been used in ongoing clinical trials and preclinical 
testing [151].  To further assess the role of cyclin D3-cdk4/6 complexes in LY18 cell 
proliferation, in corroboration with our previous findings with TAT-p16 peptides, our 
strategy was to specifically disrupt cyclin D3-cdk4/6 complexes with the cyclin 
dependent kinase 4 inhibitor, 2-bromo-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H)-dione, which will be referred to as cdk4i (Figure 15A).  Cdk4i has 
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previously been shown to inhibit cdk4 (IC50  of 0.076 µM), and at greater concentrations 
cdk2 (IC50 of 0.52 µM) and cdk1 (IC50 of 2.1µM), as determined by inhibition of Rb 
phosphorylation [169,170].  Cdk4i is a cell permeable compound that inhibits tumor cell 
growth and proliferation by blocking Rb phosphorylation and inducing G1-phase cell 
cycle arrest [169,170].  We initially sought to monitor cell viability by treating LY18 
cells with cdk4i.  Here, LY18 cells were cultured in the absence or presence of varying 
concentrations of cdk4i and the number of viable cells was measured over time.  
Treatment of LY18 cells with 5 µM cdk4i did not result in a measurable decrease in 
viable cells in comparison to untreated (Media) LY18 cells over the 72-hour time period 
observed (Figure 15B).  In contrast, LY18 cells incubated with 10 µM and 25 µM, 
demonstrated a time and dose dependent decrease in viable cells in comparison to 
untreated (Media) LY18 cells (Figure 15B).  These data suggest that at increased 
concentrations, cdk4i is potentially inhibiting cdk4/6, cdk2 and cdk1, or is toxic to LY18 
cells.   
Next we measured the effects of treating LY18 cells with cdk4i on cell cycle 
progression.  Analysis of DNA content by propidium iodide staining and flow cytometry 
[108], revealed that incubation of LY18 cells with 5 µM and 10 µM cdk4i resulted in an 
increase in the percentage of cells in G1-phase of the cell cycle in comparison to 
untreated LY18 cells (Media) (Figure 16).  Specifically, from 57.4% in media cells to 
76.0% and 79.1% in 5 µM cdk4i treated cells and 71.0% and 69.0%, in 10 µM cdk4i 
treated cells at 24 and 48 hours, respectively (Figure 16).  Also observed was a decrease 
in S-, and G2/M-phases of the cell cycle in 5 µM and 10 µM cdk4i treated LY18 cells 
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(Figure 16).  For example, at 48 hours media LY18 cells went from 12.1% S-phase and 
26.0% G2/M-phase to 3.8% S-phase and 10.5% G2/M-phase in 5 µM cdk4i treated LY18 
cells (Figure 16).  Interestingly, treatment of LY18 cells with 25 µM cdk4i resulted in a 
decrease in G1-phase and an increase in G2/M-phase of the cell cycle at 24 hours (Figure 
16).  Control (media) cells went from 57.4% in G1-phase and 26.0% in G2/M-phase to 
33.2% in G1-phase and 46.7% in G2/M-phase with treatment of 25 µM cdk4i (Figure 16).  
These observed results suggest that at higher concentrations cdk4i is inhibiting cdk2 and 
cdk1.  To avoid these results the remaining experiments were performed with 5 µM 
cdk4i.     
To obtain further evidence that cdk4i blocks cell cycle progression in LY18 cells 
we sought to measure the levels of DNA synthesis in cdk4i treated cells.  In corroboration 
with the above results, 5 µM cdk4i inhibits DNA synthesis in LY18 cells over 48 hours in 
comparison to untreated (stained media) LY18 cells, as determined by BrdU 
incorporation (Figure 17).  Specifically, proliferating LY18 cells used as a positive 
control, incorporated 62.5% BrdU (Figure 17, stained media), while LY18 cells treated 
with cdk4i demonstrated a 36.2%-7.3% decrease in BrdU incorporation from 15-48 
hours, respectively.  Of note, unstained media LY18 cells were used as a negative control 
and did not receive BrdU.  In summary, cdk4i treatment of LY18 cells inhibits cell cycle 
progression, which corresponds to a decrease in DNA synthesis.   
 
 
 
 79 
Cdk4i affects endogenous G1-phase protein expression levels 
To investigate the impact of cdk4i on LY18 cells, we re-examined endogenous 
protein expression profiles that were first observed in Figure 11 following treatment with 
cdk4i.  The expression levels of endogenous G1-proteins in LY18 cells treated with 5 µM 
cdk4i were analyzed by Western blotting performed with specific antibodies against each 
individual protein.  Endogenous cyclin D3 and cdk4 protein expression levels began to 
decrease at 18 hours and were almost undetectable at 48 hours (Figure 18).  Endogenous 
cdk6 protein expression did not show any measurable differences within 48 hours of 
cdk4i treatment in LY18 cells (Figure 18).  Phosphorylation of pRb on Ser807/811 
specifically detects cyclin D-cdk4/6 mediated phosphorylation of pRb.  To determine the 
status of endogenous pRb phosphorylation in cdk4i treated LY18 cells, whole cell 
extracts were prepared and immunoblotted with an anti-phospho-pRbSer807/811 Ab.  
Untreated LY18 cells express relatively abundant phosphorylation of endogenous pRb on 
Ser807/811 (Figure 19, Time 0, -).  In contrast, phosphorylation of constitutive pRb on 
Ser807/811 in LY18 cells was inhibited ~24 hours after incubation with cdk4i and 
continued to decrease over 48 hours (Figure 19, +).  These results suggest that cdk4i 
inhibits cyclin D3 and cdk4, thereby blocking constitutive pRb phosphorylation on the D-
type cyclin-cdk4/6 site in LY18 cells. 
Endogenous cyclin E and cdk2 form complexes later in G1-phase of cell cycle to 
further promote pRb phosphorylation and proliferation.  The phosphorylation of cdk2 on 
Thr160 is an indicator of active cyclin E-cdk2 complexes [171].  Once activated cyclin E-
cdk2 complexes phosphorylate pRb on Thr821, the cyclin E-cdk2 specific site.  To 
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determine the status of endogenous phospho-cdk2Thr160 in cdk4i treated LY18 cells, 
whole cell extracts were prepared and immunoblotted with an anti-phospho-cdk2Thr160 
Ab.  It is important to note that cdk4i has been shown to inhibit cyclin E-cdk2 complexes 
at higher concentrations [169,170].  Untreated LY18 cells express relatively abundant 
phosphorylation of endogenous cdk2 on Thr160 (Time 0, -), which was inhibited 
following incubation with cdk4i (+) (Figure 20).  Specifically, a measurable decrease in 
phospho-cdk2Thr160 was observed beginning at 12 hours, which continued to decrease to 
barely detectable levels at 48 hours.  Cdk2 levels were not affected by treatment with 
cdk4i (Figure 20).  Interestingly, the Western blot of phospho-cdk2Thr160 and cdk2 
express two distinct bands.  The cdk2 protein is closely related to cdc2 (cdk1), which is a 
proliferation marker that is significant in the G2-M transition.  We speculate that the cdk2 
Ab is cross-reactive with cdk1, as a result of the shared homology between the two 
proteins.  The nature of these immunoreactive bands needs to be clarified.  LY18 cells 
undergoing proliferation displayed constitutive phospho-pRbThr821 expression.  In 
contrast, results demonstrated that cdk4i disrupted active cyclin E-cdk2 complexes and 
blocked constitutive pRb phosphorylation on the cyclin E-cdk2 site in LY18 cells (Figure 
19).  Phosphorylation of pRb on Thr821 was inhibited in LY18 cells within 18 hours and 
was undetectable by 48 hours (Figure 19).  In summary, our results suggest that cdk4i 
disrupts cyclin D3-cdk4/6 complexes in LY18 cells, resulting in a decrease in cyclin D3 
and cdk4 protein levels, which eventually inhibits the phosphorylation of pRb on the 
cyclin D-cdk4/6 target residue Ser807/811.  In addition, our findings suggest that 
downstream of cyclin D3-cdk4 complexes there is decrease in active cyclin E-cdk2 
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complexes, by means of the observed decrease in phospho-cdk2Thr160 and phospho-
pRbThr821. 
 
Cdk4i induces p27 expression: transduction of TAT-p27 fusion proteins or siRNA-
mediated knockdown of endogenous p27 has no measurable effect on LY18 cell cycle 
progression 
 The Cip/Kip family member, p27, plays a role in negative regulation of G1-phase 
progression by inhibiting cyclin E-cdk2 complexes, thereby causing cells to accumulate 
in G1-phase of the cell cycle [158].  Upon investigation, we found that untreated LY18 
cells do not express endogenous p27, which is not uncommon for proliferating cells 
(Figure 11) [135].  However, following 5 µM treatment with cdk4i, LY18 cells display a 
time-dependent increase in endogenous p27 protein expression (Figure 21, +).  
Specifically, at 18 hours post cdk4i treatment, LY18 cells begin to express p27, which 
increases dramatically by 48 hours (Figure 21).  These results suggest that the 
upregulated expression of p27, which is consistent with loss of cyclin E-cdk2 activity, is 
contributing to the cell cycle arrest observed in cdk4i treated LY18 cells.  Germane to 
these findings, the literature reports that in many normal and tumor cells, cell cycle 
progression is dependent on the balance of sequestered p27 by cyclin D-cdk complexes 
and free p27, which is able to bind and inhibit cyclin E-cdk2 complex activity 
[92,106,135,172].  Taken together, we investigated the role of p27 in LY18 cells by 
introducing exogenous p27 via transduction with TAT-p27 fusion proteins.  Grdisa and 
coworkers [158] demonstrated that in different human tumor cell lines, transduction of 
 82 
TAT-fusion proteins affected proliferation, specifically, causing G1-phase arrest in 
certain cell types [158,159].  To mediate efficient p27 protein transduction in LY18 cells, 
full-length p27 fusion proteins were coupled to an 11-amino-acid peptide consisting of 
the NH2-terminal HIV TAT protein transduction domain [159].  A bacterial expression 
vector, pTAT-HA, was constructed, to produce genetic in-frame TAT fusion proteins 
[159].   
 To evaluate the role of exogenous p27, in the absence of cdk4i, on cell viability 
we transduced full-length wild-type TAT-p27 fusion proteins (TAT-p27 WT), functional 
truncated N-terminal-TAT-p27 fusion proteins (TAT-N’p27), or inactive point mutant-
TAT-p27 fusion proteins (TAT-ptMut-p27), into asynchronously growing LY18 cells 
[158,159].  Assuming that the increased expression of endogenous p27 plays a role in 
cdk4i-mediated LY18 cell cycle arrest, we expected to observe LY18 cells arresting in 
G1-phase following transduction of exogenous p27  (TAT-p27 WT and TAT-N’p27).  
The negative control, TAT-ptMut-p27, should have no effect on LY18 cell cycle 
progression.  Transduction of 150 nM of TAT-p27 fusion proteins did not measurably 
alter LY18 cell viability in contrast to untreated LY18 cells (Media) (Figure 22A).  
Specifically, all LY18 cells remained greater than 90% viable over 72 hours (Figure 
22A).  The minor decrease in cell viability between 48 and 72 hours is due to LY18 cells 
exhausting their media supply, as the cultures were not passed during the course of the 
experiment.  LY18 cells were first transduced with 150 nM of the TAT-p27 fusion 
proteins because that is the dose that has been shown to inhibit cell proliferation in 
different cell lines in vitro [158].  To be sure that LY18 cells do not require a higher 
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concentration of TAT-p27 fusion proteins, we performed the above experiment 
measuring LY18 cell viability with increased concentrations of TAT-p27 fusion proteins.  
Similarly, transduction with 300 nM and 450 nM TAT-p27 WT, TAT-ptMut-p27, or 
TAT-N’p27 fusion proteins into LY18 cells had no measurable effect on LY28 cell 
viability in comparison to untreated (media) cells at 48 hours (Figure 22B).  As observed 
above, LY18 cells under all conditions remained greater than 90% viable.   
To evaluate the role of exogenous p27 in LY18 cell cycle progression we 
analyzed DNA content by propidium iodide staining and flow cytometry [108].  
Transduction of 150 nM TAT-p27 WT, TAT-ptMut-p27, or TAT-N’p27 fusion proteins, 
into LY18 cells did not measurably alter the percentage of cells in G1- or S+G2/M-phases 
of the cell cycle (Figure 23A, 23B).  Specifically, under all conditions, ~50% of LY18 
were in G1-phase of the cell cycle whereas 40-50% of LY18 cells were in S+G2/M-phase 
of the cell cycle (Figure 23).  Again, the minor decrease of LY18 cells observed in the 
S+G2/M phase between 48 and 72 hours was a direct result of proliferating LY18 cells 
exhausting their media supply.  In summary, there are no measurable phenotypes 
observed in LY18 cells transduced with exogenous TAT-p27 fusion proteins.  Our results 
suggest that LY18 cells do not require the upregulation of p27 for cell cycle arrest.  Of 
note, it is also possible that TAT-p27 fusion proteins are not getting into the LY18 cells 
or they are entering the cells and being degraded. 
 As a second, independent means to investigate the role of endogenous p27 in 
cdk4i treated LY18 cells, we investigated the function of p27 using RNA interference.  
Unlike the first experiment, where LY18 cells were not treated with cdk4i, in the 
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following experiments we used cdk4i to induce the expression of p27, followed by p27-
specific siRNA to target p27 for knockdown.  See Table 1 for a complete list of siRNA 
target sequences.  In several control experiments, we found that between 200 pmol and 
400 pmol siRNA was able to reduce endogenous p27 below measurable levels as 
detected by Western blotting.  p27 protein abundance was reduced 24-72 hours after 
nucleofection of cdk4i treated LY18 cells with p27 specific siRNA, in comparison to 
untransfected (M) or control siRNA transfected cells (Figure 24A).  It is important to 
note that the negative control siRNA used in all experiments was a non-targeting 20-25 
nucleotide sequence.  Next, we examined the effect of p27 siRNA on cdk4i treated LY18 
cell viability.  siRNA-mediated knockdown of endogenous p27 had no measurable effect 
on cdk4i treated cell viability over 72 hours (Figure 24B).  Untreated cells remained over 
90% viable, while p27 siRNA treated and cdk4i treated cells were ~85% viable (Figure 
24B).   
To evaluate the role of siRNA-mediated depletion of p27 on cell cycle 
progression in cdk4i treated LY18 cells, we analyzed DNA content by propidium iodide 
staining and flow cytometry [108].  siRNA-mediated knockdown of endogenous p27 in 
cdk4i treated LY18 cells had no significant effect on the percentage of cells in G1-phase 
of the cell cycle, in comparison to LY18 cells treated with cdk4i alone (Figure 25A).  In 
agreement with the results noted in Figure 16, at 24 hours cdk4i treated LY18 cells arrest 
in G1-phase (77.8%) in comparison to untreated LY18 cells (44.9%) (Figure 25A).  
siRNA-mediated knockdown of p27 in cdk4i-treated LY18 cells had minimal effects on 
the percentage of LY18 cells in G1-phase (71%) in comparison to cdk4i treated LY18 
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cells (77.8%) at 24 hours (Figure 25A).  Similar results were observed at 48 and 72 
hours.  Furthermore, there were no significant differences observed in the percentage of 
LY18 cells in S+G2/M-phase of cdk4i treated LY18 cells and siRNA-mediated p27 
depleted, cdk4i treated cells (Figure 25B).  Collectively, these results suggest that cdk4i-
induced expression of endogenous p27 is dispensable for cell cycle arrest in LY18 cells. 
 
siRNA knockdown of individual, endogenous G1-phase proteins had no measurable 
effect on cell cycle progression in LY18 cells 
 Cyclin D3 is overexpressed in many human cancers.  Targeting cyclin D3 and 
inhibiting its expression is a novel therapeutic approach to understand tumor cell cycle 
progression, specifically in lymphoid malignancies [95].  The observed results indicate 
that cyclin D3-cdk4/6 complexes are required for LY18 cell proliferation and inhibition 
of these complexes with TAT-p16 wild-type peptides or cdk4i results in G1-phase 
accumulation.  With this in mind, we were interested in determining whether LY18 cell 
proliferation would be affected by the loss of cyclin D3, being that it is the only D-type 
cyclin expressed in these cells.  The dispensable nature of p27 induction in LY18 cells 
also suggests a role for cyclin D3.  To this end, we targeted endogenous cyclin D3 
specifically with siRNA (Table 1).  To confirm the depletion of endogenous cyclin D3 
after nucleofection with specific cyclin D3 siRNA, whole cell extracts were prepared and 
Western blotting performed.  Cyclin D3 protein expression was decreased at 10 and 24 
hours following transfection compared with untransfected LY18 cells (Media) and 
control siRNA (C) (Figure 26A).  Of note, a non-targeting control siRNA (C) was used in 
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this experiment as a negative control at 24 hours and it did not measurably affect cyclin 
D3 protein expression (Figure 26 and Figure 27).  Important to this study, we wanted to 
confirm that no other D-type cyclins were present in LY18 cells and to ensure that 
knockdown of endogenous cyclin D3 did not result in an increased expression of either 
cyclin D1 or cyclin D2 (i.e., upregulated in a compensatory manner).  To do this we 
analyzed cyclin D1 and cyclin D2 expression levels in untreated cells, cyclin D3 siRNA 
treated cells, and control siRNA treated LY18 cells.  There was no observable expression 
of cyclin D1 or cyclin D2 (Figure 26A).  Thus, cyclin D3 siRNA-mediated knockdown 
decreases cyclin D3 protein levels without inducing the expression of cyclin D1 or cyclin 
D2. 
Next, we examined the viability of siRNA-mediated knockdown of endogenous 
cyclin D3.  Note that there was no cdk4i used in the experiments to follow as only RNA 
interference was used to elucidate the role of G1-phase proteins in asynchronously 
growing LY18 cells.  Over 48 hours there was no measurable effect on LY18 cell 
viability (Figure 26B).  Specifically, untreated (Media) LY18 cells and control- or cyclin 
D3-siRNA LY18 cells remained ~90% viable.  To further measure the impact of cyclin 
D3 knockdown we analyzed cell cycle progression in LY18 cells treated with cyclin D3 
siRNA.  SiRNA-mediated knockdown of cyclin D3 did not result in G1-phase cell cycle 
arrest in LY18 cells over 48 hours (Figure 27).  For example, 24 hours post transfection 
with cyclin D3 specific siRNA, 53.5% of LY18 cells were in G1-phase in comparison to 
41.7% in control siRNA and 45.5% in untreated (Media) LY18 cells (Figure 27, 24 hrs).  
A similar trend was observed at 10 and 48 hours.  Not surprisingly, there were also no 
 87 
measurable differences in S+G2/M-phases of the cell cycle in cyclin D3-depleted LY18 
cells (Figure 27).  Specifically, at 24 hours 42.3% of cyclin D3 siRNA treated LY18 cells 
were in S+G2/M-phases in comparison to 49.8% in untreated (Media) cells and 54.4% in 
control siRNA treated LY18 cells (Figure 27).  Similar values were observed at 10 and 48 
hours.  These data suggest that siRNA targeted depletion of cyclin D3 in LY18 cells does 
not induce cell cycle arrest.   
To corroborate the above cell cycle data we measured DNA synthesis by BrdU 
incorporation.  siRNA-mediated knockdown of cyclin D3 did not significantly affect 
DNA synthesis in asynchronously growing LY18 cells (Figure 28).  At 24 hours post 
cyclin D3 siRNA transfection, BrdU incorporation was reduced 27.9% in comparison to 
untreated (Media) LY18 cells (Figure 28).  At 10 and 48 hours, a 14% and 16.2% 
decrease in BrdU incorporation, respectively, was observed in contrast to untreated (M) 
LY18 cells (Figure 28).  In corroboration with the cell cycle data, DNA synthesis is not 
measurably altered in siRNA-mediated cyclin D3 depleted LY18 cells.   
To determine the status of endogenous pRb phosphorylation in LY18 cells treated 
with cyclin D3 siRNA, whole cell extracts were prepared and immunoblotted with anti-
phospho-pRbSer807/811 Ab and anti-phospho-pRbThr821 Ab, that specifically detect cyclin 
D3-cdk4/6- and cyclin E-cdk2-mediated phosphorylation of pRb.  siRNA knockdown of 
endogenous cyclin D3 did not measurably reduce the phosphorylation of pRb on Thr821 
or Ser807/811 (Figure 29, cyclin D3).  These data imply that cyclin D3 is dispensable for 
cell cycle progression in LY18 cells. 
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 Given the results that knockdown of endogenous cyclin D3 has no measurable 
affect on LY18 cell cycle progression, we decided to knockdown all relevant G1-phase 
proteins, individually and in combination (for the complete list of the protein specific 
siRNAs that were used and their target sequences refer to Table 1).  Of note, a non-
targeting control siRNA (C) was used in all the following experiments as a negative 
control at either 24 or 48 hours and it did not measurably affect any protein expression 
levels.  In summary, individual knockdown of the G1-phase proteins did not significantly 
alter cell cycle progression in LY18 cells.   
To begin, endogenous cdk4 or cdk6 were individually targeted with specific 
siRNA to each.  Importantly, in many control experiments endogenous cdk4 and cdk6 
protein expression was decreased with siRNA treatment at 200 or 400 pmol.  To confirm 
the depletion of endogenous cdk4 or cdk6 in LY18 cells transfected with cdk4 or cdk6 
specific siRNA, whole cell extracts were prepared and immunoblotting performed.  Cdk4 
and cdk6 protein expression levels were decreased at 24 and 48 hours following 
transfection in comparison to untreated (Media) and control siRNA LY18 cells (Figure 
30A and Figure 31A, respectively).  To confirm the specificity of the cdk4 target siRNAs 
we observed endogenous protein levels of cdk6 and cdk2 in cdk4 depleted LY18 cells.  
Cdk4 siRNA was specific for only endogenous cdk4 protein and did not reduce 
endogenous cdk6 or cdk2 (Figure 30A).  Similar results were observed with cdk6 siRNA, 
as it did not affect endogenous cdk4 or cdk2 (data not shown) (Figure 31A).  In summary, 
cdk4 siRNA and cdk6 siRNA exhibit specific knockdown of endogenous cdk4 and cdk6, 
respectively, in LY18 cells.  
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We next examined the viability and cell cycle progression of siRNA-mediated 
knockdown of endogenous cdk4 or cdk6 in LY18 cells.  Over the observed 48 hours there 
was no measurable effects on LY18 cell viability (Figure 30B and Figure 31B, 
respectively).  Specifically, the viability in untreated, cdk4 siRNA (200 or 400 pmol) 
treated, and control siRNA treated LY18 cells was ~88% at 24 hours and ~91% at 48 
hours (Figure 30B).  LY18 cells that were transfected with siRNA-specific for cdk6 
displayed viable cells greater than 90% in all conditions (Figure 31B).  Individual 
knockdown of either cdk4 or cdk6 had no measurable effects on G1- or S+G2/M-phases 
of the cell cycle in comparison to LY18 cell controls (Figure 32 and Figure 33, 
respectively).  At 48 hours, 51.0% of cdk4 siRNA treated LY18 cells were in G1-phase 
and 45.5% in S+G2/M-phase; similarly, 53.1% of untreated (Media) cells and 53.8% 
control siRNA cells were in G1-phase, while 39.8% of untreated (Media) cells and 41.5% 
control siRNA cells were in S+G2/M-phase (Figure 32).  Approximately the same 
percentages were observed at 24 hours.  Furthermore, we observe the same results with 
cdk6 siRNA (Figure 33).  These results indicate that cdk4 or cdk6 depletion in LY18 
cells is not enough to affect cell cycle progression.     
To determine the status of endogenous pRb phosphorylation in LY18 cells treated 
with cdk4 or cdk6 siRNA, whole cell extracts were prepared and immunoblotted with 
anti-phospho-pRbSer807/811 Ab and anti-phospho-pRbThr821 Ab.  As stated previously, 
phosphorylation of pRb on Ser807/811 and on Thr821 are the respective target residues of 
cyclin D3-cdk4/6- and cyclin E-cdk2.  In corroboration with the above data, siRNA 
knockdown of endogenous cdk4 or cdk6 did not measurably reduce the phosphorylation 
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of pRb on Thr821 or Ser807/811  (Figure 29, cdk4, cdk6).  These data imply that 
individually, cdk4 and cdk6 are dispensable for cell cycle progression in LY18 cells. 
Given that the observed results suggest that, individually, cyclin D3, cdk4, and 
cdk6 are dispensable for LY18 cell cycle we sought to examine endogenous cyclin E and 
cdk2 proteins.  Cyclin E-cdk2 complexes function in late G1-phase to promote S-phase 
entry and cell cycle progression.  Endogenous cyclin E or cdk2 were individually targeted 
with specific siRNA to each.  To confirm the depletion of cyclin E and cdk2 in LY18 
cells transfected with cyclin E or cdk2 specific siRNA, whole cell extracts were prepared 
and Western blotting performed.  Cdk2 protein expression was decreased at 24 and 48 
hours following transfection compared with untransfected and control siRNA treated 
LY18 cells (Figure 34A).  Cyclin E siRNA treated LY18 cells also showed a decrease in 
endogenous cyclin E protein levels at 24 and 48 hrs (data not shown).  Subsequently, we 
examined the viability and cell cycle progression of siRNA-depleted cyclin E or cdk2 to 
investigate their impact on LY18 cell proliferation.  Over 48 hours there were no 
measurable differences on LY18 cell viability (Figure 34B and Figure 35).  LY18 cells 
treated with cdk2 or cyclin E siRNA remained ~ 90 % viable, similarly to control cells 
(Figure 34B and Figure 35).   
Finally, we sought to examine cell cycle progression in LY18 cells treated with 
cyclin E or cdk2 siRNA.  Individual knockdown of either cyclin E or cdk2 had no 
measurable effects on G1- or S+G2/M-phases of the cell cycle in comparison to LY18 cell 
controls (Figure 36 and Figure 37, respectively).  At 24 hours, 62.9% of cyclin E siRNA 
treated LY18 cells were in G1-phase and 31.5% in S+G2/M-phase; similarly, 51.5% of 
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untreated (Media) LY18 cells and 46.5% control siRNA LY18 cells were in G1-phase, 
while 43.9% of untreated (Media) cells and 50.3% control siRNA LY18 cells were in 
S+G2/M-phase (Figure 36).  Approximately, the same percentages were observed at 48 
hours.  Not surprisingly, at 24 hours, 47.3% of cdk2 siRNA treated LY18 cells were in 
G1-phase and 48.8% in S+G2/M-phase; similarly, 51.5% of untreated (Media) cells and 
46.5% control siRNA cells were in G1-phase, while 43.9% of untreated (Media) cells and 
50.3% control siRNA cells were in S+G2/M-phase (Figure 37).  Approximately, the same 
percentages were observed at 48 hours.  These results suggest that cyclin E or cdk2 
depletion in LY18 cells does not affect proliferation. 
To determine the status of endogenous pRb phosphorylation in LY18 cells treated 
with cdk4 or cdk6 siRNA, whole cell extracts were prepared and immunoblotted with 
anti-phospho-pRbSer807/811 Ab and anti-phospho-pRbThr821 Ab.  In agreement with the 
above data, siRNA knockdown of either endogenous cyclin E or cdk2 did not measurably 
reduce the phosphorylation of pRb on Thr821 or Ser807/811 (Figure 29, cyclin E, cdk2).  
These data imply that individually, cyclin E and cdk2 are dispensable for cell cycle 
progression in LY18 cells.  
 
siRNA knockdown of a combination of G1-phase cyclin dependent kinases impairs 
proliferation of LY18 cells by inducing G1  cell cycle arrest 
 Using RNA interference on individual G1-proteins did not result in an observable 
phenotype in LY18 cells.  Given the structural similarities of the cyclins and cyclin 
dependent kinase proteins, we wanted to investigate the possibility that the proteins not 
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targeted by siRNA are functionally compensating for the depleted proteins in LY18 cells.  
This would explain the observed normal proliferation in siRNA-transfected cells.  To 
begin we nucleofected LY18 cells with both cdk4 and cdk6 (cdk4/6) specific siRNAs.  
Combined cdk4/6 siRNA-treated LY18 cells exhibited a decrease in endogenous cdk4 
and cdk6 protein expression levels (data not shown), however, had no measurable effect 
on LY18 cell viability in comparison to untreated LY18 cells and cells transfected with 
control siRNA (Figure 38).  Specifically, under all conditions LY18 cells remained 
greater than 89% viable.  To further assess the depletion of cdk4/6 in LY18 cells we 
examined cell cycle progression at 24 and 48 hours post transfection.  siRNA-mediated 
knockdown of both endogenous cdk4 and cdk6 resulted in an increase in the percentage 
of LY18 cells in G1-phase and a decrease in the percentage of cells in S+G2/M-phases of 
the cell cycle (Figure 39).  Note that in all instances where S and G2/M phases were 
combined, the individual percentages of S- and G2/M-phase followed the same trend.  At 
48 hours post transfection of cdk4/6 siRNA, 55.4% of control cells compared to 75.8% of 
LY18 cells treated with cdk4/6 siRNA were in G1-phase, while the percentage of cells in 
S+G2/M-phase decreased from 40.1% to 19.5% (Figure 38).  Similar results were 
observed at 24 hours (Figure 39).  These data demonstrate that depletion of cdk4 and 
cdk6 results in a G1-phase accumulation. 
Next, we sought to measure the effects of siRNA-mediated knockdown of both 
cdk6 and cdk2 in LY18 cells.  Considering that cdk4 and cdk6 appear to be redundant in 
LY18 cells, it is likely that cdk2 also functions similarly.  siRNA-mediated knockdown 
of endogenous cdk6 and cdk2 had no detectable effect on LY18 cell viability, as all cells 
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were greater than 90% viable (Figure 40A).  Interestingly, there was an increase in the 
percentage of cells in G1-phase and a decrease in the percentage of LY18 cells in 
S+G2/M-phase of the cell cycle (Figure 40B).   Evaluation at 48 hours post transfection 
of cdk6/2 siRNA demonstrated that 73.8% of LY18 cells were in G1-phase in comparison 
to 59.4% of untreated control LY18 cells (Figure 40B).  The percentage of cells in 
S+G2/M-phase decreased from 35.0% in control cells, to 18.6% in cdk6/2 siRNA-treated 
LY18 cells (Figure 40B).  Similar results were observed at 24 hours (Figure 40B).  These 
data demonstrate that depletion of cdk6 and cdk2 results in a G1-phase accumulation. 
To determine the status of endogenous pRb phosphorylation in LY18 cells treated 
with cdk6 and cdk2 siRNA, whole cell extracts were prepared and immunoblotted with 
anti-phospho-pRbSer807/811 Ab and anti-phospho-pRbThr821 Ab.  Interestingly, the data 
revealed a decrease in the phosphorylation of pRb on the D-type cyclin-cdk4/6 specific 
site, but not on the cyclinE-cdk2 specific site (Figure 29, cdk2/6).  These data imply that, 
individually, cdk6 and cdk2 are dispensable for cell cycle progression, however, 
combined they arrest LY18 cells in G1-phase of the cell cycle.  Of particular interest, it 
appears that siRNA-mediate knockdown of cdk2/6 effects early G1-phase 
phosphorylation of pRb on the cyclin D3-cdk4/6 specific target residue.  
 Cdk4/6 or cdk6/2 siRNA-mediated knockdowns resulted in a significant G1 arrest 
in LY18 cells.  Collectively, these data suggest that siRNA knockdown of individual cdk 
proteins are compensated by the remaining, non-targeted cdks.  To test this hypothesis, 
we knocked down endogenous cdk4, cdk6, and cdk2 (cdk4/6/2), simultaneously in LY18 
cells.  siRNA-mediated knockdown of endogenous cdk4/6/2 had no measurable effect on 
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the viability in LY18 cells; all cells remained greater than 90% viable within 48 hours of 
nucleofection (Figure 41A).  Furthermore, we assessed cell cycle progression in 
cdk4/6/2-depleted LY18 cells.  A significant increase in the percentage of LY18 cells in 
G1-phase of cell cycle was observed (Figure 41B).  At 48 hours, 86.7% of cdk4/6/2 
siRNA treated LY18 cells accumulated in G1-phase in comparison to 55.2% of control 
cells (Figure 41B, 48 hrs).  As a direct result of LY18 cells arresting in G1-phase, there 
was a significant decrease in LY18 cells in S+G2/M-phase.  At 48 hours, 8.6% of 
cdk4/6/2 siRNA treated LY18 cells were in S+G2/M-phase in comparison to 40.0% of 
control cells (Figure 41B, 48 hrs).  It is important to note that at 24 hours similar results 
were observed.  Also, control siRNA treatment had a minimal effect on the percentage of 
G1 or S+G2/M-phase LY18 cells in comparison to untreated (Media) LY18 cells.  These 
data demonstrate that without G1-phase cdks, LY18 cells cannot progress through the cell 
cycle.   
To determine the status of endogenous pRb phosphorylation in LY18 cells treated 
with cdk4/6/2 siRNA, whole cell extracts were prepared and immunoblotted with anti-
phospho-pRbSer807/811 Ab and anti-phospho-pRbThr821 Ab.  Interestingly, the data displayed 
a significant decrease in the phosphorylation of pRb on Ser807/811 and Thr821, in 
comparison to the individual cdk siRNA knockdowns (Figure 29, cdk4/6/2).  These data 
demonstrate that cdk4, cdk6, and cdk2, are individually dispensable for cell cycle 
progression, however combined they arrest LY18 cells in G1-phase of the cell cycle. 
Collectively, these results suggest that cdk4, cdk6, and cdk2 can play compensatory roles 
in LY18 cells.  Of particular interest, it appears that siRNA-mediate knockdown of 
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cdk4/6/2 inhibits cyclin D3-cdk4/6 and cyclin E-cdk2 specific phosphorylation of pRb on 
their respective target residues Ser807/811 and Thr821.  These data suggest that these 
holoenzyme complexes are not functional without cdks.   
 
siRNA-mediated knockdown of endogenous cyclin D3 in combination with cyclin E in 
LY18 cells inhibits proliferation by inducing G1 cell cycle arrest 
 Since cyclin D3 knockdown with cyclin D3 specific siRNA does not have an 
observable phenotype in LY18 cells we wanted to examine the possibility of a 
compensatory mechanism by cyclin E.  In the literature cyclin E has been shown to 
compensate for a lack of D-type cyclins and contributes to tumor proliferation [139].  We 
investigated this hypothesis with RNA interference.  Both cyclin D3 and cyclin E protein 
levels were decreased in LY18 cells transfected with cyclin E and cyclin D3 siRNA (data 
not shown).  The viability of siRNA-mediated knockdown of cyclin D3 and cyclin E 
resulted in no measurable effect in LY18 cells, as all cells remained greater than 90% 
viable over 48 hours (Figure 42).   
 Next we sought to examine cell cycle progression and proliferation in LY18 cells 
treated with cyclin D3 and cyclin E siRNA.  At 48 hours post transfection, 83.1% of 
cyclin D3 and cyclin E depleted cells were accumulated in G1-phase in comparison to 
59.4% of untransfected control LY18 cells (Figure 43A, 48 hrs).   There was also a 
significant decrease in LY18 cells in S+G2/M; at 48 hours, 9.0% of cyclin D3/E siRNA 
treated cells were in S+G2/M-phase in comparison to 35.0% of untransfected control 
LY18 cells (Figure 43A, 48 hrs).  We observed similar results at 24 hours.  It is important 
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to note that control siRNA treatment had a minimal effect on the percentage of G1 or 
S+G2/M-phase LY18 cells in comparison to untreated (Media) LY18 cells.  Finally, we 
examined DNA synthesis in LY18 cells following siRNA depletion of endogenous cyclin 
D3 and cyclin E by BrdU incorporation.  BrdU incorporation was reduced from 50.3% to 
21.7% in cyclin D3 and cyclin E depleted cells at 24 and 48 hours, respectively, in 
comparison to untransfected LY18 cell controls (90.4% at 24 hours and 63.4% at 48 
hours) (Figure 43B).  The observed decrease in DNA synthesis was a direct result of 
LY18 cells accumulating in G1-phase of the cell cycle. These data demonstrate that 
without G1-phase cyclins, LY18 cells cannot progress through the cell cycle or 
proliferate. 
To determine the status of endogenous pRb phosphorylation in LY18 cells treated 
with cyclin D3 and cyclin E siRNA, whole cell extracts were prepared and 
immunoblotted with anti-phospho-pRbSer807/811 Ab and anti-phospho-pRbThr821 Ab. 
Interestingly, the data displayed a significant decrease in the phosphorylation of pRb on 
Ser807/811 and Thr821, in comparison to the individual cyclin siRNA knockdowns (Figure 
29, cyclin D3/E).  These data imply that cyclin D3 and cyclin E are individually 
dispensable for cell cycle progression; however, combined they arrest LY18 cells in G1-
phase of the cell cycle and inhibit DNA synthesis.  Collectively, these data suggest that 
cyclin E can compensate for siRNA-mediated depletion of cyclin D3 and vice versa.  
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FIGURES AND LEGENDS 
 
Figure 11. Protein expression profiles of relevant G1 proteins reveals LY18 cells 
uniquely express cyclin D3.  Asynchronously growing HeLa cells, A20 B cells, and 
LY18 B cells were cultured in media alone for 24 hrs.  Whole cell extracts were prepared 
and Western blotting was performed with anti-cyclin D1 Ab, anti-cyclin D2 Ab, anti-
cyclin D3 Ab, anti-cdk2 Ab, anti-cdk4 Ab, anti-cdk6 Ab, anti-p27 Ab, anti-phospho-
pRbThr821 Ab, anti-phospho-pRbSer807/811 Ab, and anti-pRb Ab.  The blot were stripped 
and re-probed with anti-hsp90 Ab to verify equal loading of each lane. 
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Figure 12.  Cyclin dependent kinase 4 (cdk4) forms complexes with cyclin D3 in 
LY18 cells.  LY18 cells were cultured in media alone.  At 24 hrs, LY18 cells were 
collected and immunoprecipitated (IP) with 1.5 µg of anti-cyclin D3 Ab and non-immune 
serum IgG (control) as described [80].  The immune complexes were separated by SDS-
PAGE and Western blotted with anti-cdk4 Ab.  
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Figure 13.  TAT-p16 wild-type peptide causes an increase in hypodiploid DNA 
resulting in apoptosis in LY18 cells.  LY18 cells cultured in media alone (M) or in the 
presence of 20 µM TAT-p16 wild-type (WT) or 20 µM TAT-p16 mutant (Mut) peptides 
for various lengths of time.  A, For cell cycle analysis, LY18 cells were stained with 
propidium iodide and analyzed by flow cytometry as described in Materials and 
Methods.  The data are represented as the percentage of LY18 cells in sub-G0/G1-phase of 
the cell cycle.  The data are representative of 10,000 cells.  B, At 24 hrs, LY18 cells were 
stained with Annexin-V and analyzed by flow cytometry as described in Materials and 
Methods.  The data are represented as the percentage of LY18 cells in the quadrants 
positive for Annexin-V/FITC and propidium iodide.  The data are representative of 
10,000 cells.  
Media WT Mut
24 hrs
B.
Figure 13
M M MWT WT WTMut Mut Mut
A.
12 hrs 24 hrs 48 hrs
102
 103 
Figure 14.  TAT-p16 wild-type peptide inhibits pRbSer807/811 phosphorylation in 
LY18 cells.  LY18 cells were cultured in media (M) alone or in the presence of 20 µM 
TAT-p16 wild-type (p16 WT) or 20 µM TAT-p16 mutant (p16 Mut) peptides.  At 90 
mins, whole cell extracts were prepared and Western blotting performed with an anti-
phospho-pRbSer807/811 Ab.  
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Figure 15.  Treatment of LY18 cells with the cyclin dependent kinase 4 inhibitor 
(cdk4i) causes a decrease in viable cells.  A, Structure of the cyclin dependent kinase 4 
inhibitor (cdk4i).  B, LY18 cells were cultured in media alone (DMSO solvent control) or 
in the presence of 5 µM, 10 µM, or 25 µM cdk4i.  At the indicated times, LY18 cells 
were collected and cell viability was determined by propidium iodide staining.  Samples 
were analyzed by flow cytometry as described in Material and Methods.  The data are 
represented as the percentage of LY18 cells that are negative for propidium iodide 
staining.  The data are representative of 10,000 cells.  
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Figure 16.  Cyclin dependent kinase 4 inhibitor (cdk4i) blocks cell cycle progression 
in LY18 cells.  LY18 cells were cultured in media alone (DMSO solvent control) or in 
the presence of 5 µM, 10 µM, or 25 µM cdk4i.  At the indicated times, LY18 cells were 
stained propidium iodide and cell cycle analyzed by flow cytometry as described in 
Materials and Methods.  The data are presented as the number of cells (counts) versus 
propidium iodide (PI-A), with percentages represented by black bars, indicating LY18 
cells in G1, S, or G2/M-phase of the cell cycle, respectively.  The data are representative 
of 10,000 cells. 
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Figure 17.  Cyclin dependent kinase 4 inhibitor (cdk4i) inhibits DNA synthesis in 
LY18 cells.  LY18 cells were cultured in media alone (DMSO solvent control) or in the 
presence of 5 µM cdk4i for various lengths of time.  DNA synthesis was monitored by 
BrdU incorporation and analyzed by flow cytometry as described in Materials and 
Methods.  The data are representative of 10,000 cells and are presented as cell number 
(counts) versus BrdU (FITC-A).  The bars reflect the percentage of BrdU positive LY18 
cells.   
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Figure 18.  cdk4 and cyclin D3 protein expression decreases over time in cyclin 
dependent kinase 4 inhibitor (cdk4i) treated LY18 cells.  LY18 cells were cultured in 
the absence (0 hrs, -) or in the presence (+) of 5 µM cdk4i for various lengths of time.  
Whole cell extracts were prepared and Western blotting performed with anti-cdk4, anti-
cdk6, or anti-cyclin D3 Abs.  The blot was stripped and reprobed with anti-hsp90 Ab to 
verify equal loading of each lane.  The densometric data (arbitrary) shown under the 
western blots are presented as fold changes as compared with their respective control. 
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Figure 19.  Cyclin dependent kinase 4 inhibitor (cdk4i) inhibits constitutive 
pRbSer807/811 and pRbThr821 phosphorylation in LY18 cells.  LY18 cells were cultured 
in the absence (0 hrs, -) or in the presence (+) of 5 µM cdk4i for various lengths of time.  
Whole cell extracts were prepared and Western blotting performed with anti-phospho-
pRbSer807/811 or anti-phospho-pRbThr821 Abs.  The blot was stripped and reprobed with 
anti-hsp90 Ab to verify equal loading of each lane.  The densometric data (arbitrary) 
shown under the western blots are presented as fold changes as compared with their 
respective control. 
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Figure 20.  Cyclin dependent kinase 4 inhibitor (cdk4i) inhibits cdk2Thr160 
phosphorylation, but does not effect total cdk2 levels in LY18 cells.  LY18 cells were 
cultured in the absence (0 hrs, -) or in the presence (+) of 5 µM cdk4i for various lengths 
of time.  Whole cell extracts were prepared and Western blotting performed with anti-
phospho-cdk2Thr160 or anti-cdk2 Abs.  The blot was stripped and reprobed with anti-hsp90 
Ab to verify equal loading of each lane.  The densometric data (arbitrary) shown under 
the western blots are presented as fold changes as compared with their respective control. 
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Figure 21.  LY18 cells treated with cyclin dependent kinase 4 inhibitor (cdk4i) 
results in a time-dependent increase in endogenous p27 protein expression.  LY18 
cells were cultured in the absence (0 hrs, -) or in the presence (+) of 5 µM cdk4i for 
various lengths of time.  Whole cell extracts were prepared and Western blotting 
performed with anti-p27 Ab.  The blot was stripped and reprobed with anti-hsp90 Ab to 
verify equal loading of each lane.  The densometric data (arbitrary) shown under the 
western blots are presented as fold changes as compared with their respective control. 
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Figure 22.  TAT-p27 fusion proteins do not measurably alter LY18 cell viability.  A, 
LY18 cells were cultured in media alone, or where indicated with 150 nM TAT-p27 
wild-type (WT), 150nM TAT-ptMut-p27, or 150nM TAT-N’p27 fusion proteins.  At the 
indicated times, LY18 cells were collected and cell viability was determined by 
propidium iodide staining.  Samples were analyzed by flow cytometry as described in 
Material and Methods.  The data are represented as the percentage of LY18 cells that are 
negative for propidium iodide staining.  The data are representative of 10,000 cells.  B, 
LY18 cells were cultured in media alone, or where indicated with 300 nM or 450 nM 
TAT-p27 wild-type (WT), 300 nM or 450 nM TAT-ptMut-p27, or 300 nM or 450 nM 
TAT-N’p27 fusion proteins.  At 48 hrs, LY18 cells were collected and viability was 
determined by propidium iodide staining.  Samples were analyzed by flow cytometry as 
described in Material and Methods.  The data are represented as the percentage of LY18 
cells that are negative for propidium iodide staining.  The data are representative of 
10,000 cells.   
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Figure 23.  Incubation of LY18 cells with TAT-p27 fusion proteins does not 
measurably alter the percentage of cells in G1-phase or S+G2/M-phase of the cell 
cycle.  LY18 cells were cultured in media alone, or where indicated with 150 nM TAT-
p27 wild-type (WT), 150 nM TAT-ptMut-p27, or 150 nM TAT-N’p27 fusion proteins.  
A, At the indicated times, LY18 cells were stained with propidium iodide and cell cycle 
analyzed by flow cytometry as described in Materials and Methods.  The data are 
represented as the percentage of LY18 cells in the G1-phase of the cell cycle.  B, At the 
indicated times, LY18 cells were stained with propidium iodide and cell cycle analyzed 
by flow cytometry as described in Materials and Methods. The data are represented as 
the percentage of LY18 cells in the S+G2/M-phase of the cell cycle.  The data are 
representative of 10,000 events. 
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Figure 24.  siRNA-mediated knockdown of endogenous p27 has no measurable 
effect on the viability of cyclin dependent kinase 4 inhibitor (cdk4i) treated LY18 
cells.  LY18 cells were nucleofected in the presence of media alone (M), 200 pmol 
control siRNA, or 200 pmol p27 siRNA and then allowed to incubate for 2 hrs before the 
addition of 5µM cdk4i.   A, At 24 and 72 hrs, whole cell extracts were prepared and 
Western blotting performed with anti-p27 Ab.  The blot was stripped and reprobed with 
anti-hsp90 Ab to verify equal loading of each lane.  B, At 24, 48, and 72 hrs, LY18 cells 
were collected and cell viability was determined by propidium iodide staining.  Samples 
were analyzed by flow cytometry as described in Material and Methods.  The data are 
represented as the percentage of LY18 cells that are negative for propidium iodide 
staining.  The data are representative of 10,000 cells.   
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Figure 25.  siRNA-mediated knockdown of endogenous p27 has no measurable 
effect on G1-phase or S+G2/M-phase of the cell cycle, in cyclin dependent kinase 4 
inhibitor (cdk4i) treated LY18 cells.  LY18 cells were nucleofected in the presence of 
media alone, 200 pmol control siRNA, or 200 pmol p27 siRNA and then allowed to 
incubate for 2 hours before the addition of 5µM cdk4i. A, At the indicated times, LY18 
cells were stained propidium iodide and cell cycle analyzed by flow cytometry as 
described in Materials and Methods.  The data are represented as the percentage of LY18 
cells in the G1-phase of the cell cycle.  B, At the indicated times, LY18 cells were stained 
with propidium iodide and cell cycle analyzed by flow cytometry as described in 
Materials and Methods.  The data are represented as the percentage of LY18 cells in the 
S+G2/M-phase of the cell cycle.  The data are representative of 10,000 events. 
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Figure 26.  siRNA-mediated knockdown of endogenous cyclin D3 has no measurable 
effect on LY18 cell viability.  LY18 cells were nucleofected in the presence of media 
alone or 300 pmol cyclin D3 siRNA for various lengths of time.  LY18 cells were 
nucleofected with 300 pmol control siRNA (C) for only 24 hrs.  A, At 10, 24, and 48 hrs, 
whole cell extracts were prepared and Western blotting performed with anti-cyclin D3, 
D2, or D1 Abs.  The blot was stripped and reprobed with anti-hsp90 Ab to verify equal 
loading of each lane.  B, At 10, 24, and 48 hrs, LY18 cells were collected and cell 
viability was determined by propidium iodide staining.  Samples were analyzed by flow 
cytometry as described in Material and Methods.  The data are represented as the 
percentage of LY18 cells that are negative for propidium iodide staining.  The data are 
representative of 10,000 cells.   
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Figure 27.  siRNA-mediated knock down of endogenous cyclin D3 does not 
measurably alter the cell cycle in LY18 cells.  LY18 cells were nucleofected in the 
presence of media alone or 300 pmol cyclin D3 siRNA for various lengths of time. LY18 
cells were nucleofected with 300 pmol control siRNA for only 24 hrs.  At 10, 24, and 48 
hrs, LY18 cells were collected and stained with propidium iodide and cell cycle analyzed 
by flow cytometry as described in Materials and Methods.  The data are presented as the 
number of cells (counts) versus propidium iodide (PI-A), with percentages represented by 
black bars, indicating LY18 cells in G1 or S+G2/M-phase of the cell cycle, respectively.  
The data are representative of 10,000 cells.  
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Figure 28.  siRNA-mediated knock down of endogenous cyclin D3 does not 
measurably affect DNA synthesis in LY18 cells.  LY18 cells were nucleofected in the 
presence of media alone or 300 pmol cyclin D3 siRNA for various lengths of time.  LY18 
cells were nucleofected with 300 pmol control siRNA for only 48 hrs.  At the indicated 
times, LY18 cells were collected and DNA synthesis was monitored by BrdU 
incorporation and analyzed by flow cytometry as described in Materials and Methods.  
The data are representative of 10,000 events. 
Figure 28
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Figure 29.  siRNA-mediated knockdown of both cyclin D3 and cyclin E and of cdk4, 
cdk6, and cdk2 reduces constitutive pRbSer807/811 and pRbThr821 phosphorylation in 
LY18 cells.  LY18 cells were nucleofected in the presence of 200 pmol cdk4, cdk6, cdk2, 
cyclin D3, or cyclin E siRNA individually, or both cyclin D3 and cyclin E siRNA 
combined, or cdk4, cdk6, and cdk2 siRNA combined.  At 48 hrs, whole cell extracts were 
prepared and western blotting performed with anti-phospho-pRbSer807/811 and anti-
phospho-pRbThr821 Abs. 
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Table 1.  Target sequences of siRNAs used to knockdown endogenous proteins in 
LY18 cells.  LY18 cells were nucleofected with varying concentrations over time with 
individual siRNA or combinations of siRNAs.  p27 and cyclin D3 siRNA are 
siGENOME target sequences, and cdk4, cdk6, cdk2, and cyclin E are siGENOME 
SMARTpool sequences.
GAUCGAAGCUGCACUCAGGcyclin D3 siRNA
GGAAAUCUAUCCUCCAAAG
GGAGGUGUGUGAAGUCUAU
CUAAAUGACUUACAUGAAG
GUAUAUGGCGACACAAGAA
cyclin E siRNA
GAGCUUAACCAUCCUAAUA
GAGAGGUGGUGGCGCUUAA
GCACCAAGAUCUCAAGAAA
GGACGGAGCUUGUUAUCGC
cdk2 siRNA
GCAAAGACCUACUUCUGAA
GAAGAAGACUGGCCUAGAG
UAACAGAUAUCGAUGAACU
GGCCUUGCCCGCAUCUAUA
cdk6 siRNA
GCAGCACUCUUAUCUACAU
GGAGGAGGCCUUCCCAUCA
UCGAAAGCCUCUCUUCUGU
GUACCGAGCUCCCGAAGUU
cdk4 siRNA
CGACGAUUCUUCUACUCAAp27 siRNA
Non-Targeting siRNA #3Control siRNA
Target Sequences
Table 1
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Figure 30.  siRNA-mediated knock down of endogenous cdk4 has no measurable 
effect on LY18 cell viability.  LY18 cells were nucleofected in the presence of media 
alone or 200 or 400 pmol cdk4 siRNA for various lengths of time.  LY18 cells were 
nucleofected with 400 pmol control siRNA (C) for only 48 hrs.  A, At 24 and 48 hrs, 
whole cell extracts were prepared and Western blotting performed with anti-cdk4, anti-
cdk6, or anti-cdk2 Abs.  The blot was stripped and reprobed with anti-hsp90 Ab to verify 
equal loading of each lane.  B, At 24 and 48 hrs, LY18 cells were collected and cell 
viability was determined by propidium iodide staining.  Samples were analyzed by flow 
cytometry as described in Material and Methods.  The data are represented as the 
percentage of LY18 cells that are negative for propidium iodide staining.  The data are 
representative of 10,000 cells.  
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Figure 31.  Knockdown of endogenous cdk6 following incubation of LY18 cells with 
cdk6 siRNA has no measurable effect on the viability.  LY18 cells were nucleofected 
in the presence of media alone (M) or 200 or 400 pmol cdk6 siRNA for various lengths 
of time.  LY18 cells were nucleofected with 400 pmol control siRNA (C) for only 24 hrs.  
A, At 24 and 48 hrs, whole cell extracts were prepared and Western blotting performed 
with anti-cdk6, or anti-cdk4 Abs.  The blot was stripped and reprobed with anti-hsp90 Ab 
to verify equal loading of each lane.  B, At 24 and 48 hrs, LY18 cells were collected and 
cell viability was determined by propidium iodide staining.  Samples were analyzed by 
flow cytometry as described in Material and Methods.  The data are represented as the 
percentage of LY18 cells that are negative for propidium iodide staining.  The data are 
representative of 10,000 cells. 
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Figure 32.  siRNA-mediated knock down of endogenous cdk4 does not measurably 
alter the cell cycle in LY18 cells.  LY18 cells were nucleofected in the presence of 
media alone or 200 pmol cdk4 siRNA for various lengths of time.  LY18 cells were 
nucleofected with 200 pmol control siRNA (C) for only 48 hrs.  At 24 and 48 hrs, LY18 
cells were collected and stained with propidium iodide and cell cycle analyzed by flow 
cytometry as described in Materials and Methods.  The data are presented as the number 
of cells (counts) versus propidium iodide (PI-A), with percentages represented by black 
bars, indicating LY18 cells in G1 or S+G2/M-phase of the cell cycle, respectively.  The 
data are representative of 10,000 cells. 
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Figure 33.  Knockdown of endogenous cdk6 following incubation of LY18 cells with 
cdk6 siRNA does not measurably alter the cell cycle.  LY18 cells were nucleofected in 
the presence of media alone or 300 pmol cdk6 siRNA for various lengths of time.  LY18 
cells were nucleofected with 300 pmol control siRNA for only 24 hrs.  At 24 and 48 hrs, 
LY18 cells were collected and stained with propidium iodide and cell cycle analyzed by 
flow cytometry as described in Materials and Methods.  The data are presented as the 
number of cells (counts) versus propidium iodide (PI-A), with percentages represented by 
black bars, indicating LY18 cells in G1 or S+G2/M-phase of the cell cycle, respectively.  
The data are representative of 10,000 cells.  
Figure 33
cdk6 siRNA
Control siRNA
Control 24
49.0%
49.2%
62.2%
34.9%
69.5%
26.1%
Media
24 hrs
52.9%
43.1%
48hrs
58.2%
37.1%
144
 145 
Figure 34.  Knockdown of endogenous cdk2 following incubation with cdk2 siRNA 
has no measurable effect on LY18 cell viability.  LY18 cells were nucleofected in the 
presence of media alone or 300 pmol cdk2 siRNA for various lengths of time.  LY18 
cells were nucleofected with 300 pmol control siRNA (C) for only 24 hrs.  A, At 24 and 
48 hrs, whole cell extracts were prepared and Western blotting performed with anti-cdk2 
Ab.  The blot was stripped and reprobed with anti-hsp90 Ab to verify equal loading of 
each lane.  B, At 24 and 48 hrs, LY18 cells were collected and cell viability was 
determined by propidium iodide staining.  Samples were analyzed by flow cytometry as 
described in Material and Methods.  The data are represented as the percentage of LY18 
cells that are negative for propidium iodide staining.  The data are representative of 
10,000 cells. 
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Figure 35.  siRNA-mediated knockdown of endogenous cyclin E has no measurable 
effect on LY18 cell viability.  LY18 cells were nucleofected in the presence of media 
alone or 300 pmol cyclin E siRNA for various lengths of time.  LY18 cells were 
nucleofected with 300 pmol control siRNA for only 24 hrs.  At 24 and 48 hrs, LY18 cells 
were collected and cell viability was determined by propidium iodide staining.  Samples 
were analyzed by flow cytometry as described in Material and Methods.  The data are 
represented as the percentage of LY18 cells that are negative for propidium iodide 
staining.  The data are representative of 10,000 cells. 
Figure 35
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Figure 36.  siRNA-mediated knockdown of endogenous cyclin E has no measurable 
effect on the cell cycle in LY18 cells.  LY18 cells were nucleofected in the presence of 
media alone or 300 pmol cyclin E siRNA for various lengths of time.  LY18 cells were 
nucleofected with 300 pmol control siRNA for only 24 hrs.  At 24 and 48 hrs, LY18 cells 
were collected and stained with propidium iodide and cell cycle analyzed by flow 
cytometry as described in Materials and Methods.  The data are presented as the number 
of cells (counts) versus propidium iodide (PI-A), with percentages represented by black 
bars, indicating LY18 cells in G1 or S+G2/M-phase of the cell cycle, respectively.  The 
data are representative of 10,000 cells.   
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Figure 37.  Knockdown of endogenous cdk2 following incubation of LY18 cells with 
cdk2 siRNA does not measurably alter the cell cycle.  LY18 cells were nucleofected in 
the presence of media alone or 300 pmol cdk2 siRNA for various lengths of time.  LY18 
cells were nucleofected with 300 pmol control siRNA for only 24 hrs.  At 24 and 48 hrs, 
LY18 cells were collected and stained with propidium iodide and cell cycle analyzed by 
flow cytometry as described in Materials and Methods.  The data are presented as the 
number of cells (counts) versus propidium iodide (PI-A), with percentages represented by 
black bars, indicating LY18 cells in G1 or S+G2/M-phase of the cell cycle, respectively.  
The data are representative of 10,000 cells. 
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Figure 38.  siRNA-mediated knockdown of endogenous cdk4 and cdk6 has no 
detectable effect on LY18 cell viability.  LY18 cells were nucleofected in the presence 
of media alone or 200 pmol of both cdk4 and cdk6 siRNA for various lengths of time.  
LY18 cells were nucleofected with 200 pmol control siRNA for only 24 hrs.  At 24 and 
48 hrs, LY18 cells were collected and cell viability was determined by propidium iodide 
staining.  Samples were analyzed by flow cytometry as described in Material and 
Methods.  The data are represented as the percentage of LY18 cells that are negative for 
propidium iodide staining.  The data are representative of 10,000 cells.  
Figure 38
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Figure 39.  siRNA-mediated knockdown of endogenous cdk4 and cdk6 results in an 
increase in the percentage of LY18 cells in G1-phase of cell cycle and a decrease in 
the percentage of LY18 cells in S+G2/M-phase of the cell cycle.  LY18 cells were 
nucleofected in the presence of media alone or 200 pmol of both cdk4 and cdk6 siRNA 
for various lengths of time.  LY18 cells were nucleofected with 200 pmol control siRNA 
for only 24 hrs.  At 24 and 48 hrs, LY18 cells were collected and stained with propidium 
iodide and cell cycle analyzed by flow cytometry as described in Materials and Methods.  
The data are presented as the number of cells (counts) versus propidium iodide (PI-A), 
with percentages represented by black bars, indicating LY18 cells in G1 or S+G2/M-phase 
of the cell cycle, respectively.  The data are representative of 10,000 cells.   
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Figure 40.  siRNA-mediated knockdown of endogenous cdk6 and cdk2 has no 
detectable effect on LY18 cell viability, however, it results in an increase in the 
percentage of LY18 cells in G1-phase of cell cycle and a decrease in the percentage 
of LY18 cells in S+G2/M-phase of the cell cycle.  LY18 cells were nucleofected in the 
presence of media alone or 200 pmol of both cdk6 and cdk2 siRNA for various lengths of 
time.  LY18 cells were nucleofected with 200 pmol control siRNA for only 24 hrs.  A, At 
24 and 48 hrs, LY18 cells were collected and cell viability was determined by propidium 
iodide staining.  Samples were analyzed by flow cytometry as described in Material and 
Methods.  The data are represented as the percentage of LY18 cells that are negative for 
propidium iodide staining.  The data are representative of 10,000 cells.  B, At 24 and 48 
hrs, LY18 cells were collected and stained with propidium iodide and cell cycle analyzed 
by flow cytometry as described in Materials and Methods.  The data are presented as the 
number of cells (counts) versus propidium iodide (PI-A), with percentages represented by 
black bars, indicating LY18 cells in G1 or S+G2/M-phase of the cell cycle, respectively.  
The data are representative of 10,000 cells.  
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Figure 41.  siRNA-mediated knockdown of endogenous cdk4, cdk6, and cdk2 has no 
measurable effect on LY18 cell viability, however, it results in an increase in the 
percentage of LY18 cells in G1-phase of cell cycle and a decrease in the percentage 
of cells in S+G2/M-phase of the cell cycle.  LY18 cells were nucleofected in the 
presence of media alone or 200 pmol of cdk4, cdk6, and cdk2 siRNA for various lengths 
of time.  LY18 cells were nucleofected with 200 pmol control siRNA for only 24 hrs.  A, 
At 24 and 48 hrs, LY18 cells were collected and cell viability was determined by 
propidium iodide staining.  Samples were analyzed by flow cytometry as described in 
Material and Methods.  The data are represented as the percentage of LY18 cells that are 
negative for propidium iodide staining.  The data are representative of 10,000 cells.  B, At 
24 and 48 hrs, LY18 cells were collected and stained with propidium iodide and cell 
cycle analyzed by flow cytometry as described in Materials and Methods.  The data are 
presented as the number of cells (counts) versus propidium iodide (PI-A), with 
percentages represented by black bars, indicating LY18 cells in G1 or S+G2/M-phase of 
the cell cycle, respectively.  The data are representative of 10,000 cells.  
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Figure 42.  siRNA-mediated knockdown of endogenous cyclin D3 and cyclin E has 
no measurable effect on the viability in LY18 cells.  LY18 cells were nucleofected in 
the presence of media alone or 200 pmol of both cyclin D3 and cyclin E siRNA for 
various lengths of time.  LY18 cells were nucleofected with 200 pmol control siRNA for 
only 24 hrs.  At 24 and 48 hrs, LY18 cells were collected and cell viability was 
determined by propidium iodide staining.  Samples were analyzed by flow cytometry as 
described in Material and Methods.  The data are represented as the percentage of LY18 
cells that are negative for propidium iodide staining.  The data are representative of 
10,000 cells. 
Figure 42
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Figure 43.  siRNA-mediated knockdown of endogenous cyclin D3 and cyclin E 
results in an increase in the percentage of LY18 cells in G1-phase of the cell cycle 
and inhibits DNA synthesis.  LY18 cells were nucleofected in the presence of media 
alone or 200 pmol of both cyclin D3 and cyclin E siRNA for various lengths of time.  
LY18 cells were nucleofected with 200 pmol control siRNA for only 24 hrs.  A, At 24 
and 48 hrs, LY18 cells were collected and stained with propidium iodide and cell cycle 
analyzed by flow cytometry as described in Materials and Methods.  The data are 
presented as the number of cells (counts) versus propidium iodide (PI-A), with 
percentages represented by black bars, indicating LY18 cells in G1 or S+G2/M-phase of 
the cell cycle, respectively.  The data are representative of 10,000 cells.  B, At the 
indicated times, LY18 cells were collected and DNA synthesis was monitored by BrdU 
incorporation and analyzed by flow cytometry as described in Materials and Methods.  
The data are representative of 10,000 events.   
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Chapter 3:  Function and regulation of ATP citrate lyase (ACL)  
in B-Lymphocyte growth 
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RESULTS 
 
Glucose-derived carbon is incorporated into de novo lipid synthetic pathways prior to 
the onset of blastogenesis in splenic B cell stimulated through the B cell receptor 
(BCR) 
 One of the biosynthetic fates of glucose is the conversion to lipids during de novo 
lipogenesis.  Bauer et al. has reported that glucose supports de novo lipid synthesis in 
growing hematopoietic cells in a manner that is regulated by cytokine availability [45].  
Lymphocytes undergoing growth and proliferation require a constant supply of lipids to 
fuel membrane biogenesis and protein modifications that are essential for membrane 
integrity, permeability, and signal transduction.  For our study, we analyzed whether 
glucose-derived carbons were incorporated into de novo lipid synthesis in B cells 
stimulated through the BCR.  To determine if glucose was utilized to synthesize de novo 
lipids in growing cells, B cells cultured with anti-IgM and IL-4 were incubated in the 
presence of radiolabeled glucose, cellular lipids extracted, and radioactive counts 
determined.  A significant incorporation of glucose into lipids was observed in anti-
IgM/IL-4 stimulated B cells (Figure 44A).  We then analyzed the content and distribution 
of neutral lipids by means of high-performance thin-layer chromatography (HPTLC) and 
quantitatively analyzed radiolabeled lipids using a Bioscan imaging system.  When 
evaluated at 48 hours, cholesterol (C) and phosphatidylcholine (PC) accounted for the 
bulk of total lipid synthesis, 22.98% and 44.3%, respectively (Figure 44B).  Results 
obtained at 72 hours demonstrated similar levels of cholesterol (C) (14.95%) and 
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phosphatidylcholine (PC) (46.33%), and an increase in triglycerides (TG) (5.45%-
12.94%) (Figure 44B).  Other classes of lipids synthesized included:  cholesterol esters 
(CE), triglycerides (TG), ceramide (CM), phosphatidylethanolamine (PE), and at lower 
levels sphingomyelin (SPM) (Figure 44).  Collectively, these results suggest that glucose 
derived carbon is incorporated into de novo lipid synthesis in B cell stimulated through 
the BCR.  Interestingly, the major lipids synthesized were phosphatidylcholine and 
cholesterol, which make up the major components of biological cell membranes.  
 
ATP citrate lyase (ACL) phosphorylation and ACL enzyme activity is regulated by 
BCR- and IL-4-stimulated splenic B cells 
 ACL is a key enzyme linking glucose metabolism to lipid synthesis.  As discussed 
in the Introduction section, ACL cleaves citrate to generate cytosolic acetyl CoA, a 
lipogenic building block [42,43].  Studies have demonstrated that Akt phosphorylates 
ACL on Ser454 and this phosphorylation stimulates the enzymatic activity of ACL [47-
49].  To determine if ACL is regulated in response to BCR and IL-4 signaling, 
phosphorylation on Ser454 was monitored.  Anti-IgM in addition to IL-4 stimulation led to 
an increase in phospho-ACLSer454 over the 24 hours observed in comparison to untreated 
(M) B cells, while ACL levels remained the same (Figure 45A).  It is important to note 
that we observed two bands in the Western blots probed with anti-ACLSer454 Ab and anti-
ACL Ab.  Currently, we do not know if the second band reflects a non-specific 
interaction of the Ab with an unrelated protein or phosphorylation of ACL on another 
phospho-specific site.  There has been no further analysis at this time.  To test the 
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regulation of ACL in response to cytokine signaling alone, ACL phosphorylation was 
determined in IL-4 stimulated B cells.  Similar results were observed, in that IL-4-
stimulated B cells led to an increase in the phosphorylation of ACL on Ser454 beginning 
at 30 minutes and remained elevated through 24 hours (Figure 46A).  In contrast, 
untreated (M) B cells did not express measurable levels of phospho ACLSer454 (Figure 
46A); total ACL expression levels remained constant over 24 hours (Figure 46A).  To 
assess whether BCR- and IL-4-stimulated phosphorylation of ACL on Ser454 
corresponded to an increase in the ACL enzyme activity we measured enzyme activity by 
the malate dehydrogenase-coupled assay (see Materials and Methods section).  ACL 
enzyme activity is expressed as the oxidation of NADH, to NAD+ + H+, over time as 
measured by the change in absorbance (OD340/mins).  Anti-IgM/IL-4 stimulated B cells 
resulted in a time dependent increase in ACL enzymatic activity (Figure 45B).  
Specifically, an 82.6% increase in ACL enzyme activity was observed from 0-48 hours in 
anti-IgM/IL-4 stimulated splenic B cells (Figure 45B).  Similar results were obtained in 
IL-4 treated B cells in comparison to untreated (0 hrs) cells (Figure 46B).  ACL enzyme 
activity increased by 63.8% in IL-4 stimulated splenic B cells, as measured from 0-30 
hours (Figure 46B).  Of note, the percentage increase in ACL enzyme activity is more 
pronounced in anti-IgM/IL-4 stimulated B cells in comparison to IL-4 alone, because of 
the nature of the stimulation and the time interval observed.  Anti-IgM/IL-4 stimulation is 
a more robust signal, which allows B cells to enter the cell cycle and proliferate.  In 
contrast, IL-4 alone supports B cell growth and survival, but not proliferation.  These 
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results demonstrated that signaling through the BCR and IL-4-stimulated B cells 
phosphorylates ACL on Ser454, thereby increasing ACL enzyme activity over time. 
 
PI-3K activity is required for BCR- and IL-4-induced ACL phosphorylation on Ser454 
and ACL enzyme activity in splenic B cells 
 The PI-3K pathway is activated and plays a role in modulating glycolysis in 
response to BCR cross-linking [24].  We wanted to examine the role of PI-3K activity in 
the regulation of ACL enzyme activity.  To begin, we analyzed ex vivo splenic B cells 
isolated from mice deficient in the p85α subunit of PI-3K, to evaluate the role of PI-3K 
on phospho-ACLSer454 and on ACL enzyme activity.  Specifically, p85α is a regulatory 
subunit of PI-3K, and p85α-deficient mice display a Xid-like immunodeficiency, 
resulting in a shortened life span of ~3 months [173].  The total number of splenic B cells 
isolated from p85α-deficient mice are less then half the number isolated from a wild-type 
littermates [173].  Germane to our studies, p85α deficient B cells treated with LPS, anti-
IgM, or anti-CD40 display impaired proliferative responses as a direct result of impaired 
BCR-induced PI-3K activation [173].  Notably, impairment of BCR-induced glycolysis 
in response to BCR cross-linking was observed in p85α deficient B cells [24].  B cells 
isolated from wild-type mice (PI-3K+/+) that were treated with anti-IgM/IL4 display 
increased levels of phospho-ACLSer454 (Figure 47).  In contrast, anti-IgM/IL4-stimulated 
B cells isolated from p85α subunit deficient mice (PI-3K-/-) did not express measurable 
levels of phospho-ACLSer454 (Figure 47).  Furthermore, ACL enzymatic activity was 
decreased by 52% in p85α deficient mice (KO) and by 51% in p85α heterozygous mice 
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(HT) in comparison to wild-type littermate control mice (WT) at 18 hours (Figure 47 B).  
It is of importance to note that p85α heterozygous mice (HT) display a ~50% decrease of 
p85α subunit expression, in comparison to the KO mice, which display a ~100% 
decrease of the p85α subunit [174].  In summary, these results demonstrate that p85α 
deficient splenic B cells, stimulated through the BCR in addition to IL-4, cannot 
phosphorylate ACL on Ser454, resulting in a decrease in ACL enzyme activity, in 
comparison to wild-type control B cells.   
As a second, independent means to investigate the significance of the PI-3K 
pathway in regulating phosphorylation of ACL on Ser454 and on ACL enzyme activity, B 
cells were stimulated with IL-4 in the presence or absence of the PI-3K inhibitors 
LY294002 (LY) or Wortmannin (WT).  Wortmannin is a fungal metabolite obtained 
from Penicillium fumiculosum, which specifically inhibits PI-3K (IC50 of 2-4 nM) 
through a direct interaction with its catalytic subunit, p110 [174].  LY294002 is also a 
highly selective inhibitor of PI-3K (IC50 of 1.40 µM), which inhibits PI-3K competitively 
with respect to ATP [175].  At 24 hours, treatment with LY, and to a lesser extent WT, 
reduced phopho-ACLSer454 protein expression levels in comparison to IL-4 treated B cells 
(Figure 48A).  ACL levels remained constant (Figure 48A).  Enzymatic activity of ACL 
measured by the malate dehydrogenase-coupled ACL assay revealed that treatment with 
LY and WT significantly reduced ACL catalytic activity (Figure 48B).  At 15 and 24 
hours, IL-4 stimulated B cells that were pretreated with LY displayed a 52.8% and 54.5% 
decrease in ACL activity, respectively, compared to control (IL4) B cells (Figure 48B).  
IL-4 stimulated B cells that were pretreated with WT displayed a 29.8% and 29.6% 
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decrease in ACL activity at 15 and 24 hours, respectively, in comparison to control (IL4) 
B cells (Figure 48B).  Collectively these data suggest that PI-3K activity is required for 
BCR- and IL-4-induced ACL phosphorylation on Ser454 and ACL enzyme activity.   
 
Inhibition of ACL with hydroxycitrate (HC) results in a decrease in BCR-stimulated 
splenic B-lymphocytes 
 Knockdown of ACL results in a decrease in cytokine stimulated cell growth and 
proliferation in normal and malignant cells [45,46].  We sought to begin to understand the 
function of ACL in BCR-induced glucose directed lipogenesis and growth in B cells.  
First, we inhibited ACL activity with hydroxycitrate (HC), which is the main compound 
of Garcinia cambogia extract [176,177].  HC is a competitive blocker of ACL, therefore 
a potential inhibitor of lipid biosynthesis [176,177].  We analyzed the affect of HC on 
cell viability in B cells stimulated through the BCR.  In contrast to anti-IgM/IL4 treated B 
cells, anti-IgM/IL4 incubated cells treated with HC resulted in 15.6% decrease in viable 
B cells at 40 hours (Figure 49).  In summary, these preliminary findings suggest that 
specific inhibition of ACL affects B cell growth and proliferation.   
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FIGURES AND LEGENDS 
 
Figure 44.  Glucose-derived carbon is incorporated into de novo lipid synthetic 
pathways in splenic B cells stimulated via the BCR.  B cells were cultured in 4 ng/ml 
IL-4 (IL4) and 10 µg/mL anti–mouse IgM (IgM) for 48 and 72 hrs.  At several time 
points the cultures were pulsed for 3 hrs with 4 µCi/ml D-[6-14C]glucose to monitor 
glucose-dependent lipid synthesis.  A, HPTLC of neutral lipids from anti-IgM/IL4 
stimulated B cells.  Neutral lipids were isolated, purified, and analyzed by high-
performance thin-layer chromatography (HPTLC) described in Materials and Methods.  
4000 dpm of neutral lipids were spotted per lane.  The plate was developed to a height of 
4.5 cm with chloroform : methanol : acetic acid : formic acid : water (35 : 15 : 6 : 2 : 1 by 
vol), then developed to the top with hexanes : diisopropyl ether : acetic acid (65 : 35 : 2 
by vol).  The bands were visualized by charring with 3% cupric acetate in 8% phosphoric 
acid solution.  CE, cholesterol esters; TG, triglycerides; C, cholesterol; CM, ceramide; 
CB, cerebrosides (doublet); PE, phosphatidylethanolamine; PC, phosphatidylcholine; 
SPM, sphingomyelin; LPC, lysophosphatidylcholine; O, origin; SF, solvent front; Std, 
neutral lipid standard.  The concentration of radiolabeled neutral lipids was determined 
by scintillation counting.  B, Neutral lipid distribution in anti-IgM/IL4 stimulated B cells.  
The percentage distribution of the individual radiolabeled lipid bands were determined by 
densitometric scanning of HPTLC plates on a Bioscan imaging system as previously 
described [166].  Values represent percentages of individual lipids.  
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Figure 45.  Phosphorylation of ATP citrate lyase (ACL) on Ser454 and ACL enzyme 
activity increases in splenic B-lymphocytes stimulated through the BCR.  B cells 
were cultured in the absence (M) or presence of 4 ng/ml IL-4 (IL4) and 10 µg/mL anti–
mouse IgM (IgM).  A, At the indicated times, whole cell extracts were prepared and 
Western blotting was performed with an anti-phospho-ACLSer454 Ab.  The blot was 
stripped and reprobed with an anti-ACL Ab or an anti-hsp90 Ab to ensure equal loading.  
B, At the indicated times, whole cell extracts were prepared and ACL enzyme activity 
was measured via the malate dehydrogenase-coupled method as described in Materials 
and Methods.  ACL enzyme activity is expressed as the oxidation of NADH over time as 
measured by the change in absorbance (OD340/mins). 
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Figure 46.  ATP citrate lyase (ACL) phosphorylation on Ser454 and ACL enzyme 
activity increases in IL-4-stimulated splenic B-lymphocytes.  B cells were either 
untreated (M) or cultured in 4 ng/ml IL-4 (IL4).  A, At the indicated times, whole cell 
extracts were prepared, and Western blotting was performed with an anti-phospho-
ACLSer454 Ab (pACLSer454).  The blot was stripped and reprobed with an anti-ACL Ab or 
anti-hsp90 Ab to ensure equal loading.  B, At the indicated time, whole cell extracts were 
prepared and ACL enzyme activity was measured via the malate dehydrogenase-coupled 
method as described in Materials and Methods.  ACL enzyme activity is expressed as the 
oxidation of NADH over time as measured by the change in absorbance (OD340/mins).  
Results represent mean values of triplicate cultures with lines indicating standard errors 
of the means.  The data are representative of three independent experiments. 
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Figure 47.  Increased phospho-ATP citrate lyase (ACL)Ser454 and ACL enzyme 
activity in response to BCR cross-linking is impaired in PI-3K-deficient B-
lymphocytes.  A, B-lymphocytes were isolated from PI-3K wild-type mice (PI-3K+/+) 
and PI-3K-deficient mice (PI-3K-/-) and were either untreated (M) or stimulated with       
4 ng/ml IL-4 (IL4) and 10 µg/mL anti–mouse IgM (IgM).  At the indicated times, whole 
cell extracts were prepared and Western blotting was performed with an anti-phospho-
ACLSer454 Ab.  The blot was stripped and reprobed with an anti-ACL Ab or anti-hsp90 
Ab to ensure equal loading.  B, B cells were isolated from PI-3K wild-type mice (WT), 
PI-3K heterozygous mice (HT), and PI-3K-deficient mice (KO), and were stimulated 
with 4 ng/ml IL-4 (IL4) and 10 µg/mL anti–mouse IgM (IgM) for 0 and 18 hrs.  At the 
indicated time, whole cell extracts were prepared and ACL enzyme activity was 
measured via the malate dehydrogenase-coupled method as described in Materials and 
Methods.  ACL enzyme activity is expressed as the oxidation of NADH over time as 
measured by the change in absorbance (OD340/mins). 
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Figure 48.  Phosphorylation of ATP citrate lyase (ACL) on Ser454 and ACL enzyme 
activity in IL-4 stimulated B-lymphocytes requires PI-3K activity.  B cells were 
either untreated (IL4, -) or cultured in 4 ng/ml IL-4 (IL4, +) containing a DMSO vehicle 
for 24 hrs; parallel B cells were pretreated (30 mins) in the absence (-) or presence (+) of 
10 µM LY294002 (LY) or 20 nM Wortmannin (WT) and then stimulated with IL-4.  A, 
At the indicated times, whole cell extracts were prepared, and Western blotting was 
performed with an anti-phospho-ACLSer454 Ab.  The blot was stripped and reprobed with 
an anti-ACL Ab or anti-hsp90 Ab to ensure equal loading.  B, At the indicated time, 
whole cell extracts were prepared and ACL enzyme activity was measured via the malate 
dehydrogenase-coupled method as described in Materials and Methods.  ACL enzyme 
activity is expressed as the oxidation of NADH over time as measured by the change in 
absorbance (OD340/mins).  
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Figure 49.  Treatment of splenic B-lymphocytes stimulated via the BCR with 
hydroxycitrate (HC) causes a decrease in viable cells.   B cells were cultured in the 
absence (Media) or presence of 4 ng/ml IL-4 (IL4) and 10 µg/mL anti–mouse IgM (IgM) 
for 40 hrs; parallel anti-IgM/IL-4 stimulated B cells were cultured with 100 µM 
hydroxycitrate (HC).  At the indicated times, B cells were collected and cell viability was 
determined by propidium iodide staining.  Samples were analyzed by flow cytometry as 
described in Material and Methods.  The data are represented as the percentage of B cells 
that were negative for propidium iodide staining.  The data are representative of 10,000 
cells.  
Figure 49
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DISCUSSION 
 
I. Chapter 1 
 In summary, the non-overlapping expression between cyclin D2 and cyclin D3 in 
B-1a cells allowed us to examine the role of cyclin D3 in late G1-phase.  The early and 
transient up-regulation of cyclin D2 is not enough to drive stimulated B-1a cells into S-
phase of the cell cycle.  This is supported by our data, which indicated that inhibition of 
cyclin D3-cdk4/6 complexes with TAT-p16 wild-type peptide blocked normal B-1a cell 
proliferation in response to PMA, LPS, and CD40L.  However, studies in PMA-
stimulated B-1a cells deficient in cyclin D3 (cyclin D3-deficient mice) did not 
demonstrate a decrease in proliferation.  Our studies demonstrated that a compensatory 
increase in cyclin D2 mRNA (data not shown) and continuous expression of functional 
cyclin D2 protein was able to overcome the cyclin D3 deficiency and drive cells into S-
phase.  Therefore, dysregulated cyclin D2 expression can compensate in PMA-stimulated 
B-1a cells deficient in cyclin D3 and drive cell cycle progression.  It is important to note 
that compensation by cyclin D2 in cyclin D3-deficient mice can mask the normal 
function that cyclin D3 provides in the mitogenesis of B-1a cells.  
 Previous findings from the Chiles’ Lab demonstrate that cyclin D3 is uniquely 
positioned to progress B-1a cells from G1-S-phase [65,134].  Specifically, cyclin D2 
expression increases rapidly and transiently in PMA-stimulated B-1a cells and forms 
active complexes with cdk4/6, which accounts for a minor amount of pRb 
phosphorylation [65].  However, in late G1-phase, phosphorylation of pRb on cdk4/6 
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specific sites dramatically increases (during the time when cyclin D2 protein level were 
not detectable), which corresponded with an increase in cyclin D3 expression levels and 
active cyclin D3-cdk4/6 complexes [134].  We were able to transduce TAT-p16 peptides 
into ~100% of primary B-1a cells [124].  This technology is very specific and efficient as 
it allowed us to avoid any of the associated problems with plasmids, such as artifacts 
induced by the unregulated expression of recombinant proteins [157].   TAT-p16 peptide 
(a p16INK4a mimetic) was able to bind cdk4 and cdk6, however the charge-matched 
mutant control TAT-p16 was not.  TAT-p16 wild-type peptide blocked cyclin D3-cdk4/6 
assembly and resulted in a loss of PMA-stimulated phospho-pRb on the specific cdk4/6 
phosphorylation site.  Induction of TAT-p16 peptides into PMA-stimulated B-1a cells 
produced an inhibition in B-1a cell proliferation, as evidence by reduced PMA-stimulated 
tritiated thymidine incorporation and reduced percentage of B-1a cells in S+G2/M-phases 
of the cell cycle.  Comparable results were observed in B-1a cells stimulated with LPS or 
CD40L.   
 Mice have been generated that are deficient in individual D-type cyclins.  
Interestingly, although D-type cyclin expression is widespread, mice with an individual 
D-type cyclin deficiency display very narrow, tissue specific phenotypes [89].  
Specifically, cyclin D1-deficient mice are viable and display neurological abnormalities 
and cyclin D2-deficient mice are viable and display cerebellar development 
abnormalities, B-lymphocyte proliferation abnormalities, and pancreatic β-cell 
proliferation abnormalities [89].  Finally, cyclin D3-deficient mice are viable and display 
defects in the development of T-Lymphocytes [89].  Mice lacking combinations of the D-
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type cyclins have also been generated.  Double knockout mice display the sum of the 
abnormalities observed in the individual deletions and mice deficient in cyclin D1, D2, 
and D3, die at embryonic day 17.5 [89].  Specifically, mice deficient in all D-type cyclins 
are lethal because of the failure of HSCs to proliferative, demonstrating that specific 
lineages of cells (i.e., lymphocytes) critically require D-type cyclins [72].  These 
observations suggest that in D-type cyclin knockout mice the remaining intact D-cyclins 
allow for relatively normal development.  
 An interesting finding from our results is that cyclin D2 induction alone is not 
sufficient to mediate proliferation induced by PMA, LPS, or CD40L, in B-1a cells where 
cyclin D3-cdk4/6 complex assembly has been selectively disrupted by TAT-p16 peptide.  
This might reflect the relatively low pRb kinase activity associated with cyclin D2-cdk4/6 
complexes and/or the transient nature of cyclin D2 holoenzyme activation in stimulated 
B-1a cells [65].  Without further phosphorylation on pRb by cyclin D3-cdk4/6 
complexes, the duration of active cyclin D2-cdk4/6 complexes may not be strong enough 
to drive progression through the R point and into S-phase of the cell cycle.  It is important 
to point at that we do not believe that TAT-p16 was able to block cell cycle progression 
in B-1a cells because of disruption of cyclin D2 that may be below our level of detection.  
pRb kinase activity of cyclin D2 is relatively low as compared with cyclin D3.  
Alternatively, in actively proliferating B-1a cells, cyclin D2 function may not be directly 
involved in cell proliferation, but rather it may be involved and limited to cell growth 
(i.e., accumulation of cell mass) and survival, occurring early in G1-phase of the cell 
cycle.  It is well documented that in rapidly proliferating human germinal center B cells 
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that cyclin D2 complexes fail to mediate significant pRb phosphorylation, suggesting that 
cyclin D3, is the key D-type cyclin regulating cell cycle progression [92].  Interestingly, 
studies performed in pro-B cell lines demonstrate a role of cyclin D2 in survival.  
Specifically, ectopic expression of cyclin D2 is sufficient to prevent apoptosis induced by 
cytokine withdrawal [178].  These findings provide further evidence for cell type-specific 
utilization of D-type cyclins.  It is also of importance to note that while studies in cyclin 
D2-deficient mice has revealed significantly decreased numbers of peritoneal B-1a cells, 
the molecular mechanism(s) underlying this loss remains to be established [81]. 
 The possibility that cyclin D3 may carry out addition roles in B-1a cells separate 
from regulating pRb phosphorylation and G1-S-phase progression, can not be ruled out.  
Although the D-type cyclins show high amino acid homology within the cdk-binding 
region (75-78%), the extent of homology outside of that region is 39-47% [77,78].  In 
addition to their cell cycle role, D-type cyclins have cdk-independent functions that act as 
either positive or negative regulators of transcription factors, such as STAT3 and cyclin 
D-interacting myb-like protein-1 [72]. Specifically, the cdk-independent role of cyclin D1 
as an inhibitor of STAT3 activation, suggests a novel biological role of cyclin D1 in 
feedback regulation [179].  Furthermore, cyclin D3 was identified as a negative regulator 
of the hemopoietic transcription factor acute myeloid leukemia 1 (AML1), presumably by 
a mechanism that involves displacement of core binding factor β from AML1, thereby 
inhibiting AML1 DNA binding to target gene promoters [180].  The direct association of 
AML1 with cyclin D3 functions as a potential feedback mechanism to regulate cell cycle 
progression [180].  Recent reports by Gu and coworkers [181] have served to extend the 
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list of cyclin D3 partner proteins beyond transcriptional regulators to include the signal 
transduction protein kinase ERK3.  Extracellular signal-related kinase 3 (ERK3) 
potentially inhibits cell cycle progression [181].  The functional consequences of the 
interaction between cyclin D3 and ERK3 need to be further investigated to elucidate the 
involvement in cell cycle regulation [181].  Nonetheless, our results provide the first 
direct proof that cyclin D3 assembled complexes with cdk4/6 are required for the G1-S 
phase progression in stimulated B-1a cells.   
 We further analyzed the function of cyclin D3 by isolating and then stimulating 
B-1a cells from cyclin D3-deficient mice.  Homozygous mice containing a mutant allele 
with a targeted deletion of the first two coding exons of cyclin D3 are viable, but suffer 
defects in thymocyte development characterized by reduced CD4+CD8+ double-positive 
T cells [95].  Cyclin D3-deficient mice display a decrease over wild-type littermates in 
the total splenocytes produced, specifically, by a decrease in the number of splenic B-2 
cells.  Further studies need to be performed to investigate these findings. Importantly, a 
cyclin D3 deficiency did not impact the peritoneal B-1 compartment in comparison to 
wild-type littermate controls.  These results suggest that cyclin D3, but not cyclin D2, is 
dispensable for B-1 cell development, self-renewal, and function.  As mentioned, cyclin 
D2-deficient mice have a significant decrease in peritoneal CD5+ B cells [87].  Thus , 
cyclin D2 provides a nonredundant function in the development and/or self-renewal of 
peritoneal B-1a cells.  
 PMA-stimulated peritoneal B-1a cells isolated from cyclin D3-deficient mice, 
proliferate at a normal rate in comparison to wild-type B-1a cells.  Our results with the 
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use of TAT-p16 peptides in normal cells B-1a cells indicates that cyclin D3 is significant  
for mediating proliferation in PMA-, LPS-, and CD40L-stimulated cells.  Results in 
cyclin D3-deficient B-1a cells displayed an increase in cyclin D2 gene expression 4-fold 
above the levels found in PMA-stimulated wild-type B-1a cells [124].  Furthermore, the 
elevated levels of cyclin D2 mRNA [124] is associated with an increased and sustained 
expression of cyclin D2 protein throughout G1-S-phase in cyclin D3-deficient B-1a cells.  
The sustained expression of cyclin D2 contrasts with the early and transient expression of 
cyclin D2 in wild-type, PMA-stimulated B-1a cells.  The possibility that cyclin D2 may 
functionally replace cyclin D3 is strengthened by the observation that the level of 
endogenous pRb phosphorylation on cdk 4/6-targeted residues in cyclin D3-deficient B-
1a cells is comparable to that of wild-type B-1a cells similarly stimulated with PMA for 
21 hours.  Additional support for the notion that cyclin D2 may be functioning to 
compensate for cyclin D3 loss in driving B-1a cell proliferation by PMA was obtained in 
that DNA synthesis was blocked by transduction of TAT-p16 wild-type, but not TAT-
p16 mutant peptides into cyclin D3-deficient B-1a cells.  It is important to note, that mice 
with both cyclin D2 and cyclin D3 genes knocked out are not viable and die by E18.5 
[182].  While death is due to severe anemia, other hematopoietic lineages were not 
evaluated [182].  Although we cannot entirely rule out the possibility of a compensatory 
role by a cyclin D-independent pathway in PMA-induced B-1a cell proliferation, it is 
noteworthy that no measurable changes in the timing and level of gene expression for the 
E-type cyclins were observed between wild-type and cyclin D3-deficient B-1a cells 
stimulated with PMA [124].  Taken together, we interpret these finding as indicating that 
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although cyclin D3 normally fulfills a critical role in late G1-phase, in the absence of 
cyclin D3, PMA can drive B-1a cell proliferation via sustained expression of cyclin D2.  
Currently, the molecular mechanisms underlying the sustained expression of cyclin D2 in 
cyclin D3-deficient mice is unknown.   
 The compensatory accumulation of cyclin D2 raises the possibility of a negative 
feedback loop, in which cyclin D3 limits the duration of cyclin D2 accumulation in 
normal B-1a cells.  Genetic ablation of cyclin D3 would then be predicted to relieve this 
restriction, thereby allowing for sustained accumulation of cyclin D2 throughout the G0-S 
interval.  It remains unclear whether the apparent compensatory mechanism for cyclin D2 
up-regulation identified here is present (but not activated) in wild-type B-1a cells, or only 
comes into play when cyclin D3 is completely absent. 
The finding that sustained accumulation of cyclin D2 is functioning in a 
compensatory manner, with regard to mediating S-phase entry, represents a unique 
opportunity to understand the molecular mechanisms that control the accumulation of 
cyclin D2.  Importantly, induction of D-type cyclins by mitogens is controlled, in part, 
through de novo transcription and increased translation, whereas D-type cyclin turnover 
is controlled by ubiquitin-mediated proteasome degradation [60].  Our knowledge of 
these events is largely limited to studies performed with cyclin D1.  To begin to 
understand the molecular basis for the sustained accumulation of cyclin D2 in cyclin D3-
deficient B-1a cells, we examined the stability (half-life of protein turnover) of 
endogenous cyclin D2 and cyclin D3 proteins in PMA-stimulated B-1a cells.  Our data 
supports that cyclin D2 and D3 are degraded via ubiquitination and the proteasome 
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pathway.  These preliminary data suggest that cyclin D2 is less stable and has an 
increased turnover rate in comparison to cyclin D3 in B-1a cells isolated from wild-type 
mice.  Should further analysis support these findings, then experiments will be performed 
to compare these readouts with data from parallel experiments in cyclin D3-deficient B-
1a cells.  We hypothesize that cyclin D2 protein will exhibit an increase in stability (i.e., 
half-life) in cyclin D3-null B-1a cells in comparison to wild-type B-1a cells.  To note, 
should there be no differences in protein stability, we will evaluate the potential 
differences in de novo cyclin D2 transcription rates in both wild-type and cyclin D3-
deficient B-1a cells.  Should our results support our hypothesis, then we will begin to 
investigate the pathway(s) involved in the turnover of cyclin D2 and whether or not they 
are altered in cyclin D3 B-1a cells.  For example, we will evaluate the contributions of 
putative phosphorylation events and ubiquitination of cyclin D2.  Additional experiments 
are underway to further elucidate the molecular basis of sustained cyclin D2 
accumulation in cyclin D3-deficient mice. 
In summary, our findings report that disruption of cyclin D3 blocks proliferation 
of normal B-1a cells, but loss of cyclin D3 is compensated by cyclin D2 in cyclin D3-
deficient mice.  The importance of understanding the molecular mechanisms that regulate 
entry into S-phase in B-1 cells cannot be overstated as proliferation represents a 
fundamental determinant in the maintenance of the self-replenishing population of 
peritoneal B-1 cells in the adult.  Moreover, the expansion of auto reactive B-1 cells is 
associated with malignancy and autoimmune disease, a fact that emphasizes the 
importance of understanding the biology of R point control in this B cell subset.  
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II. Chapter 2 
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of lymphomas 
characterized by a diffuse pattern of growth.  DLBCL’s commonly display 
overexpression of the genes CDK2 in 12q13.3 and CDK4 in 12q14.1 along the 12q region 
[146-149]; however, little is known regarding the function of the G1-cdk-dependent 
pathways in DLBCL.  Our studies herein demonstrate that human LY18 cells express 
endogenous cyclin D3 protein with no measurable detection of cyclin D1 or D2 proteins 
by Western blotting.  Furthermore, they express endogenous cdk4, cdk6, and cdk2 
proteins.  Together, these findings suggest that G1-phase proteins in LY18 tumor cells 
form constitutively active cyclin-cdk complexes, which phosphorylate pRb and 
potentially promote deregulated cell cycle progression.  In support of the former, we find 
that cyclin D3 forms active complexes with cdk4 and cdk6, and that cyclin E forms active 
complexes with cdk2 (data not shown).  This is confirmed by our results that demonstrate 
that endogenous pRb is constitutively phosphorylated on Ser807/811 and Thr821, the cdk4/6 
and cdk2 target sites, respectively.  Importantly, no measurable levels of endogenous 
cdk-inhibitors (i.e., p16, p21, or p27) were observed. 
The majority of tumor cells express two or three D-type cyclins [76].  
Interestingly, our studies have revealed that LY18 cells express cyclin D3 as the only 
detectable D-type cyclin.  The selective expression of cyclin D3 provides a unique 
opportunity to investigate its role in DLBCL cell cycle progression and survival.  As 
opposed to cyclin D1 and cyclin D2, cyclin D3 has not been conclusively shown to 
promote oncogenesis [76].  For example, the cyclin D1 gene is amplified or rearranged 
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and the protein is overexpressed in several human cancers (e.g., breast carcinomas, 
mantle cell lymphomas, and MM) [95,135].  The cyclin D2 gene is amplified in human 
testicular tumors, while the protein is overexpressed in B cell lymphocytic leukemias, 
lymphoplasmacytic lymphomas, and chronic lymphocytic leukemias [95].  Extensive 
studies in lymphocytes have shown that endogenous cyclin D3 expression correlates with 
proliferation [76,92,94].  LY18 cells are classified as GC-like DLBCL, meaning they 
exhibit a similar gene and protein expression profile [93] of normal GC B cells, which 
undergo rapid proliferation and clonal expansion.  GC B cells actively repress cyclin D2 
and growth, in order to rapidly proliferate, which may be mediated by cyclin D3 [181].  
Gene expression profiling of distinct types of DLBCL by Staudt and colleagues, note the 
expression of BCL-6, a well-established germinal center marker, in the GC B-like 
DLBCL signature [93].  Microarray analysis of B cell lines that express BCL-6 revealed 
that cyclin D2 is repressed by BCL-6 [183].  Collectively, these data suggest that in GC B 
cells, BCL-6 actively represses cyclin D2, to promote rapid cell proliferation.  Being that 
LY18 cells are GC-like B cells, it is probable that cyclin D2 is repressed in these cells by 
BCL-6.  The mechanism by which cyclin D3 is constitutively expressed in LY18 cells is 
currently unknown.  Interestingly, it is hypothesized that BCL6 may indirectly induce c-
myc expression, which promotes progression through the cell cycle by induction of D-
type cyclins [135]. As noted in the Introduction section, LY18 cells carry a translocation, 
which leads to an alteration of myc-IgH genes and a high transcription rate of c-myc 
[150].  The role of c-myc and cyclin D3 in LY18 cells remains to be characterized. 
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 The unique expression of cyclin D3 complexed with cdk4/6 provided the means 
to dissect the role of cyclin D3 in G1-to-S-phase progression in LY18 cells.  To 
summarize the findings herein, inhibition of cyclin D3-cdk4/6 complexes with TAT-p16 
wild-type peptide resulted in an increased expression of hypodiploid DNA and LY18 cell 
apoptosis.  In untreated LY18 cells and TAT-p16 mutant peptide treated cells, high 
expression levels of endogenous phospho-pRbSer807/811 were observed, which was 
expected in these hyper-proliferative tumor cells.  However, LY18 cells treated with 
TAT-p16 wild-type peptide displayed a decrease in endogenous phosphorylation on 
pRbSer807/811, supporting the idea that TAT-p16 is disrupting cyclin D3-cdk4/6 complex 
formation and activity.  Our data reveals that disruption of active cyclin D3-cdk4/6 
complexes with TAT-p16 peptides results in an inhibition in LY18 cell proliferation and 
ultimately apoptosis.  The molecular mechanism linking cell cycle arrest and apoptosis 
are currently unknown in LY18 cells and are under investigation. 
 The use of cyclin dependent kinase inhibitors has recently received attention, 
because inhibiting cdk function has been shown to induce cell cycle arrest as well as 
apoptosis in cancer cell types [151,184,185].  Specifically, the cdk inhibitors flavopiridol, 
seliciclib, and BMS-387032 (SNS-032) have been extensively tested in clinical trials 
[96].  Flavopiridol is a pan cdk inhibitor, while seliciclib and BMS-387032 are cdk2 
specific inhibitors [96].  Currently these cdk inhibitors are undergoing analysis to 
determine whether promiscuous cdk inhibitors are preferable to selective cdk inhibition 
[96].  To corroborate the TAT-p16 study, we investigated the contribution of cdk4 
inhibition in LY18 cells.  In this study cdk4 was inhibited using the small molecular 
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weight compound, 2-bromo-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-
5,7(6H)-dione (denoted as cdk4i), which has previously been shown, in vitro, to inhibit 
cdk4 with an IC50  of 0.076 µM for cdk4, 0.52 µM for cdk2, and 2.1µM for cdk1, as 
determined by inhibition of Rb phosphorylation [169,170].  Cdk4i is a cell permeable 
compound that has been previously shown to induce G1 arrest in human colon carcinoma 
and non-small-cell lung carcinoma cell lines [169,170].  The use of low-molecular-
weight compounds to inhibit protein function has the benefit of being more stable with 
better bioavailability as compared with other biologic and peptide inhibitors [151].   
We show for the first time that 5 µM cdk4i induces G1-phase arrest in LY18 cells.  
Our results also strike a cautionary note by demonstrating that increased concentrations 
of cdk4i have different effects on cell cycle progression and viability.  At 10 and 25 µM, 
we observed a significant decrease in cell viability, whereas there is no measurable effect 
with 5 µM cdk4i.  Notably, treatment of LY18 cells at 25 µM results in a G2/M-phase 
block in cell cycle progression followed by apoptosis.  We believe these results 
exemplify the fact that at higher concentrations cdk4i targets cdk2 and cdk1.  This is not 
uncommon; as studies demonstrate that the majority of compounds that inhibit cdk2 also 
inhibit cdk1, resulting in an observed S-G2/M arrest [96].  Specifically, this has been 
observed and is undergoing analysis in the cdk2-specific inhibitors, seliciclib and BMS-
387032.  To avoid promiscuous cdk4i activity, we used 5 µM cdk4i in the remaining 
experiments to examine the G1-phase arrest that was observed in LY18 cells.  Finally, in 
corroboration with the cell cycle studies above, cdk4i inhibited DNA synthesis in LY18 
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cells.  These results suggest that cyclin D3-cdk4/6 activity is critical for proliferation of 
LY18 cells.  
 To begin to delineate the molecular mechanism(s) underlying the observed 
results, we evaluated specific G1-protein expression profiles in LY18 cells treated with 
cdk4i.  Treatment with cdk4i resulted in a decrease in endogenous cdk4 and cyclin D3 
protein levels over the observed length of time, but had no effect on cdk6 levels.  The 
turnover of cyclin D3 is not surprising as cyclin D3-cdk4 complex formation was 
disrupted and the D-type cyclins are only stable when bound to cdk4/6 (data not shown).  
However, it cannot be ruled out that cdk6 turnover could take longer then 48 hours in 
LY18 cells.  Our results demonstrated that cyclin D3 forms complexes with cdk6, 
however the extent of their activity in LY18 cells needs to be further evaluated.  
Additional data revealed that phosphorylation of cdk2 on Thr160, a step is necessary to 
activate cdk2 kinase activity, is decreased in cdk4i treated LY18 cells.  Total levels of 
cdk2 were not affected.  These data suggest that following inhibition of cyclin D3-cdk4 
complexes, downstream inhibition of cyclin E-cdk2 complexes occurs.  Further evidence 
of functional inhibition of active cyclin D3-cdk4/6 and cyclin E-cdk2 complexes was 
supported by our findings that cdk4- and cdk2-mediated phosphorylation of pRb on 
Ser807/811and Thr821, respectively, were decreased over time.  
As the results demonstrate thus far, the disruption of cyclin D3-cdk4 complexes 
results in a decrease in pRb phosphorylation at the cdk4/6 specific site.  Downstream 
there is inhibition of cyclin E-cdk2 complex activation as evidence by the decrease in 
pRb phosphorylation on Thr821, the cdk2 target residue.  Strikingly, our data revealed that 
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in LY18 cells treated with cdk4i there was a dramatic increase in endogenous p27 protein 
expression levels over 48 hours.  This would provide the molecular link between cyclin 
D3-cdk4 complexes and cyclin E-cdk2 complexes.  It was hypothesized that the observed 
expression of p27, in LY18 cells treated with cdk4i, functions to bind and inhibit cyclin 
E-cdk2 complexes.  Germane to these findings, the literature reports that in many cell 
types (although not universal), cell cycle progression is dependent on the balance of 
sequestered p27 by cyclin D-cdk complexes and free p27, which is able to bind and 
inhibit cyclin E-cdk2 complex activity [92,106,135,172].  In lymphoid tissues, the 
expression of p27 is inversely related to proliferation; strong p27 expression is detected 
in quiescent cells, whereas p27 is down regulated in proliferating cells (i.e. GC-B cells).  
Recent studies have also identified p27 expression in malignant lymphomas as having 
independent prognostic significance, in which low p27 and high cyclin E expression are 
significantly associated with a poor prognosis [186].  Collectively, these studies 
demonstrate that p27 has the potential to be a major factor in regulating cell growth arrest 
in certain cell types [92,106].   
To test the hypothesis that upregulation of endogenous p27 regulates cell cycle 
arrest in cdk4i treated LY18 cells, we transduced TAT-p27 fusion proteins into untreated 
LY18 (i.e., no cdk4i).  Introduction of various concentrations of exogenous TAT-p27 did 
not have any affect on LY18 cell viability or on cell cycle progression.  At this time, p27 
does not appear to mediate G1-phase arrest in LY18 cells.  TAT-protein signal technology 
typically displays rapid and efficient uptake into cells, however, it is important to note 
that we do not know whether TAT-p27 was efficiently transduced into LY18 cells.  Nor 
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is it known whether transduced TAT-p27 was being degraded or sequestered by the 
abundant amount of cyclin D3.  To circumvent these concerns, we adopted a siRNA-
based approach to knockdown endogenous p27 protein levels.  LY18 cells pretreated 
with cdk4i, followed by p27 siRNA did not display a decrease in viability or any changes 
in cell cycle progression in comparison to LY18 cells treated with cdk4i alone.  It is of 
interest to point out that in numerous experiments we were able to significantly 
knockdown p27 protein expression with siRNA and there was no observed compensatory 
increase of p21.  As the aforementioned data supports, it is likely that increased 
expression of p27 plays no role in cdk4i mediated LY18 cell cycle arrest.  Germane to the 
findings, it has been reported that a broad range of p27 expression exists in DLBCL, 
ranging from absence of protein expression to overexpression with no positive or 
negative correlation between p27 and proliferation in DLBCL [135,140].  Should 
additional analysis confirm that p27 does not play a role in the cdk4i-mediated cell cycle 
arrest observed in LY18 cells, then the promiscuity of cdk4i will be investigated.  At this 
time, we cannot rule out that 5 µM cdk4i is binding cdk4/6, cdk2, and cdk1.  While this 
may represent a potential caveat to our interpretations, the importance of understanding 
the role of cyclin-cdk complexes and cell cycle progression in LY18 cells remains 
significant.  
Given that there was no observable phenotype in cdk4i treated LY18 cells, 
depleted of p27, we decided to analyze the role of cyclin D3 by RNA interference.  
Surprisingly, our results indicated that specific knockdown of cyclin D3 with cyclin D3 
siRNA, had no effect on LY18 cell viability, cell cycle progression, or DNA synthesis.  
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Importantly, these results are not due to compensation via upregulation of cyclin D1 or 
D2 as our analysis points out.  siRNA-mediated knockdown of cyclin E also displayed no 
significant effect on LY18 cell viability or cell cycle progression.  Interestingly, our data 
revealed that in cells without cyclin D3 the cdk4/6 specific phosphorylation target residue 
on pRb is phosphorylated, which suggests that cdk4 and/or cdk6 are enzymatically active 
in the absence of cyclin D3.  Similar results were observed in siRNA-mediated 
knockdown of cyclin E with regards to phosphorylation on pRbThr821, the cdk2-specific 
residue. 
Given this data and the propensity for G1-protiens to functionally overlap it is 
likely that there is a compensatory mechanism in LY18 cells.  Our results suggest that 
cyclin E can compensate where cyclin D3 is depleted and vice versa.  This observation 
has also been reported in breast cancer cells, where cyclin E can compensate for a cyclin 
D deficiency [139,187].  A built-in redundancy for critical cell cycle regulators seems to 
exist in LY18 cells.  Depletion of cyclin D3 or cyclin E individually, failed to result in 
cell cycle arrest, whereas combined, the depletion of cyclin D3 and cyclin E was 
sufficient to induce G1-phase arrest, which coincided with a decrease in DNA synthesis.  
Importantly, we also observed with siRNA-mediated knockdown of both cyclin D3 and 
cyclin E a decrease in phospho-pRb on Ser807/811 and Thr821.  The question remains, when 
cyclin D3 is depleted does cdk4 and cdk6 bind cyclin E in early G1, or are cyclin E-cdk2 
complexes enough to drive LY18 cell cycle progression?  Also, it cannot be ruled out that 
cdk4, cdk6, or cdk2 are functioning independently of cyclin activation.  In studies 
performed with mice deficient in D-type cyclins, there was an observed decrease in pRb 
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phosphorylation on Ser807/811, but there was still phosphorylation on pRbThr821.  These 
results provide evidence that cyclin E-cdk2 can function independently of cyclin D-
cdk4/6 complexes [72].  At this time it is unclear how induction of cyclin E occurs 
without the initial cyclin D-dependent phosphorylation on pRb to induce cyclin E 
expression.  We observed that the cdk4/6 phospho-specific target sites on pRb were 
phosphorylated in cyclin D3 depleted LY18 cells.  Based on these observations, we 
speculate that cdk4 and cdk6 form active complexes with cyclin E in early G1-phase, 
while active cyclin E-cdk2 complexes function in late G1-phase.  In support of our 
observations, studies performed in cyclin D1-deficient mice, where cyclin E was 
knocked-in are phenotypically normal [138].  Cyclin E knock-in rescued all phenotypic 
manifestations of cyclin D1 deficiency and restored normal development in cyclin D1-
dependent tissues [138].  Thus, cyclin E can functionally replace D-type cyclins.  
Mice depleted of all D-type cyclins die before E17.5 due to severe anemia, 
cardiac abnormalities, and severely defective hematopoietic lineages [72].  In a parallel 
study, mice lacking cdk4 and cdk6 were generated, which displayed similar phenotypes 
to the D-type cyclin knockouts [188].  Cdk4 and cdk6-deficient mice die between E14.5 
and the end of gestating due to severe anemia and hematopoietic abnormalities [188].  
The hematopoietic abnormalities were less pronounced in the cdk4- and cdk6-deficient 
mice due to compensation by cdk2 [188].  These results conclude that mice lacking either 
the D-type cyclins or their catalytic partners display similar phenotypes.  With this in 
mind, we sought to evaluate cell cycle control in LY18 cells by RNA interference 
targeted against cdk4, cdk6, and cdk2.  Depletion of cdk4, cdk6 or cdk2 individually, 
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failed to result in cell cycle arrest, whereas different combinations of the three were 
sufficient to induce G1-phase arrest and a decrease in DNA synthesis.  Specifically, we 
found that knockdown of cdk4 and cdk6 with siRNA resulted in 75% of cells in G1-
phase, siRNA-mediated knockdown of cdk6 and cdk2 resulted in a 70% G1-phase arrest, 
and siRNA-mediated knockdown of cdk4, 6, and 2 combined resulted in an 86.7% G1-
phase arrest.  We hypothesize that in cdk4, 6, or 2 deficient LY18 cells, the remaining 
cdks are able to compensate.  In support of our hypothesis, the data demonstrated that 
phosphorylation of pRb on cdk4/6 and cdk2-specific residues were not disrupted where 
individual cdks were knocked down.  For example, LY18 cells that are proliferating 
without cdk2 show that cdk4 and/or cdk6 can phosphorylate pRb at the cdk2 specific site.  
It is only with depletion of cdk4 and cdk6, cdk6 and cdk2, or cdk4, 6, and 2 that we 
observe a decrease in pRb phosphorylation on Ser807/811 and Thr821.   
In summary, our siRNA data supports that cdk4 and cdk6 can form active 
complexes with cyclin E and phosphorylate pRb on Thr821.  Also, that cdk2 can form 
complexes with cyclin D3, which in turn phosphorylates pRb on Ser807/811.  In support of 
this hypothesis the literature demonstrates that cyclin D3 can form active complexes with 
cdk2 [189].  Also, it is reported that cdk2 activity can be dispensable for cancer cell 
proliferation due to high levels of cdk4 activity, which compensates for the loss cdk2 that 
is typically required during cell cycle progression [140].  Currently, the molecular 
mechanisms underlying these observed results are unknown and present the need for 
future studies. 
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In conclusion, we find that cyclin D3 is dispensable for the growth and survival of 
LY18 cells, as evidence for redundancy by cyclin E.   
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III. Chapter 3 
 Maintaining glucose energy metabolism is essential for B-lymphocyte growth and 
function.  B-lymphocytes rapidly increase glucose uptake and hyper-induce glycolytic 
flux in response to BCR-crosslinking [24].  The fate of glucose-derived carbon in B cells 
remains unknown.  An advantage of catabolizing glucose through glycolysis at a rate that 
exceeds bioenergetic demand, instead of undergoing complete oxidation of glucose by 
the TCA cycle, is that the growing cell can redirect excessive pyruvate toward lipid 
synthesis.  Growing cells must be able to double their macromolecular mass and 
continuously duplicate phospholipids, sphingolipids, cholesterol, and lipid moieties for 
protein modifications that are essential for signal transduction and cell membrane 
integrity.  Specifically, the differentiation of activated B cells into plasma cells is 
characterized, in part, by the expansion of the intracellular membrane network (i.e., the 
endoplasmic reticulum and the Golgi compartments), where immunoglobulins are 
synthesized and assembled into functional antibodies [190].  We hypothesize that 
activated B cells process glucose at such high rates to produce biosynthetic substrates.  
We found that glucose-derived carbons were incorporated into de novo lipid synthetic 
pathways in B cells stimulated through the BCR.  Importantly, at 48 hours, IgM- and IL4-
stimulated B cells primarily synthesized phosphatidylcholine and cholesterol.  
Phosphatidylcholine is a phospholipid that makes up the major component of biological 
cell membranes, thereby supporting our hypothesis that glucose-derived carbons must be 
shuttled towards new membrane synthesis to support cell growth and division.  Germane 
to our studies, phosphatidylcholine is also the primary phospholipid of the ER membrane, 
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leading to increased ER membrane surface area, ER volume, and cell size, in order to 
support copious amounts of Ig production.  Furthermore, a compelling body of evidence 
supports the importance of cholesterol in maintaining plasma membrane heterogeneity 
and regulating BCR signaling and B cell fate [50].  Additional studies to elucidate the 
regulation and expansion of ER membranes and the regulation of plasma membrane 
cholesterol content in B cell subsets will be performed.   
 ACL is a key enzyme that links glucose metabolism to lipid synthesis.  ACL 
deficiency in mice results in embryonic lethality, suggesting that other enzymes (i.e., 
acetyl-CoA synthetase 1) cannot compensate to supply cytosolic acetyl CoA [191,192].  
Our results indicate that ACL is regulated by extrinsic signals in B cells.  Specifically, 
our studies reveal that BCR-stimulated B cells activated ACL enzymatic activity through 
a post-translational phosphorylation on Ser454.   Phosphorylation of ACL on Ser454 was 
able to abolish the homotrophic allosteric regulation by citrate and enhance the catalytic 
activity of the enzyme [47], thereby allowing ACL activity to be modulated by extrinsic 
growth factors.  Previous findings demonstrate that IL-4 increases glucose transport and 
glycolysis in B cells [27], whether IL-4 modulates additional metabolic pathway is 
unknown.  Our results herein, demonstrated that IL-4 increased ACL enzyme activity 
through post-translational phosphorylation on Ser454 in B cells.  These data suggest that 
IL-4 cytokines and signaling through the BCR, stimulates survival and proliferation of B 
cells through the upregulation of ACL activity, in part, to support B cell growth and 
macromolecule synthesis.   
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 BCR cross-linking triggers activation of PI-3K, which plays an essential role in 
normal and malignant B cell growth and proliferation [38].  Specifically, PI-3K signaling 
orchestrates glucose carbon flow by regulating key rate-limiting enzymes that control 
macromolecular synthetic demands imposed by BCR ligation [24].  Mice deficient in the 
p85α subunit of PI-3K were used to assess the contribution of PI-3K on the 
aforementioned glucose-directed de novo lipogenesis in BCR-stimulated B cells.  Our 
results indicated that expression of phospho-ACLSer454 and ACL enzyme activity depends 
on signaling through the PI-3K pathway, as p85α-deficient mice display undetectable 
expression of phospho-ACLSer454 and half the ACL enzymatic activity in comparison to 
wild-type controls.  In addition to the aforementioned results, additional studies revealed 
that PI-3K plays a role in ACL directed de novo lipogenesis in that treatment with 
LY294002 (LY) and Wortmannin (WT) blocked ACL phosphorylation on Ser454 and 
significantly reduced its enzymatic activity.  It should be mentioned that LY is a potent 
PI-3K inhibitor, but it has also been shown to inhibit other signaling molecules [193].  
While this may represent a potential caveat to our interpretations we provide similar 
results with the PI-3K inhibitor, WT.   
Interestingly, a growing body of literature demonstrates that knockdown of ACL 
results in a decrease in cytokine stimulated cell growth and proliferation in normal and 
malignant cells [45,46].  In future studies, we plan to inhibit endogenous ACL with 
specific ACL inhibitors and siRNA to establish the functional requirement of ACL in the 
regulation of glucose-directed lipogenesis in response to BCR engagement.  Preliminary 
studies with hydroxycitrate (HC), a potent ACL inhibitor, are currently underway.  
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Specifically, anti-IgM- and IL-4-stimulated B cells treated with HC displayed a time 
dependent decrease in viable cells.  These data suggest that ACL is potentially regulating 
growth and proliferation.  These studies are of interest because of the growing body of 
literature that demonstrates that ACL inhibition can suppress tumor cell growth in highly 
glycolytic tumors [46].  Cancer cells displaying high rates of glucose metabolism are 
more severely affected.  Cells with a higher flux of glycolytic carbons from the cytosol to 
the mitochondrial depend on glucose for lipid synthesis to support cell growth, thereby 
increasing their sensitivity to ACL targeted inhibition.  ACL inhibition provides an 
advantage over strategies targeting other lipogenic enzymes because ACL is located 
upstream of other enzymes.  In future experiments we plan to elucidate the physiological 
effects of inhibiting endogenous ACL enzyme activity on B-cell growth responses.  
Specifically, we will use multiple readouts of growth, including increased cell size, 
increased de novo protein and RNA synthesis, and cell cycle progression.  Other potent 
ACL inhibitors will be analyzed to corroborate the data.  Finally, ACL studies are on 
going in CH12.LX B-cells rendered deficient in ACL.  CH12.LX cells represent a model 
to study IgM synthesis and secretion in response to LPS. 
Many transformed cells exhibit high rates of glycolysis and activation of PI-
3K/Akt growth factor signaling pathway(s).  With the growing body of evidence that 
supports that PI-3K signaling can positively regulate ACL, ACL is a particularly 
appealing target for the treatment of malignancy.  Future experiments will help to 
evaluate its role.   
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